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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so,
it provides its audiences with an evidence-based picture of the drug
phenomenon at European level. 
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU Member States and Norway and is an essential
reference book for those seeking the latest findings on drugs in Europe.
The printed publication is complemented by an expanded online version
available at: http://annualreport.emcdda.eu.int.
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Foreword
With this 2003 annual report, the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) presents
to the EU and its Member States an overview of the drug
phenomenon in Europe. The publication of the report
coincides with the 10th birthday of the EMCDDA 
(1993 founding regulation). This is also the last time that
we will focus only on the 16 countries that constitute our
current membership (the 15 Member States and Norway). 
It therefore seems appropriate to reflect briefly on both the
changes that have occurred in the drug phenomenon during
this initial period and the progress made by the Monitoring
Centre in our mission to provide policy-makers with a
sound, up-to-date and insightful commentary on the
evolving European drug problem.
A key feature of the drug phenomenon is its dynamic
nature. It is a sobering thought that, even if we restrict our
attention to the short time that the EMCDDA has been in
existence, the differences in the developments that have
occurred in both the nature of the drug problem and the
way in which Member States respond are profound.
Patterns of drug consumption have always varied between
European countries, especially in respect of scale.
This remains true, but the data in this report show that,
increasingly, trends are observable that illustrate the global
and European nature of the issue. At one time, any
comparison of drug use in Europe would be marked more
by differences than by similarities; this is no longer the
case. While the overall situation is complex and
considerable local variation exists, more general and
common patterns in drug use are also apparent.
Increasingly, we can conclude that in many ways we share
as Europeans a common drug problem and also, we
believe, a common responsibility to learn from our shared
experiences. We are not alone in this conclusion. The EU
action plan on drugs demonstrates the political commitment
given to this issue, and there is now a near universal
recognition that policy in this area must be based on a
clear understanding of the situation.
If drug problems have evolved during the last 10 years
then, equally, so has our ability to report on them. Credit
for this rests not with the EMCDDA alone, but also with the
many dedicated professionals throughout the EU who have
worked to understand the nature of the problem, to develop
effective responses and to critically assess the impact of
their work. We do believe, however, that the EMCDDA has
played a vital role both in acting as a catalyst for the
development of a sound evidence base and by providing
the forum necessary for collaboration and progress at the
European level. Ten years ago, no one could have talked
with confidence or authority on the nature of the European
drug situation. Today, this report demonstrates that this is
ever more possible. We are now both better prepared and
better informed to deal not only with the drug problem we
face at present, but also with any potential threats that we
may be confronted with in the future. We would like to
acknowledge the considerable investment that has been
made both within Member States and at European level to
develop the tools and infrastructure to provide this evidence
base, and to express our thanks, in particular, to the focal
points of the Reitox network.
We hope you will find this report a comprehensive
overview of the European drug situation — further and
more detailed data can also be found in the extended
online version of this document. For the EMCDDA,
this report also successfully marks the end of the first phase
of development of the organisation’s work, and we must
now look to the challenges that the future will bring.
Among these will be the need to continue to improve the
availability, quality and comparability of the European data
set, and we will need to develop our systems and capacity
to manage efficiently a growing knowledge base on
the drug situation across an enlarged European Union.
We are in no doubt that we will increasingly be faced with a
larger, more diverse and complex picture on which to report.
A central challenge for the organisation will remain the
need to exploit fully the information available to us to
provide an informed, timely and policy-relevant analysis
that reflects the value of an EU perspective and a
harmonised approach.
Marcel Reimen
Chairman, EMCDDA Management Board
Georges Estievenart
Executive Director, EMCDDA
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Introductor y note
This annual report is based on information provided to the EMCDDA by the EU Member States and Norway (participating
in the work of the EMCDDA since 2001) in the form of a national report. The statistical data reported here relate to the 
year 2001 (or the last year available) for Chapter 1, ‘Drug situation’, but may refer to 2002 or later for developments 
in the area of responses to drug use and for the selected issues.
The national reports of the Reitox focal points are available at:
http://www.emcdda.eu.int/infopoint/publications/national_reports.shtml.
An expanded online version of the annual report is available in 12 languages and may be found at:
http://annualreport.emcdda.eu.int. This online version comprises a wealth of additional material and statistics in the form of
tables, graphics and boxes. It also provides further detail on the methodology used as well as links to the data sources,
reports and background documents used in assembling the report.
All elements — included in both the printed and online version of the report — are listed thematically online
(http://annualreport.emcdda.eu.int).
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Trends in the drug situation
Cannabis
Cannabis remains the most commonly used drug in the EU,
with many countries reporting lifetime prevalence rates in
excess of 20 % of the general population. A conservative
estimate would suggest that at least one in every five adults
in the EU has tried the drug.
Indicators suggest that cannabis use has been increasing
across the EU, although this increase appears to have
stabilised in some countries, albeit at what can generally be
considered to be historically high levels. Some evidence of
a convergence in patterns of use is also found, although
rates still vary considerably, with France, Spain and the
United Kingdom, in particular, reporting relatively high
levels of use, and Finland, Sweden and Portugal reporting
comparatively low figures. In all countries, estimates of the
prevalence of recent use (last-year prevalence) among
the adult population remain below 10 %. When young
adults are considered, rates of use rise considerably.
In all countries, recent use (last-year) prevalence peaks in
the 15- to 25-year age group, with France, Germany,
Ireland, Spain and the United Kingdom all reporting that
over 20 % of this age group have used cannabis in the last
12 months. Lifetime use estimates are higher, with most
countries reporting lifetime prevalence estimates of between
20 % and 35 % among young people. The number of
people using cannabis on a regular basis is small in overall
population terms (generally less than 1 %), although higher
rates of regular use may be found among young people,
and in particular among young men.
A worrying trend is the increasing frequency with which
cannabis is mentioned in the context of the treatment
demand indicator (TDI). In many countries, cannabis is now
the drug most frequently reported after heroin, and a
steady increase in cannabis-related demand for treatment
can be observed. Caution is needed in interpreting these
data as a number of factors are likely to be important here.
This issue is currently being explored by an EMCDDA
technical working group and will be the focus of a
publication in 2004.
In most EU countries, the majority of reports for drug law
offences are related to cannabis. Cannabis seizures have
exhibited an increasing trend over the last decade,
although there are signs that seizures have stabilised.
Europe remains the world’s biggest market for cannabis
resin, with as much as three quarters of the world total of
cannabis resin being seized within the borders of the EU.
Many countries also now report that herbal cannabis is
being grown within the EU. The content of THC
(tetrahydrocannabinol), the main active chemical in
cannabis, varies greatly in street-level samples. On
average, the THC content of resin and herbal cannabis is
similar (5–14 % and 5–11 % respectively), although some
samples of both forms of the drug are found to have a very
high THC content.
Amphetamines and ecstasy (MDMA)
Europe remains an important area for the production and
use of amphetamines and ecstasy but not
methamphetamine. After cannabis, the most commonly used
drug in EU countries is usually either ecstasy or
amphetamine, with rates of lifetime experience among the
adult population generally ranging between 0.5 % and
5 %. In the past, prevalence of amphetamine use was
generally higher than prevalence of ecstasy use, but this
difference is now less apparent. Among school populations,
lifetime experience of inhalants is second only to that of
cannabis and in general is considerably higher than
experience of either ecstasy or amphetamines.
As with cannabis, the highest rates of lifetime and recent
use are found among young adults. A number of indicators
suggest that ecstasy use has continued to spread among
some sections of urban youth in Europe. Some studies have
found extremely high prevalence rates among such groups,
although a pronounced increase in use of the drug is not
generally observable in the wider population.
The numbers of people treated for an amphetamine
problem in Europe vary widely: just under a third of drug
users in treatment in Sweden and Finland are amphetamine
users, compared with around 9 % in Germany and 3 % or
less in all other countries. In almost all countries, rates of
treatment demand related to ecstasy are very low. A small
number of deaths in Europe can be directly attributed to the
use of ecstasy, but overall the numbers remain low in
comparison with deaths related to opioids.
Although there have been some fluctuations in recent years,
and possibly signs of stabilisation in some areas, both
amphetamine and ecstasy seizures (numbers and quantities)
have increased substantially in the EU over the last decade.
Overall trends and developments
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In Finland, Sweden and Norway, amphetamines are the
second most commonly seized drug (after cannabis).
Cocaine and crack cocaine
Survey data suggest an increase in cocaine use in the
United Kingdom and, to a lesser extent, in Denmark,
Germany, Spain and the Netherlands. Cocaine use and
increases in use appear to be more common among young
people living in urban areas. National figures may
therefore reflect local trends in some major European cities
to only a limited extent.
A number of indicators suggest that concern about levels of
cocaine use and related problems is justified. Such
indicators include treatment demand, toxicological findings
in victims of overdose deaths, drug seizures and studies of
at-risk populations. Apart from a decrease in 2000, the
number of cocaine seizures has increased steadily since
1985. Similarly, the quantity of cocaine seized has
generally exhibited an upward trend over the same period,
although figures tend to fluctuate from year to year.
Relatively high rates of drug-treatment attendance for
cocaine use are reported from the Netherlands and Spain
(30 % and 19 % respectively) and to a lesser extent from
Germany, Italy, Luxembourg and the United Kingdom
(between 6 % and 7 %). With the exception of the
Netherlands and the United Kingdom, most cocaine
treatment demand appears to be related to the use of
cocaine powder (cocaine hydrochloride) as opposed to
crack cocaine (cocaine base).
The prevalence of use of crack cocaine in Europe
appears to be relatively low, although sporadic local
reports suggest a problem among marginal groups in
some cities. As crack cocaine is particularly associated
with negative health and social consequences, even when
prevalence rates are low, more detailed attention needs to
be paid to any emerging trends in this area as the public
health impact of even a moderate increase in use could
be considerable.
Heroin and injecting drug use
Problem drug use is defined as ‘injecting drug use or
long duration/regular use of opiates, cocaine and/or
amphetamines’. Although small in terms of overall
numbers, problem drug users are responsible for a
disproportionate share of the health and social problems
resulting from drug consumption. In most countries in the
EU, with the exception of Sweden and Finland, where
amphetamine use is more prevalent, problem drug use
remains characterised by the use of heroin, often in
combination with other drugs. As estimation in this area is
difficult, and the precision and reliability of estimates vary
considerably, caution is required both in interpreting trends
and in making comparisons between countries.
National estimates of problem drug use vary between
two and 10 cases per 1 000 of the adult population (that is
between 0.2 % and 1 %). No common trend in the number
of problematic drug users in the EU can be observed,
although studies suggest that in at least half of EU countries
some increase has occurred since the mid-1990s.
Probably around half of ‘problem drug users’ in the EU are
drug injectors, i.e. around 500 000–750 000 of the EU’s
estimated 1–1.5 million problem drug users. The proportion
of injectors varies considerably between countries and has
changed over time, with levels of injection falling in almost
all countries during the 1990s, although there is some
evidence of more recent increases. National estimates of
injecting drug use vary between two and five cases per
1 000 of the adult population (or 0.2–0.5 %).
Despite a dramatic decrease in opium production in
Afghanistan in 2001, there does not seem to be any
evidence that this had a direct impact on the availability of
heroin on the European illicit market. This can probably be
explained by the existence of stocks of the drug.
Human immunodeficiency virus (HIV), 
hepatitis C (HCV) and hepatitis B (HBV)
Of particular concern in the EU is the drug-related spread
of HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV),
usually through behaviours associated with drug injection.
Available data suggest that the prevalence of HIV
infection among drug injectors (IDUs) varies greatly
between, as well as within, European countries, from
about 1 % in the United Kingdom to over 30 % in Spain.
In some countries and regions, HIV prevalence among
IDUs has remained very high (over 25 %) since the 
mid-1990s. Although these data may reflect 
well-established epidemics, in these areas special
prevention efforts remain important to prevent further
infections.
It may be misleading to rely completely on national data
sets, which in general have suggested a fairly stable
situation across the EU, as trends may differ widely within
regions and cities. Increases in HIV prevalence among
subgroups of IDUs have recently been reported from
regions or cities in Spain, Ireland, Italy, the Netherlands,
Austria, Portugal, Finland and the United Kingdom. This
picture remains diverse, as in some of these countries
decreases were also recorded in other subgroups, and in
Overall trends and developments
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Developments in responses to drug use
EU policy
The mid-term evaluation of the EU action plan on drugs
2000–04, undertaken by the European Commission,
observes that Member States give priority to demand
reduction and follow the lines set out in the action plan.
However, it perceives a need for the EU to make an even
stronger effort to develop innovative prevention
programmes. While acknowledging achievements, it
stresses that much work remains to be done, including the
development of systems of evaluation of national and EU
activities. 
The presidencies of the Council in 2002, Spain and
Denmark, introduced resolutions in order to improve the
commitment of Member States to further invest in drug-
prevention programmes in school curricula, to intensify
efforts aimed at the prevention of the recreational use of
drugs and to improve the treatment of drug users in
prisons. In May 2002, the Commission presented a
proposal prepared in consultation with the EMCDDA for a
Council recommendation on the prevention and reduction of
risks associated with drug dependence, addressing the
target of the EU drugs strategy to reduce substantially the
incidence of drug-related health damage using risk-
reduction measures that have been shown to be successful.
Member States’ policies
The trend observed in recent years of organising national
drug policy through national action plans and coordinated
systems continued in 2002. Sweden and Norway and some
Austrian provinces joined other EU partners in adopting a
coherent drugs plan, programme or strategy. At the same
time, members of the public are becoming increasingly
aware of drug abuse and its consequences and are taking
an interest in national policy. Surveys show that the clear
majority of the public remains opposed to legalisation of
cannabis. The low level of support for legalisation probably
reflects the belief that cannabis is a gateway drug.
However, varying levels of support were given to the idea
of modifying punishments for the use of cannabis in certain
circumstances.
An overview of developments of drug use and responses to
it in the educational, health, social and criminal justice
systems shows that both problems and problematic groups
are often not clear-cut. National and local policies
increasingly reflect an awareness of the insidious character
of the phenomenon by making boundaries between the
systems more permeable and flexible through increasing
cooperation and diversification. 
other countries prevalence has remained stable or
decreased.
Data on HIV infection in young and in new IDUs may be a
better indicator of recent infections and again indicate that
new infections are continuing to occur in some regions.
AIDS incidence has fallen across the EU since the
introduction of more effective treatments. 
Hepatitis C infection can cause severe chronic health
problems, and the treatment of conditions related to HCV
infections is likely to become a major cost to European
healthcare systems. The prevalence of hepatitis C is
extremely high among drug injectors in all countries, with
infection rates varying between 40 % and 90 %. Among
notification data where a risk category is known, 90 % of
cases of hepatitis C and 40–80 % of cases of hepatitis B
are related to injecting drug use. Trends over time show a
mixed picture, with increases and decreases being
observed in different regions. The prevalence of HCV
infection among young IDUs and new IDUs is high in
general (40 % or more), confirming a high incidence of
new infections, with injectors continuing to acquire the
disease after relatively short periods of injecting.
Throughout the EU, approximately 20–60 % of IDUs have
antibodies against hepatitis B, suggesting a large potential
for vaccination programmes directed at this disease in
IDUs.
Overdoses
Each year, 7 000–9 000 acute drug-related deaths are
reported in the EU. The overall EU trend has continued to
increase in recent years, although less dramatically than
was the case in the 1980s and early 1990s, and with a
more complex and divergent picture appearing at the
national level. Most of the victims are young people in
their 20s or 30s, representing a considerable cost to
society and loss of life.
In most cases (typically over 80 %), opioids are present
in the toxicological analyses, often in combination
with other substances (such as alcohol, benzodiazepines
or cocaine). Cocaine or ecstasy alone is found in a smaller
number of cases. Some of the factors that appear
to be associated with increased risk of opioid-related
deaths are drug injecting, polydrug use and, in
particular, the concurrent use of alcohol or depressants,
loss of tolerance and not being in contact with treatment
services. It is known that proper and timely interventions
can help to prevent many fatal overdoses, supporting
the need for interventions in this area that encourage
those witnessing a drug-related overdose to take
appropriate action.
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Healthcare, educational and social policies are becoming
more important in reducing drug-related problems in the
widest sense, and it is increasingly recognised that the
criminal justice system alone is not always capable of
handling the problem of drug use. The link between social
exclusion policy and drug issues is stronger in some
countries, such as Ireland and the United Kingdom, than in
others. Several countries in the EU have introduced
legislative changes to facilitate the treatment and
rehabilitation of addicts and other legal changes have
opened up possibilities for early interventions among young
experimental drug users. Denmark, Germany, the United
Kingdom and Norway have increased healthcare
investment in an attempt to reduce the number of drug-
related deaths. In line with the EU action plan’s commitment
to provide a variety of wide and easily accessible treatment
options, some countries, for example Finland and Greece,
have changed their financing schemes as well as
regulations regarding substitution treatment.
Against a background of increased security, a number of
countries report legal changes to improve the monitoring of
traffickers and users, including telecommunications
monitoring, body searching and drug testing. Other legal
changes have aimed at minimising the social impact of
drug use by providing stricter control of public order and
public nuisance.
Interventions
School-based prevention remains at the core of activities
directed towards all young people, usually from the pre-
teens upwards. Although a broad evidence base exists
identifying effective approaches, such as interactive
teaching with a focus on personal and social life skills, only
a few countries, such as Spain, Greece and Ireland,
systematically implement such programmes in the school
curriculum. Of the other countries, Sweden and France
concede that school drug-prevention practice is not state of
the art but often rather eclectic, non-professionalised action.
However, a growing concern that the most vulnerable
young people will not be reached in schools has triggered
the development of specific preventions aimed at groups
experimenting with drugs in recreational settings, such as
discos, clubs and music events. Peer and on-the-spot
counselling seem to be the most promising approaches.
Prevention initiatives and early interventions directed at
socially excluded youths and young offenders similarly
seem to be most effective when implemented using a
personalised methodology. Good results have been
reported from projects in Germany, Austria, Portugal and
the United Kingdom. Although vulnerable families, possibly
with drug-using parents, are considered to be at high risk,
supportive services for such families are rare.
Syringe exchange is now an established method to
prevent the spread of infectious disease through injecting
drug use, although the availability and coverage of such
programmes is variable and accessing sterile equipment
can still be a problem. Only in Spain are syringe-
exchange services being implemented systematically in
prisons. Specific measures to prevent hepatitis C
transmission as well as hepatitis B vaccination are
increasingly considered as important complements to HIV
prevention. First aid training and risk education have
become more prominent as particular interventions to
prevent fatal overdoses. Another important development is
that medical care is increasingly becoming available at
low-threshold level, integrated in local drug services. 
Drug-related treatment still very much equals treatment for
opiate use, or polydrug use including opiates, with the
exception of Sweden and Finland, where injecting
amphetamine use is still important. More recent
developments in problem drug use, partly away from
opiates and injecting drug use, have triggered the
emergence of new kinds of early interventions, as described
above, rather than reform of existing drug-treatment
structures. Substitution treatment is prominent and has
further expanded and diversified in recent years. Over the
EU as a whole, the expansion in the last five years is
estimated to be 34 %, the largest increases being reported
from countries with a low initial provision, such as Greece,
Ireland, Portugal, Finland and Norway. Care for long-term,
ageing, deprived drug users, often with psychiatric
comorbidity, is a serious challenge to drug policy, which
has not found adequate solutions. The EMCDDA will look
into this issue further in the coming year.
Innovations in penal policy have introduced alternatives to
prison, diverting drug users to quasi-compulsory treatment
or community service on the assumption that their needs are
better met by such interventions. Alternatives to prison
specifically prevent young drug users coming into contact
with the criminal subculture in prisons. The need for
alternatives to prison has also arisen from acute
overcrowding in prisons. Drug use and drug users in
prisons are an increasingly important problem, calling for
flexible responses. Health and welfare authorities are
increasingly involved and taking responsibilities for service
provision for drug users in prisons, although there is still
room for improved cooperation. Often, treatment that is
standard in the community is not available or accessible in
prison. In most countries, harm-reduction measures in
prisons are relatively limited.
Overall trends and developments
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partly funded by the pharmacological industry, large
national evaluation studies provide little direction as to best
practice of other treatment modalities.
The transfer of scientific evidence to policy and practice can
be improved. Closer cooperation and greater mutual
understanding between research and decision-makers are
urgently needed. Only a few countries are reviewing their
school-based prevention practice on the basis of scientific
evidence. While scientific evidence is increasingly
acknowledged in the area of prevention of infectious
diseases, it seems that in many cases quality of care is not
taken into sufficient consideration in the areas of drug-
related treatment and services for drug users in prisons.
Scientific evidence is largely lacking in the area of
alternatives to prison. However, more formalised quality
assurance is gaining ground in Member States with the
establishment of guidelines, quality standards and
accreditation systems.
Quality assurance
A number of recent studies focus on innovative
and controversial interventions such as consumption
rooms, heroin prescription or pill testing. While these types
of intervention remain controversial, decision-makers are in
need of information on the effects of such strategies in
order to provide the basis for a more informed debate.
European research on psychosocial interventions in
prevention and treatment is lacking. In the area of
prevention, evidence from North American research has
been widely used. However, both the objectives and the
settings of prevention differ from the European situation.
Nevertheless, it has been possible to replicate some
successful approaches, and this evidence is increasingly
taken into consideration in policy-making. Although a
substantial body of research and evidence-based
knowledge exists regarding medically assisted treatment,

(1) For further explanation, see Box 1 OL: Methods used to estimate drug use in the general population (online version).
(2) See the EMCDDA guidelines for the key indicator ‘prevalence and patterns of drug use among the general population — population surveys’
(http://www.emcdda.eu.int/multimedia/project_reports/situation/population_survey_handbook.pdf). 
(3) Figure 1 OL: Patterns of cannabis use among the general population — lifetime experience versus current use (last 30 days), national (drug use)
prevalence survey 2001 (the Netherlands) (online version).
(4) Figure 2 OL: Recent use (last 12 months) of cannabis, amphetamines, ecstasy and cocaine among young adults (15–34 years) in European countries,
measured by national population surveys (online version). 
Drug use in the general population (1) (2)
Reliable information on the extent and patterns of drug use
and age at first use among the general population and
young people, as well as on the characteristics of users and
risk perceptions, is important when formulating and
evaluating drug policies and prevention initiatives. Drug use
in the general population is measured by surveys, which
provide estimates of the proportion of the population who
have used drugs at any time. The most common measures
are:
• any use during a person’s life (lifetime prevalence),
often called ‘lifetime experience’;
• any use during the previous year (last 12 months
prevalence), often called ‘recent use’; and
• any use during the previous month (last 30 days
prevalence), often called ‘current use’.
The figures for ‘lifetime experience’ are always higher than
for the other two groups, as this group includes everyone
who has ever tried drugs, no matter how long ago this was.
‘Recent use’ figures are generally lower but better reflect the
prevailing situation. ‘Current use’ may be an indicator of
the number of people who use drugs regularly, but figures
are generally low. A combination of lifetime experience and
recent or current use can provide insight into drug-use
patterns (e.g. continuation rates).
Many surveys also investigate age at first drug use and
frequency of use, data which allow estimations of incidence
and reveal differences in patterns of use, such as higher
doses or more frequent use (which imply increased risk). In
addition, correlations between drug use and
sociodemographic factors, opinions and risk perceptions,
lifestyles, health problems, etc. can be established.
A number of factors need to be taken into account when
considering differences in the overall national figures. 
The relative sizes of the urban and rural populations
in each country may partly account for the differences.
Other sources of variation include factors to do with
generation (for example, the birth cohort in which drug use
became widespread) and the extent of convergence of the
lifestyles of young men and women. Social and cultural
context can also influence self-reporting of drug use.
Finally, methodological questions such as sampling errors
and non-response can influence results. Comparative
analysis across countries should be made with caution, in
particular where differences are small, and formulation and
evaluation of drug policy should take into consideration,
among other criteria, specific age groups, birth cohorts,
gender and place of residence (i.e. urban versus rural) of
the studied population.
Prevalence and patterns of drug use 
in the general population
Despite methodological limitations to the comparison of
survey results across countries, some common patterns of
drug use throughout the EU can be identified. These basic
patterns have remained relatively unchanged since the last
annual report.
Cannabis continues to be the illegal substance most
commonly used in all EU countries. Lifetime experience is
much higher than recent or current use, suggesting that
cannabis use tends to be occasional or to be discontinued
after some time (3). Current drug use is unusual in people
over 40 years of age. Some countries report a small
proportion of adults (0.5–1 %) who consume the substance
almost daily, and particular attention should be paid to this
group.
Illegal substances other than cannabis are used by much
smaller proportions of the population, although there are
considerable differences between countries (4). Again,
regular or sustained use of drugs is uncommon — for most
Chapter 1
Drug situation
This chapter provides an overview of the situation of drug use and supply in the EU and Norway
and highlights recent developments and emerging trends.
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(5) This is expressed as ‘continuation rate’, i.e. the proportion of people who, having used a substance during their lifetime, have also used it during the last
12 months or last 30 days. 
(6) See Statistical Table 1: Lifetime prevalence (LTP) of drug use in recent nationwide surveys among the general population in the EU countries and Norway
(online version).
(7) See Statistical Table 2: Last-12-months prevalence (LYP) of drug use in recent nationwide surveys among the general population in the EU countries and
Norway (online version).
(8) Source: SAMHSA, Office of Applied Studies, national household survey on drug abuse, 2001 (www.samhsa.gov/oas/nhsda.htm). Note that the age range
in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64 years). This means that the reported figures
in the US survey will tend to be somewhat lower than if the EU range had been used because of the low level of drug use among 12- to 15-year-olds and, in
particular, among people over 65 years.
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and ecstasy use by 1.4 % (8). Cannabis lifetime experience
and recent use are higher in the United States than in any
EU country. Cocaine lifetime experience is also higher in
people their drug use is relatively short-lived (i.e. lifetime
experience is clearly higher than recent use) (5).
The use of illegal substances is highest in young adults (e.g.
15–34 years), among whom prevalence rates are
approximately twice those among adults as a whole. In all
countries and all age groups, men are more likely than
women to have ever used drugs. Drug use is more prevalent
in urban areas, although some spread to smaller towns and
rural areas may be taking place.
Lifetime experience of cannabis use is reported to range
from about 7–10 % (Portugal and Finland) to around 30 %
(Denmark and the United Kingdom) of the whole adult
population, with most other countries reporting figures in
the range 20–25 %. Reported rates of drug use other than
cannabis are 0.5–6 % for amphetamines (except in the
United Kingdom, where the figure is 11 %) and 0.5–5 % for
cocaine and ecstasy (6). Generally, heroin has been tried by
less than 1 % of the population, although in some countries
up to 2–3 % of young men report having experimented with
the drug.
Recent use of cannabis is reported by 1–10 % of all adults,
although in most countries (10) prevalence varies between
5 % and 10 %. Recent use of amphetamines, cocaine or
ecstasy is in general reported by less than 1 % of adults. In
Spain, Ireland and the United Kingdom, the rates of use of
all of these drugs are somewhat higher, while in Denmark
and Norway the use of amphetamines is relatively higher,
and in the Netherlands ecstasy use is more common (7).
Drug use (in terms of both lifetime experience and recent
use) is higher among young adults than among the
population as a whole. Recent cannabis use is reported by
5–20 % of young adults (Sweden 1–2 %), with a substantial
number of countries (seven) reporting rates between 10 %
and 20 % (Figure 1). Recent amphetamine use is generally
reported by 0.6 %, cocaine use by 0.5–4.5 % and ecstasy
use by 0.5–5 % (Figure 2).
For comparison, in the 2001 United States national
household survey on drug abuse, 36.9 % of adults
(12 years and older) reported lifetime experience of
cannabis, 12.3 % lifetime experience of cocaine and 3.6 %
lifetime experience of ecstasy. Recent (last 12 months)
cannabis use was reported by 9.3 %, cocaine use by 1.9 %
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Figure 1: Recent use (last 12 months) of cannabis among young
adults (15–34 years) in European countries, measured by national
population surveys
NB: Data are from the most recent national surveys available in each country.
Sample sizes (n) refer to the number of respondents for the 15–34 age group.
For details regarding number of respondents for the whole survey, see
Statistical Table 2: Last-12-months prevalence (LYP) of drug use in recent
nationwide surveys among the general population in the EU countries and
Norway (online version). The standard EMCDDA definition of young adults
is age 15–34 years. In Denmark and the United Kingdom, young adults are
aged 16–34 years and in Germany and Ireland 18–34 years. Variations in
age ranges may, to a small extent, account for some national differences. In
some countries, the figures were recalculated at national level to adapt as
far as possible to the standard EMCDDA age groups.
(1) France conducted a new survey in 2002 but with a substantially smaller
sample (2 009 respondents). See Statistical Table 1: Lifetime prevalence (LTP)
of drug use in recent nationwide surveys among the general population in
the EU countries and Norway (online version).
(2) In Ireland, the sample for the whole survey (18–64 years) is 6 539.
(3) England and Wales.
Sources: Reitox national reports 2002, taken from surveys, reports or scientific arti-
cles. See also Statistical Table 1: Lifetime prevalence (LTP) of drug use in
recent nationwide surveys among the general population in the EU countries
and Norway (online version).
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the United States than in any EU country, and recent use is
higher than in most countries, except Spain (2.6 %) and the
United Kingdom (2.0 %). Ecstasy use is higher than in all
EU countries except Spain, Ireland, the Netherlands and the
United Kingdom.
Trends in drug use among the general population
It is difficult to define clear-cut trends that apply to the EU
as a whole. A consistent series of surveys has been carried
out in only a very few countries and, even then, generally
for only a few years. In addition, social/cultural context
varies widely among EU countries. Lifetime experience is
of limited value in analysing trends as it is a cumulative
measure that may increase as a result of a generational
effect even if current drug use is stable or falling.
On the other hand, in the case of very young people
(aged 13–15 years), lifetime experience will tend to reflect
recent use.
Different types of surveys (national or local or surveys of
military conscripts or schoolchildren) show that cannabis
use, particularly among young people, increased markedly
during the 1990s in almost all the EU countries. At the
same time, cannabis use in different countries tended to
converge, with a significant number of countries reporting
rates of around 20–25 % lifetime experience and 5–10 %
recent use.
Although many countries report a continued increasing
trend in cannabis use, it is worth noting that a number of
countries (Ireland, Italy, the Netherlands, Finland, Sweden
and Norway) report that use may be levelling off based on
studies among school students, military conscripts and
teenagers.
European trends in the use of other substances (e.g.
cocaine, ecstasy and amphetamines) are more difficult to
track, partly because in many cases survey samples are
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Figure 2: Recent use (last 12 months) of amphetamines, ecstasy and cocaine among young adults (15–34 years) in European countries,
measured by national population surveys
NB: E&W, England and Wales.
Data are from the most recent national survey available in each country. Sample sizes (n) refer to the number of respondents for the 15–34 age group. For details regard-
ing number of respondents for the whole survey, see Statistical Table 2: Last-12-months prevalence (LYP) of drug use in recent nationwide surveys among the general
population in the EU countries and Norway (online version). The standard EMCDDA definition of young adults is age 15–34 years. In Denmark and the United Kingdom,
young adults are aged 16–34 years and in Germany and Ireland 18–34 years. Variations in age ranges may, to a small extent, account for some national differences.
In some countries, the figures were recalculated at national level to adapt as far as possible to the standard EMCDDA age groups.
(1) France conducted a new survey in 2002 but with a substantially smaller sample (2 009 respondents). See also Statistical Table 2: Last-12-months prevalence (LYP) of
drug use in recent nationwide surveys among the general population in the EU countries and Norway (online version).
(2) In Ireland, the sample for the whole survey (18–64 years) is 6 539.
Sources: Reitox national reports 2002, taken from surveys, reports or scientific articles. See also Statistical Table 2: Last-12-months prevalence (LYP) of drug use in recent nation-
wide surveys among the general population in the EU countries and Norway (online version).
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(9) Although, according to the Home Office, it seems to be levelling off (see Figure 3). Studies among people in England and Wales age 16–29 years found
significant changes (at the 5 % level) between 1996 and 1998 and between 1998 and 2000. However, differences between 2000 and 2001/2 were not
significant.
(10) For more detail see Box 2 OL: Definition of and methods used to estimate problem drug use (online version).
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small and partly because of the much lower prevalence of
use of these drugs overall. In addition, new trends tend to
concentrate in selected groups, and a focused analysis
(e.g. of drug use by young men in urban areas) would be
necessary to determine such trends and assess their true
extent. Ideally, surveys should be complemented by targeted
anthropological studies.
Ecstasy use clearly increased during the 1990s (and seems
to be still diffusing) among certain youth groups, but
only four countries (Spain, Ireland, the Netherlands
and the United Kingdom) report a rate of recent use
(last 12 months) among young adults of more than 3 %.
Worryingly, indicators of drug use (treatment demand,
seizures, post-mortem toxicological findings) suggest that
the use of cocaine is increasing in some countries. Although
cocaine use among the population as a whole remains low,
increases in recent cocaine use (last 12 months) among
young people seems to be a consistent finding
(1994–2000) in the United Kingdom (9) and possibly, to a
lesser extent, in Denmark, Germany, Spain and the
Netherlands. Other countries have reported (2001 or 2002
Reitox national reports) increases based on local or
qualitative information (Greece, Ireland, Italy and Austria).
This phenomenon should be closely monitored, in particular
among young people in urban areas (Figure 3).
See http://annualreport.emcdda.eu.int for statistical tables
related to this section:
Statistical Table 1: Lifetime prevalence (LTP) of drug use in
recent nationwide surveys among the general population
in the EU countries and Norway
Statistical Table 2: Last-12-months prevalence (LYP) of drug
use in recent nationwide surveys among the general
population in the EU countries and Norway
Statistical Table 3: School surveys — lifetime prevalence
among students, 15–16 years of age
Problem drug use
Problem drug use is defined as ‘injecting drug use or long
duration/regular use of opiates, cocaine and/or
amphetamines’ (10).
Given the dependability of current estimation methods, data
quality and data availability, it is not always possible to
interpret trends reliably. In addition, there is no estimation
method that can be used in all countries in a comparable
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Figure 3: Evolution of recent (last 12 months) cannabis (A) and cocaine
(B) use among young adults (15–34 years) in some EU countries
Figure 3 (A): Evolution of cannabis use
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Figure 3 (B): Evolution of cocaine use
NB: E&W, England and Wales.
Data are from the most recent national survey available in each country. The
figures and methodology for each survey can be obtained from Statistical
Table 2 (online version).
The standard EMCDDA definition of young adults is age 15–34 years. In
Denmark and the United Kingdom, young adults are aged 16–34 years and
in Germany and Ireland 18–34 years. In France, the age range is
25–34 (1992), 18–39 (1995) but 15–34 for the other years.
Sample sizes (respondents) for each survey can be obtained in Statistical Table
2 (online version).
In Denmark, the figure for 1994 is for use of ‘hard drugs’.
Sources: Reitox national reports 2002, taken from surveys, reports or scientific 
articles. See individual sources in Statistical Table 2 (online version).
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(11) See Box 3 OL: Trends and patterns of problem drug use by country (online version).
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In Finland and Sweden, the majority of problem drug users
are primary amphetamine users (an estimated 70–80 % in
Finland in 1999). This is in contrast to the situation in other
countries, where problem drug users are mostly primary
opiate users (and often polydrug users). In Spain, cocaine
has become an important factor in recorded drug problems
(treatment and emergency data), and this is confirmed by
recent prevalence estimates. Some countries (Germany, the
Netherlands) report a high prevalence of crack cocaine use
among problem drug users, although mainly in large cities
and principally among primary opiate users.
Separate estimates are given for injecting drug use, a
subcategory of all problem drug use. These estimates are
based on multiplier methods using mortality data and rates
of human immunodeficiency (HIV) or hepatic C virus (HCV)
infection. As it is difficult to distinguish rates of current
injection (probably best represented by mortality-based
estimates) and lifetime injection (from the HIV/HCV
estimates), the estimates are difficult to compare. Estimates
of injecting drug use are in general between two and five
way, therefore between-country comparisons should be
carried out with caution.
Several countries report changes in estimates, suggesting
increases in problem use since the mid-1990s. Out of
16 countries, eight report higher estimates of problem drug
use (Germany, Spain, Italy, Luxembourg, Finland, Sweden)
or injecting drug use (Belgium and Norway) during the
1990s, although the increase reported in Sweden at
national level does not seem to be confirmed in two local
studies) (11).
The prevalence estimates of problem drug use are all
between two and 10 cases per 1 000 of the population
aged 15–64 (using the midpoints of the estimates). The
highest rates are reported in Italy, Luxembourg, Portugal
and the United Kingdom (6–10 per 1 000 inhabitants aged
15–64). Rates are lowest in Germany, the Netherlands and
Austria, each with about three problem drug users per
1 000 inhabitants aged 15–64. Data for Belgium and
Norway are not available (Figure 4).
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Figure 4: Estimates of problem drug use in different EU Member
States (most recent one-year prevalence per 1 000 inhabitants
aged 15–64)
NB: Figures show the combined country range of different estimates. They may
be based on different methods and data sources and should be interpreted
with caution (see online statistical tables for specific estimates and full details).
The dot shows the midpoint of the range, while the line represents the uncer-
tainty range or 95 % confidence interval. The longer this line, the wider the
range of the prevalence estimates is (not available for Spain or Ireland). All
estimates are compatible with the EMCDDA definition of problem drug use.
The Swedish estimate has been adjusted to fit this definition.
Sources: National focal points through the EMCDDA project: ‘National prevalence esti-
mates of problem drug use in the European Union, 1995–2000’, CT.00.RTX.23,
Lisbon, EMCDDA, 2003. Coordinated by the Institut für Therapieforschung,
Munich.
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Figure 5: Estimates of injecting drug use in EU Member States
(most recent one-year prevalence per 1 000 inhabitants
aged 15–64)
NB: Figures show the combined country range of different estimates. They may
be based on different methods and data sources and should be interpreted
with caution (see online statistical tables for specific estimates and full details).
The dot shows the midpoint of the range, while the line represents the uncer-
tainty range or 95 % confidence interval. The longer this line, the wider the
range of the prevalence estimates is (not available for France, Luxembourg
or the United Kingdom).
Sources: National focal points through EMCDDA project: ‘National prevalence esti-
mates of problem drug use in the European Union, 1995–2000’, CT.00.RTX.23,
Lisbon, EMCDDA, 2003. Coordinated by the Institut für Therapieforschung,
Munich.
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(12) A full report on the treatment demand indicator is available online
(http://www.emcdda.eu.int/multimedia/project_reports/situation/treatment_indicator_report.pdf).
Annual report 2003: the state of the drugs problem in the European Union and Norway
See http://annualreport.emcdda.eu.int for statistical tables
related to this section:
Statistical Table 4: Estimated number of problem drug users
in EU Member States, 1995–2001
Statistical Table 5: Estimated rate of problem drug users in
EU Member States, 1995–2001 (rate per 1 000 aged 15–64)
cases per 1 000 of the population aged 15–64 (data are
not available for five Member States). The estimate for
Luxembourg is higher, at almost 6 per 1 000. Estimates of
injecting drug use indicate the population at risk for serious
health consequences or drug-related death (Figure 5).
Analysis of the proportions of injectors among heroin users
in treatment suggest marked differences in prevalence of
injecting drug use between countries and varying trends
over time (Figure 6). In some countries, injecting drug use
appears to be low (Portugal, the Netherlands), whereas in
other countries levels of injection among heroin users in
treatment are high (Greece, Luxembourg). In almost all
countries, injecting drug use among treated heroin users
seems to have fallen during the 1990s, although data for
some countries suggest increases since 1996 and more
recently (Ireland, Finland), which, if confirmed, are
worrying and should be acted upon. In the United
Kingdom, the proportion of injectors fell until 1996, but it
increased the next year and since then has remained stable.
The same data on the percentage of current injecting
among opiate users in treatment, weighted by the estimated
absolute numbers of problem drug users (see Statistical
Table 4), suggest that roughly 60 % of problem drug users
in the EU are injectors, but with large variation between
countries (not shown). If the rate of problem drug use in the
EU as a whole is between four and six cases per
1 000 population aged 15–64, this translates into between
1 and 1.5 million problem drug users, of whom
600 000–900 000 are injectors.
Demand for treatment
The characteristics (e.g. social characteristics) of clients
entering treatment as well as their consumption behaviour
(e.g. the proportion of injectors or opiate users) are
potential indicators of wider trends in problem drug use.
Treatment demand data also offer a view of the
organisation of treatment centres in Europe. However,
biases may arise owing to different methods of information
collection and variation in the type of treatment services on
offer in different countries. Data collection was based for
the second time on a common European protocol (treatment
demand indicator, TDI), including information on around
150 000 patients (12).
Substances
Despite differences in treatment policies and recording
practices, it is possible to identify both common and
divergent trends across Europe.
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Figure 6: Trends in injecting drug use in EU Member States,
1990–2001 (percentage of current injectors among heroin users
in treatment)
(1) Italy: data from Standard Table 4 (2002).
(2) Data are not available for France 1998; figure is based on interpolation.
Data represent several thousands of cases per country per year and in most
countries include almost all treated cases at national level.
Sources: National focal points through EMCDDA project: ‘Treatment demand indicator’
(http://www.emcdda.eu.int/situation/themes/demand_treatment.shtml).
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Information sources
In 2002, as in 2001, two information sources were used:
the extended TDI protocol in treatment centres where data
were available and a concise form of the TDI protocol,
which is included in the tables collected since 1993. In order
to be consistent with previous years and see trends over
time, in some cases the second information source has been
used. The number of covered cases for each country by data
source is reported in the online version (1).
(1) Table 1 OL: Number of covered cases by data source (online ver-
sion).
(13) Figure 3 OL: New clients admitted to treatment by source of referral (online version).
(14) For various reasons (including, for example, the imposition of administrative sanctions such as a driving ban), the proportion of users referred by the
criminal justice system does not necessarily correspond to the proportion of offenders.
(15) Figure 4 OL: Source of referral among new clients in some countries (online version).
(16) See Statistical Table 6: Characteristics of persons treated for drug problems in the EU (online version); and Statistical Table 7: Characteristics of persons
treated for drug problems in the EU for the first time (online version).
(17) Figure 5 OL: Primary drug among all clients by centre type (online version).
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As in previous years, for 2001, all countries report an
increase in the overall number of people treated for drug
problems. According to the national reports, there are
several reasons for this: improved methods of registration
(more persons treated are reported), increased availability
of treatment facilities (especially substitution treatments and
low-threshold services), differentiation of programmes
(there are now specialised services for specific target
groups and different substances used in substitution
programmes, such as buprenorphine as well as
methadone), increasing treatment duration of existing
clients and an increase in the number of persons being
treated in rural/non-urban areas (National reports, 2002).
Drug users mainly demand treatment spontaneously or
because family members exert pressure on them to do so;
other sources account for only a small proportion of
referrals (13). Referrals to drug-treatment centres vary from
country to country, for several reasons: differences in
distribution of use of abused substances; differences in the
national organisation of health, social and judicial services;
and social or cultural differences. For example, the
proportion of clients referred by the courts, police or other
judicial services is highest in Germany, possibly because of
the high proportion of cannabis users there (14). In contrast,
in Sweden, which has a highly structured welfare system,
social services play an important role in referring drug
users to specialised services. In Greece, the family is a
central institution in society and plays an important role as
a source of referral (National report, 2002) (15).
Opiates (especially heroin) remain the main substances of
abuse among all clients seeking treatment in most countries
(Figure 7). In most EU countries, between 50 % and 70 % of
clients requesting treatment are heroin users, but the figure
varies widely. It is possible to categorise EU Member States
into four groups depending on the extent to which opiates
abuse accounts for referrals to drug-treatment centres:
• below 50 % (Finland, Sweden);
• 50–70 % (Denmark, Germany, France, Ireland, the
Netherlands);
• 70–80 % (Spain, Luxembourg, the United Kingdom); and
• over 80 % (Greece, Italy, Portugal) (16).
It seems that attendees of outpatient treatment centres tend
to be more differentiated than users of other treatment
services (17) either because outpatient clinics specialise in
specific drug-related problems or because such clinics have
developed in response to demand for treatment of different
types of drug abuse (such as cannabis or cocaine abuse)
(Molinae et al., 2002).
In many countries, heroin is followed by cannabis in terms
of the number of users seeking treatment, and the figure is
highest among new clients (24.7 % of the total number of
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Figure 7: All clients admitted to treatment — presented 
by main drug
NB: n = 300 414.
(1) 1999 data. 
(2) 2000 data.
Sources: Reitox national reports (2002). See also Statistical Table 6: Characteristics
of persons treated for drug problems in the EU (online version).
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(18) Figure 6 OL: Distribution of new and all clients by primary drug (online version).
(19) Figure 5 OL: Primary drug among all clients by centre type (online version).
(20) Figure 7 OL: Most used secondary drugs among all clients (online version).
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The trend towards an increase in demand for treatment for
cannabis use (Figure 9) could have several reasons:
increasing prevalence of regular cannabis use, an increase
new admissions are cannabis users) (18); clients requesting
treatment for cannabis use mainly attend outpatient and
inpatient clinics (19). Often, cannabis is used in association
with other substances and is used as a secondary drug (20).
The proportion of people seeking treatment for cannabis
use varies greatly between countries: from 7.3 % in Greece
to 27.2 % in Germany (Figure 7).
Spain (19 %) and the Netherlands (29.9 %) remain the
countries with the highest percentages of clients seeking
treatment for cocaine as their main drug. Rates in other
countries are lower — from 0.8 % in Greece to 7 % in
Luxembourg. A specific study of treatment data conducted in
the Netherlands found that the two largest groups of people
requesting treatment for cocaine use in the last years were
cocaine base/crack users and those using cocaine in
combination with heroin or methadone. Base/crack users
may be particularly challenging for treatment services as
crack cocaine is associated with high levels of dependence
and problems and those who use it, either alone or in
combination with heroin, are often poorly integrated socially
(Mol and van Vlaanderen, 2002).
The drug group for which demand for treatment shows the
widest disparity between countries is amphetamines, with the
proportion of demand accounted for by amphetamine users
being 3 % in Denmark, 8.7 % in Germany, 1.5 % in the
Netherlands, 31.1 % in Finland, 29 % in Sweden, 2.7 % in
the United Kingdom and less than 1 % in the other countries.
Polydrug use is increasingly apparent in treatment data.
In all countries, over 50 % of all clients use at least one
other drug in addition to their first drug, mainly cannabis
(18.4 %) or cocaine (19 %). The most frequently reported
combinations of substances are heroin with cocaine or
cannabis, and cocaine with alcohol or cannabis (National
reports, 2002).
Trends
Common trends across European countries are reported for
treatment demand for heroin and cannabis use; heroin use
appears to be stable or decreasing in all countries, whereas
cannabis use is increasing almost everywhere, especially
among new clients (Figure 8).
Possible reasons for the apparent decrease in the numbers
of heroin users could include the end of the heroin epidemic
that occurred in the late 1980s and early 1990s and the
consequent decrease in requests for treatment; saturation
of treatment services for heroin users; and increased
differentiation of treatment programmes, with more facilities
now available for users of other drugs (including cannabis).
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Figure 8: New clients admitted to treatment for (A) heroin/opiates
use or (B) cannabis use
Figure 8 (A): Heroin/opiates use
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Figure 8 (B): Cannabis use
NB: Data were not available for Belgium, Italy, Luxembourg, Austria and the
United Kingdom. See Statistical Table 7 for the number of cases (online version).
(1) Heroin includes all opiates.
Sources: Reitox national reports (2002). See also Statistical Table 7: Characteristics
of persons treated for drug problems in the EU for the first time.
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(21) Figure 8 OL: New clients admitted to treatment for cocaine use (online version).
(22) Figure 10 OL: Age at first use of main drug among all clients (online version).
(23) Figure 9 OL: Frequency of use of main drug among all clients (last 30 days before starting treatment) (online version).
(24) Table 2 OL: Mean age of clients in treatment (online version).
(25) See Statistical Table 8: Characteristics of women treated for drug problems in the EU; and Statistical Table 9: Characteristics of men treated for drug
problems in the EU (online version).
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in the number of cases reported by the criminal justice
system, market factors (such as greater availability or lower
prices) and an increase in the number of adolescents with
social or psychological problems unable to find other
suitable services. The increase in the number of new clients
demanding treatment for cannabis appears to be
particularly marked in some countries where prevalence
data, seizures of cannabis, cannabis offences and demands
for treatment for cannabis use are following parallel
trajectories (National reports, 2002). Ongoing research in
Germany is focusing on those groups referred to the
treatment services by the justice system and/or social
services for cannabis use; first results seem to indicate that
some young cannabis users meet the criteria for
dependence according to ICD-10 codes (R. Simon, personal
communication, 2002).
Trends in the use of cocaine (21) and other substances are
less homogeneous among countries: in Spain and the
Netherlands, the sharp increase seen in previous years
seems to have slowed down, with demand for treatment now
stable or increasing only slightly, mainly among first-time
clients.
Patterns of use and routes of administration
Mostly, users take drugs for the first time during
adolescence (between 15 and 29 years and in particular
from ages 15 to 19). However, age at first use differs by
substance: 33.6 % of clients start to use cannabis before the
age of 15 and 56.3 % when aged between 15 and
19 years, and 63.3 % use stimulants for the first time at the
same age (15 to 19). In contrast, the age at first use of
heroin and cocaine appears to be higher (more than 40 %
of clients first use heroin and cocaine when aged between
20 and 29 years, and a group even after this age) (22).
Heroin, cocaine and cannabis users demanding treatment,
if they have used drugs in the last 30 days, have usually
taken them on a daily basis, while stimulants are typically
used two to six times a week (23).
The routes of administration of the primary drugs most
frequently reported are injection and smoking for heroin,
snorting or smoking/inhaling for cocaine and
ingestion/drinking for stimulants (Figure 10). Taking into
account the methodological limitations (the sample was not
exactly the same as in the previous year (2001) and there
were fewer unknown data in 2001), a change in patterns
of use has been reported in 2001: fewer clients inject
heroin and more sniff or smoke cocaine. Possible reasons
could be related to market factors, especially price and
availability of smokable heroin and crack/cocaine, and the
impact of prevention and harm-reduction programmes
(EMCDDA, 2002a; National reports, 2002).
Social characteristics
Clients entering treatment tend to be men in their 20s or 30s.
The mean age is 29.8 years overall, and 26.9 years among
first-time clients. Germany, Ireland and Finland have the
youngest treated population, while the oldest clients seeking
treatment are to be found in Spain, Italy and the Netherlands
(24). The age distribution of clients seeking treatment seems to
be correlated with the type of substance consumed — in
general, cannabis consumers are younger, whereas heroin and
cocaine users are older. The highest proportion of cannabis
users is in Germany, while the greatest proportions of cocaine
and heroin users are found in Spain and Italy respectively. The
high proportion of young drug users in Finland might be partly
explained by the relatively late development of drug culture in
that country. The gender distribution varies from a
male–female ratio of 2:1 to 6:1 (25). The higher proportion of
men may reflect generally higher levels of drug use among
males or may be influenced by differential access to services
(EMCDDA, 2002a). Gender distribution patterns tend to be
similar among southern countries or northern countries (e.g.
the proportions of male users are higher in southern countries).
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Figure 9: Trend in demand for treatment for cannabis use,
1996–2001
NB: Valid percentage weighted on the number of clients per country. New clients
only. ‘N’ value varies by year from 31 143 – 56 394. More details are avail-
able in Table 1 OL.
Sources: Reitox national reports (1996 to 2001).
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(26) See ‘Social exclusion and reintegration’, p. 65.
(27) A more detailed insight into this issue is provided in the 2001 Annual report, Chapter 3, Selected issues — Drug-related infectious diseases. Available
online (http://ar2001.emcdda.eu.int). 
(28) See the EMCDDA web site (http://www.emcdda.eu.int/situation/themes/infectious_diseases.shtml) for more detail on methods and guidelines.
(29) For more detail on these data and for original sources, see Statistical Table 10: Summary table of prevalence of HIV infection among injecting drug users
in the EU; and Statistical Table 12: Prevalence of HIV infection (per cent infected) among injecting drug users in the EU and Norway (online version).
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In general, the social conditions of clients demanding
treatment, for example education, living and labour status,
are deteriorating compared with the general population (26).
Drug-related infectious diseases (27)
Prevalence and trends in HIV and AIDS
Infectious diseases related to injecting drug use have a
major impact on the economic and social costs of drug use,
even in countries where HIV prevalence is low (Postma et
al., 2001; Godfrey et al., 2002). They can be prevented by
providing injecting drug users (IDUs) with information about
disease transmission, clean needles (Hurley et al., 1997;
Commonwealth of Australia, 2002) and vaccination against
hepatitis A and B viruses. Effective treatment for HIV and
HCV infections is now available and, as the prevalence of
infections is often very high among IDUs, policies aimed 
at prevention and treatment of infections are highly 
cost-effective.
The EMCDDA is systematically monitoring the prevalence of
HIV infection and hepatitis B and C among IDUs in the
European Union. Information on aggregate prevalence
(overall and within subgroups) is collected from different
routine settings (e.g. drug-treatment or needle-exchange
programmes, prisons) as well as from special studies (28).
Although the data are difficult to compare because they
come from a variety of sources, they provide an overall
impression of differences between countries, regions and
settings. More importantly, following trends over time,
especially prevalence in young and in new injectors, provides
crucial information on the spread of infections among IDUs
and the success of preventative policy measures. The longer-
term aim is to improve data quality and comparability from
existing routine sources and to set up truly comparable local
European seroprevalence studies among IDUs.
The data that are available suggest that the prevalence of
HIV infection among IDUs varies greatly between, as well
as within, countries. The levels of infection reported by
different sources vary from about 1 % in the United
Kingdom (surveys and unlinked anonymous screening) to
over 30 % in Spain (routine diagnostic tests in drug
treatment), but they are, in general, stable (29). This overall
picture has not changed in recent years (Figure 11).
In some countries and regions, HIV prevalence has
remained extremely high among IDUs since 1995. Although
in most cases this reflects old epidemics, special prevention
This is attributable to a difference in the pattern of substances
use between northern and southern countries (the southern
countries have a higher proportion of heroin users, who are
mainly men) and to cultural and social differences.
See http://annualreport.emcdda.eu.int for statistical tables
related to this section:
Statistical Table 6: Characteristics of persons treated for drug
problems in the EU
Statistical Table 7: Characteristics of persons treated for drug
problems in the EU for the first time
Statistical Table 8: Characteristics of women treated for drug
problems in the EU
Statistical Table 9: Characteristics of men treated for drug
problems in the EU
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Figure 10: Route of administration among all clients at EU level
NB: Valid percentage.
Data were not available for France, Ireland, Austria and Portugal for 2000
or for Belgium, France, Italy and Portugal for 2001.
Sources: Reitox national reports (2001, 2002). TDI data (2000, 2001) from out-
patient treatment centres.
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(30) See Box 4 OL: Areas with high HIV prevalence, increases and decreases in HIV transmission among IDUs in some EU countries, HIV prevalence among
young IDUs (online version). 
(31) See Box 4 OL: Areas with high HIV prevalence, increases and decreases in HIV transmission among IDUs in some EU countries, HIV prevalence among
young IDUs (online version).
(32) See Figure 11 OL: Prevalence of HIV infection in Italian IDUs in treatment, by region (online version).
(33) See Statistical Table 15: HIV infections newly diagnosed among injecting drug users in the EU and Norway (online version).
(34) See Box 4 OL: Areas with high HIV prevalence, increases and decreases in HIV transmission among IDUs in some EU countries, HIV prevalence among
young IDUs (online version).
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efforts are very important (e.g. efforts to prevent
transmission to new IDUs, to sexual partners of IDUs and
from mother to child). Prevalence was over 25 % in some
regions and cities (30).
Trends in HIV prevalence provide important information for
making and evaluating policy. More action is needed if
trends suggest that levels of infection are increasing but
may be unnecessary if infection levels appear to be
declining. However, even in areas where prevalence is
stable or decreasing, new infections may still occur. In
recent years, increases in HIV transmission in (subgroups
of) IDUs may have occurred in regions or cities in Spain,
Ireland, Italy, the Netherlands, Austria, Portugal, Finland
and the United Kingdom, although in some of these
countries large decreases were also recorded (31). The
Italian data demonstrate that in countries with significant
numbers of infections national averages are of limited
value, and breakdowns by smaller regions or cities are
important to evaluate the success of prevention (32).
However, few countries can yet provide national data
broken down by region. To facilitate the detection of trends
over time, prevalence data should, ideally, be supplemented
by notifications of newly diagnosed cases. Although not yet
available for the countries with the highest prevalences, and
still highly dependent on testing patterns, in Finland,
notification data have helped reveal new increases in
transmission rates. Recently, Portugal has started to provide
HIV notification data, revealing much higher rates per
million population than the other reporting countries (33).
HIV prevalence among young IDUs may provide further
feedback on the effectiveness of prevention measures, as
infection in young people will typically be more recent than
in the IDU population as a whole. Although sample sizes
are small, these data suggest that infections have occurred
in young IDUs in several regions in recent years (34).
For some countries, information is available on HIV
prevalence among new injectors. This is a much better
indicator of recent HIV infections and may reflect incidence
of HIV infection, thus providing stronger evidence for the
effectiveness of prevention measures. Assuming that
injectors who have been injecting for less than two years
have, on average, been injecting for one year, prevalence
in that group may provide an estimate of incidence. The
available data suggest that incidence per 100 person-years
of exposure among new injectors (95 % confidence
intervals) may vary from 0–3.7 in England and Wales
(0/122, 1998), through 0.8–11.4 in the Belgian Flemish
Community (3/77, 1998–99) and 4.4–14.5 in Coimbra,
Portugal (12/127, 1999–2000), to 4.4–15.5 in France
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Figure 11: Prevalence of HIV infection among IDUs in the EU
Member States and Norway
NB: Figures in brackets are local data. Differences between countries should be
interpreted with caution because of the different source types and use, in some
cases, of local or self-reported data. The colour for each country indicates
the midpoint of the range of prevalence estimates obtained from different data
sources.
This summary map is meant to give a global overview of HIV prevalence among
IDUs in the EU. In this map, data are reported for the most recent year avail-
able. Data from samples with no information on IDU status were excluded. If
this led to exclusion of sources that clearly improve generalisability (e.g. national
data, out-of-treatment data) data from more than one year were combined.
Data for Italy, Portugal and Norway are limited to HIV prevalence among IDUs
in treatment and are not representative of HIV prevalence among IDUs who
are not in treatment. Having health problems is one selection criterion for
admission to drug treatment in some countries or cities (Greece, Portugal,
Rome); because of long waiting lists or special programmes for infected IDUs,
this may result in upward bias of prevalence. Prevalence in this map should
not be compared with previous versions to follow changes over time, as inclu-
sion of sources may vary according to data availability. For time trends, methodo-
logical detail and for sources see Statistical Table 12: Prevalence of HIV infec-
tion (percentage infected) among injecting drug users in the EU and Norway;
and Box 6 OL: Data sources — prevalence (online version).
Sources: Reitox national focal points. For full details and primary sources, see Statistical
Table 10: Summary table of prevalence of HIV infection among injecting
drug users in the EU; and Statistical Table 12 (online version).
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(35) See Statistical Table 15: HIV infections newly diagnosed among injecting drug users in the EU and Norway (online version).
(36) Figure 12 OL: Incidence of AIDS related to injecting drug use in EU Member States (online version).
(37) Box 5 OL: Trends in prevalence of hepatitis C (online version).
(38) See Box 5 OL: Trends in prevalence of hepatitis C (online version).
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infectious than HIV and can be transmitted more easily
through injecting materials other than syringes, such as
cotton, spoons and water (but is very much less readily
transmitted sexually). Both increases and decreases are
found in different regions (38).
(11/111, self-reported serostatus in needle-exchange
scheme attendees, 1998) (35). However, the data from
Belgium, France and Portugal are from routine testing and
may be affected by selection bias. (The data for Portugal
may be an overestimation because of the selection criteria
of detoxification units, which give priority to problematic
and/or seropositive drug users).
AIDS data provide little information for following trends in
new HIV infections because of the long incubation time of
HIV before onset of symptoms of AIDS and the major
improvements in HIV treatment that delay the onset of AIDS.
However, AIDS incidence does reflect trends in the burden
of disease from HIV infection in the different countries. The
incidence of AIDS has fallen in most countries since about
1996 as a result of improved treatment of HIV infection and
possibly lower infection rates in the 1990s. In Portugal, the
latest data show that the incidence of AIDS among IDUs has
been decreasing since 1999 (36). This may indicate
increased uptake of HIV treatment consistent with reports
from the drug-treatment system. 
Prevalence of and trends in hepatitis C virus infection
Data on prevalence of infection with HCV are less readily
available and, where provided, are subject to the same
limitations as the HIV data. However, the overall picture is
clear — HCV prevalence is extremely high in all countries
and settings, with infection levels of between 40 % and
90 % among different countries and subgroups of IDUs
(Figure 12).
Although all prevalence figures show very high levels of
infection, the range is still wide. As for HIV, this may partly
reflect different selection mechanisms in the different data
sources, and comparisons should be made with caution. In
2000 and 2001, levels over 75 % were reported for
Antwerp, Belgium (80 % of IDUs in drug-treatment and low-
threshold services, 2001), Frankfurt and Berlin, Germany
(82–90 % in a low-threshold service and two prisons),
northern Greece and Greece at national level (83 % of IDUs
in methadone-treatment programmes), the Italian regions of
Piedmont, Trentino, Friuli-Venezia Giulia, Liguria, Emilia-
Romagna, Basilicata and Sardinia and the cities of Trento
and Bolzano (drug treatment), and in Lisbon and some
smaller Portuguese cities (drug-treatment clients) (37).
As an indicator of high-risk injecting behaviour (e.g.
sharing needles or other equipment) and the effectiveness of
prevention programmes, trends in HCV prevalence may be
much more sensitive than trends in HIV. HCV is more
26
Figure 12: Prevalence of hepatitis C virus infection among IDUs in
the EU Member States 
NB: Figures in brackets are local data.
Differences between countries should be interpreted with caution because of
different source types and use, in some cases, of local data or saliva tests,
which underestimate prevalence. The colour for a country indicates the mid-
point of the range of prevalence estimates obtained from different data
sources.
This summary map is meant to give a global overview of HCV prevalence
among IDUs in the EU. In this map, data are reported for the most recent year
available. Data from samples with no information on IDU status as well as
self-reported test results were excluded. If this led to exclusion of sources that
clearly improve generalisability (e.g. national data, out-of-treatment data)
data from more than one year were combined. Data for Ireland and
Luxembourg are limited to IDUs in prisons, while data for Italy are limited to
HCV prevalence among IDUs in treatment and are not representative of HCV
prevalence among IDUs who are not in treatment. Having health problems
is one selection criterion for admission to drug treatment in some countries
or cities (Greece, Portugal, Rome); because of long waiting lists or special
programmes for infected IDUs, this may result in upward bias of prevalence.
Prevalence in this map should not be compared with previous versions to fol-
low changes over time, as inclusion of sources may vary according to data
availability. For time trends, more methodological detail and for sources see
Statistical Table 16 and Box 6 OL.
Source: Reitox national focal points. For primary sources, see Statistical Table 16:
Prevalence of hepatitis C infection among injecting drug users in the EU
(online version).
40 < 60 % 
20 < 40 %
0 < 20 %
36–(80)
(30–52)
(91)
72–(73)
32–
(46)
(47–73)
(75–85)
(66–97)
53–80
38–81
79 (61–91)
(49–92)
(45–92)
(40–68)
(48–71) 37
Belgium and Luxembourg
≥ 60 %
(39) See Statistical Table 21: Notified cases of hepatitis C infection among injecting drug users in the EU and Statistical Table 22: Notified cases of hepatitis B
infection among injecting drug users in the EU and Norway (online version).
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As far as they are available, data from treatment
programmes indicate that the prevalence of HCV infection
in IDUs aged under 25 varies from 12 % in Tampere,
Finland (2001), to around 60 % in Dublin, Ireland (1997),
and Italy (1999). Prevalence in young IDUs seems to be
decreasing in Belgium and Greece but increasing in
England and Wales (1998–2001).
Information regarding the prevalence of HCV infection in
new injectors (those who have been injecting for less than
two years) is still not available from most sources. Where
data are available, they generally suggest that the
prevalence is very high — 40 % or more — although lower
figures have been reported from Belgium and the United
Kingdom (Figure 13).
Prevalence of and trends in hepatitis B virus infection
The presence in the blood of antibodies to a virus indicates
that someone has at one time been infected with or
vaccinated against the virus. In contrast to HIV and HCV,
there is an effective vaccine against hepatitis B virus (HBV).
Thus, in the case of HBV, the proportion of IDUs who do not
have antibodies (aHBs or aHBc) against the virus constitutes
the potential vaccination population and is an important
indicator of the need for a vaccination programme. In the
EU, there is greater variation in the proportion of drug
users who have (any type of) antibodies against HBV than
in those with antibodies to HCV. Throughout the EU,
approximately 20–60 % of IDUs have antibodies against
hepatitis B, suggesting a large potential for vaccination
programmes directed at IDUs (40–80 %).
Current hepatitis B infection, as indicated by the presence in
the blood of a serological marker called HbsAg, can be either
recent or chronic. High levels of current infection suggest a
risk of a high future level of severe, long-term complications
and of widespread transmission to others through high-risk
injecting behaviour or unsafe sex. The prevalence of current
HBV infection is recorded in only a few countries, but appears
to differ widely and in some cases is high.
Notified cases of hepatitis B and C
Notification data for HBV and HCV are available for some
countries. Although definitions differ and do not allow
direct comparisons to be made, trends over time may
provide useful information. Reported cases of hepatitis C
seem to have decreased over time in Denmark, Finland and
Sweden, whereas numbers have increased in the
Netherlands and the United Kingdom. In the case of
hepatitis B, decreases have also occurred in Denmark and
Finland, whereas the numbers of cases have increased in
Norway and the United Kingdom. Increased testing may
partly account for increasing trends. The proportion of all
cases accounted for by IDUs is very high (about 90 % in the
case of HCV and 40–70 % in the case of HBV) in most
countries, suggesting that the majority of HBV and almost
all cases of HCV infection in the EU are due to injecting
drug use (39).
See http://annualreport.emcdda.eu.int for further information
related to this section:
Box 6 OL: Data sources — prevalence (for Statistical Tables
10–14, 16–20)
Box 7 OL: Data sources — notifications (for Statistical
Tables 21 and 22)
Statistical Table 10: Summary table of prevalence of HIV
infection among injecting drug users in the EU
Statistical Table 11: Summary table of prevalence of HCV
infection among injecting drug users in the EU
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Figure 13: Prevalence of hepatitis C virus infection among IDUs
who have been injecting for less than two years
NB: Brackets indicate the 95 % confidence interval.
Source: Reitox national focal points. For primary sources, see Statistical Table 18:
Prevalence of hepatitis C infection among new injecting drug users in the EU
(online version).
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(40) Box 8 OL: The methodology and definitions used to estimate drug-related deaths and mortality (online version).
(41) Box 9 OL: Definitions of ‘acute drug-related death’ in EU Member States, as used in the EMCDDA annual report and reported in national reports (online
version).
(42) Box 10 OL: Drug-related deaths — EMCDDA definition (online version). See also the EMCDDA protocol for drug-related death
(http://www.emcdda.eu.int/multimedia/project_reports/situation/drd_standard_3.pdf).
(43) See Statistical Table 24: Number of ‘acute drug-related deaths’ recorded in EU countries (according to national definitions used to report cases to the
EMCDDA), 1985–2001 (online version).
(44) Figure 13 OL: Proportion of drug-related deaths with or without the presence of opiates in the EU countries in 2000–01; and Statistical Table 25: 
Summary of characteristics of victims of acute drug-related death in the EU countries (online version).
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number of drug-related deaths can be a useful indicator of
trends in severe forms of drug use, especially when
analysed together with other indicators.
Drug overdose is an important cause of death among
young people, particularly young men, in most EU
countries. Deaths from AIDS and other causes (violence,
accidents, etc.) account for additional drug-related
mortality, with important differences between countries and
cities. Generally, these deaths are reported from different
data sources.
Drug-related deaths among injectors and opiate users are
much higher than in the general population, and problem
drug use is a major cause of death among young adults in
most EU countries. Studies in the 1990s in some EU cities
(Glasgow, Madrid, Rome) found that a significant
proportion of deaths among young adults could be
attributed to problem drug use (in particular injection of
opiates). Although deaths from AIDS are declining,
overdose deaths are stable or continuing to increase, and
new studies are needed to provide more recent information
on drug-related mortality in other cities.
Impact of drug-related deaths
For the last 10 years, the annual number of acute drug
deaths reported by EU countries in total has varied between
7 000 and 9 000 (43). These figures can be considered as
minimum estimates as it is likely that in most countries there
is some level of under-reporting (which could sometimes be
substantial). Most of the victims are young people and, in
addition, many of these deaths are preventable.
Despite some encouraging findings of a stabilisation or
decrease in the number of drug-related deaths in some
EU countries, in many other EU countries (and in other
parts of the world) overdose deaths continue to increase.
Risk factors
Opiates are present in the blood of most victims of
overdose death due to illegal substances, although
concentrations found in toxicology vary widely, and other
substances are very frequently present (44).
Several risk factors for opiate overdose are known:
administration by injection; concomitant use of other
Statistical Table 12: Prevalence of HIV infection (percentage
infected) among injecting drug users in the EU and Norway
Statistical Table 13: Prevalence of HIV infection among
injecting drug users under age 25 in the EU
Statistical Table 14: Prevalence of HIV infection among new
injecting drug users in the EU
Statistical Table 15: HIV infections newly diagnosed among
injecting drug users in the EU and Norway
Statistical Table 16: Prevalence of hepatitis C infection among
injecting drug users in the EU
Statistical Table 17: Prevalence of hepatitis C infection among
injecting drug users under age 25 in the EU
Statistical Table 18: Prevalence of hepatitis C infection among
new injecting drug users in the EU
Statistical Table 19: Prevalence of current hepatitis B infection
(HbsAg) among injecting drug users in the EU
Statistical Table 20: Prevalence of antibodies against 
hepatitis B virus among injecting drug users in the EU
Statistical Table 21: Notified cases of hepatitis C infection
among injecting drug users in the EU
Statistical Table 22: Notified cases of hepatitis B infection
among injecting drug users in the EU and Norway
Statistical Table 23: Incidence of hepatitis C infection among
injecting drug users in the EU
Drug-related deaths 
and mortality among drug users (40)
National statistics on ‘drug deaths’ usually refer to acute
deaths directly related to drug consumption or ‘overdoses’,
although differences between countries exist (41). The
EMCDDA key indicator ‘Drug-related deaths’ is also
defined in this way (42). The development of the key
indicator has prompted work in different Member States to
improve reporting procedures on drug-related deaths.
Direct comparisons of national statistics should still be made
with caution owing to differences in definitions, reporting
quality and coverage. However, if consistent recording
methods are maintained over time within a country, the
28
(45) Figure 14 OL: Proportion of males and females among victims of drug-related death in the EU countries in 2000–01.
Chapter 1: Drug situation
depressant drugs (e.g. alcohol or benzodiazepines); loss of
tolerance after a period of abstinence (e.g. on release from
prison or discharge from a treatment programme); injecting
in public places (which may be associated with the use of
untested drugs); a long history of opiate dependence; older
age (perhaps as a result of concomitant liver or respiratory
diseases); and possibly unexpected changes in purity
(although studies present divergent results). In addition,
most opiate overdoses take place in the presence of other
users and, as death is usually not immediate, there is time
for intervention. Unfortunately, however, bystanders are
often unable or unwilling to assist because of either lack of
knowledge or fear of police intervention.
The fact that risk factors are well known and that death is
not immediate should mean that it is possible to prevent a
significant proportion of drug overdoses, or at least to
prevent a fatal outcome in many cases, and stresses the
need to implement appropriate interventions, especially for
older injectors and those who have lost tolerance after a
period of relative abstinence.
Characteristics of victims
The majority (80–90 %) of overdose victims in most
EU countries are men (range 69–90 %) (45). This may reflect
the high proportion of men among opiate addicts, as some
studies suggest that the risk of overdose is similar among
men and women. However, in many cases, the proportion
of overdose victims who are men is higher than the
proportion of men among clients admitted to treatment.
Most victims are in their late 20s or 30s and have been
using opiates for several years. Among EU countries, the
mean age of drug-related death victims ranges from
30.2 to 40 years, and in most countries the age of victims
is tending to increase (Figure 14). This trend has also been
reported from countries outside Europe. However, in
Finland and, to a lesser extent, the United Kingdom, there
was an increase in the proportion of younger victims, a
finding that deserves particular attention as it might
indicate an increased incidence of injection or opiate use in
recent years, and in Greece and Sweden no such trend
towards an increase in the age of victims was apparent.
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Figure 14: Changes in the proportion of victims of drug-related deaths over 35 years among EU countries from 1990 (1) until 2000–01
(1) Danmark  1996. Years presented are those with the necessary breakdown or those for which a comparative analysis was possible (same age distribution).
For some countries, ages ranges differ between years (Greece: 1990, ≥ 31; and 2001, ≥ 30; Germany: 1990 and 2001, ≥ 30). In Ireland and Luxembourg the pro-
portion of victims over 35 in 1990 was 0 %.
Sources: Reitox national reports 2002, taken from general mortality registries or special registries (forensic or police). Based on national definitions as presented Box 9 OL: Definitions
of ‘acute drug-related death’ in EU Member States, as used in the EMCDDA annual report and reported in national reports (online versions). See also Statistical
Table 25: Summary of characteristics of victims of acute drug-related death in the EU countries (online version).
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(46) Note that numbers of and trends in drug-related deaths for the EU as a whole are available only up to 2000. Nine countries reported 2001 data, but for
seven countries only 2000 data were available at the time of data collection (autumn 2002). Whenever possible, 2001 information was used for countries that
reported it. 
(47) Figure 15 OL: Trends in acute drug-related deaths among EU countries, 1985–2001 (online version).
(48) See EMCDDA annual report (2002a, p. 17), Figure 10, ‘Route of administration of heroin in Spain, first treatments 1991–2000’ and the section
‘Availability of treatment facilities’ (p. 49) and Table 3 of this report: Development of substitution treatment in the 15 EU Member States and Norway. 
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Trends in acute drug-related deaths
Trends in drug-related deaths vary from country to
country, and even between regions or cities within a
country. With these limitations in mind, some general
trends can be outlined for the EU countries. A marked
increase in the number of drug-related deaths was
observed during the 1980s and early 1990s (Figure 15 A).
During the period 1990–2000, the overall increasing
trend continued, albeit at a lower rate. In 2000,
8 731 acute drug deaths were reported throughout
the EU, compared with 6 394 in 1990 (an increase
of 36.5 %) (Figure 15 B) (46).
This overall trend may reflect the rapid expansion of
heroin injection in many European countries during the
1980s and early 1990s. Recent trends might be related to
the apparent stabilisation of the prevalence of problem
drug use in some countries, a decrease in injection in
others and, probably, the increase of treatment availability
— including substitution programmes. On the other hand,
the increasing age of problem drug users and polydrug
use may contribute to an increase in the number of
fatalities.
It should be emphasised that within the EU different, and
sometimes divergent, national trends exist (47). Many EU
countries continue to report increases in drug deaths up to
the present or very recently, while some report stabilisations
or decreases. Changes in reporting procedures and
reporting quality should always be taken into account when
interpreting national or local trends.
Several countries reported a stabilisation or a downward
trend in the number of acute drug deaths during the second
half of the 1990s. France and Spain showed an apparently
consistent decreasing trend. Although these findings may be
subject to the limitations of under-reporting (in the case of
France) or limited coverage (only five big cities in Spain), it
is important to investigate further the reasons for these
trends. Changes in the route of heroin administration and a
substantial expansion of treatment programmes (especially
substitution treatment) might be influencing these trends (48).
In other countries (Germany, Italy and Austria), the number
of drug deaths has fluctuated in recent years and, thus,
although the number of drug deaths appears to have
stabilised, albeit at a high level, there is no guarantee that
a decrease for two or three years will not be followed by
an increase.
Deaths due to substances other than opiates
Deaths due to overdose of cocaine, amphetamine or 
ecstasy in the absence of opiates are infrequent in Europe.
However, several countries (Spain, France, Italy, the
Netherlands and the United Kingdom) have reported
national or local increases in the number of victims in
whom cocaine was found, generally in addition to other
substances, although information is reported in
heterogeneous ways. Some countries (e.g. Spain and
Portugal) reported the frequent presence of cocaine in the
victims of opiate overdose. In addition, cocaine may
contribute to death from cardiovascular disease and such
deaths may pass unnoticed.
Although deaths associated with ecstasy use arouse
considerable public concern, they are relatively rare
compared with deaths associated with opiates use, despite
the fact that ecstasy use is far more common. The number
of cases in which toxicology findings for ecstasy are
positive has increased as ecstasy use has become more
popular, but, frequently, other substances are also present,
and it is not clear whether death can be attributed solely to
ecstasy. Short- and long-term risks associated with ecstasy
use need to be assessed more accurately. Although adverse
reactions to ecstasy appear to be unpredictable, some
deaths could be prevented by the adoption of relatively
simple measures (e.g. supply of water) in dance clubs, as
well as by improved health education.
Although deaths associated with abuse of volatile
substances generally attract less attention, in countries
where information is available, the numbers of such deaths
are far from negligible. For instance, in the United Kingdom
over the period 1992–2000, such deaths amounted to
64–85 cases per year, with most victims being very young
(Field-Smith et al., 2002). The collection of information
about such deaths should be improved in other countries.
Research clearly shows that substitution treatment reduces
the risk of overdose mortality among programme
participants. However, in several EU countries and cities,
methadone has been detected in a significant number of
victims of drug-related deaths. Several studies have found
that death is more likely to be associated with use of illicit
rather than prescribed methadone, while other studies have
found a higher risk during the initial phases of methadone
substitution. These findings suggest that there is a need to
assure quality standards of substitution programmes.
30
(49) The recently developed ‘Drug strategy definition’ focuses on drugs of abuse (drugs controlled under the Misuse of Drugs Act of 1971 but not indirectly
related deaths such as deaths from AIDS) and is relatively similar to the EMCDDA definition. Using the drug strategy definition, the number of reported cases
almost doubled in England and Wales between 1993 (864) and 2001 (1 623). The application of the EMCDDA definition produces 1 606 cases in England
and Wales in 2000 and 1 443 in 2001. 
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Still other countries have reported substantial upward trends
in the second half of the 1990s (e.g. Greece, Ireland,
Portugal, Finland and Norway); in some cases these may
be partly due to improved reporting. In Portugal, this trend
was reversed in 2000, and the same appears to have
occurred in Finland in 2001. These increases might be
related to the later expansion of heroin use in these
countries, although improved reporting systems may have
played a role in some cases.
The United Kingdom exhibited a steady, although moderate,
increasing trend in acute drug deaths until 2000 according
to the traditional definition (which includes some medicine-
related cases; Office for National Statistics), but if
heroin–morphine cases are considered independently a
much steeper upward trend is evident: a fivefold increase in
2000 compared with 1993 in England and Wales
(Griffiths, 2003) (49).
Finally, in some countries, trends are less clearly defined, or
changes are difficult to interpret because of the switch
between ICD classifications (from 9th to 10th edition),
changes in national definitions or the small number of cases
involved.
The fact that there are no indications of an overall decrease
at EU level emphasises the fact that drug-related health
damage is far from being overcome, and stresses the need
for further investigation of risk factors for drug-related
deaths as well as appropriate targeted interventions.
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Figure 15 (A): Overall long-term trend in acute drug-related
deaths in the EU, 1985–2000 (indexed: 1985 = 100 %)
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Figure 15 (B): Overall recent trend in acute drug-related deaths
in the EU, 1990–2000 (indexed: 1990 = 100 %)
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(1) A few countries did not provide data for some years (see Statistical Table 24: Number of ‘acute drug-related deaths’ recorded in EU countries (according to national
definitions used to report cases to the EMCDDA), 1985–2001 (online version)). To correct this situation, the computation method defined in Project CT99.RTX.04,
EMCDDA (2001) (http://www.emcdda.eu.int/multimedia/project_reports/situation/guidelines_deaths_report.pdf) was used.
In all, 10 countries provided information for 2001 and six did not. The index for 2001 has not been computed. The trends for those countries that provided informa-
tion can be seen in Figure 15 OL: Trends in acute drug-related deaths among EU countries, 1985–2001 (online version). Numbers of cases per country per year are
presented in Statistical Table 24.
Sources: Reitox national reports 2002, taken from general mortality registries or special registries (forensic or police). Based on national definitions as presented in Box 9 OL:
Definitions of ‘acute drug-related death’ in EU Member States, as used in the EMCDDA annual report and reported in national reports (online version).
Figure 15: Trends in acute drug-related deaths in the EU, 1985–2000 (1)
(50) EMCDDA projects CT.99.EP and CT.00.EP.13, Mortality of drug users in the EU, coordinated by the Department of Epidemiology, Rome E Health Authority
(http://www.emcdda.eu.int/situation/themes/death_mortality.shtml).
(51) See Statistical Table 26: Mortality cohorts participating in EMCDDA multi site project — characteristics of participants and results (online version).
(52) SMR estimates the mortality excess (number of times) of problem drug users compared with people of the same age and gender in the general population. 
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problem drug users was, respectively, 24 and 64 times
higher than in individuals of the same age and gender in
the general Spanish population. In Lisbon, Hamburg and
Rome, the risk of death among female problem drug users
was 30- to 40-fold higher than in the general population.
The high SMRs among female problem drug users can be
explained, to some extent, by the low baseline mortality
among young women in the general population.
See http://annualreport.emcdda.eu.int for further information
related to this section:
Box 9 OL: Definitions of ‘acute drug-related death’ in EU
Member States, as used in the EMCDDA annual report and
reported in national reports
Box 10 OL: Drug-related deaths — EMCDDA definition
Statistical Table 24: Number of ‘acute drug-related deaths’
recorded in EU countries (according to national definitions
used to report cases to the EMCDDA), 1985–2001
Overall mortality among problem drug users
Problem drug users account for less than 1 % of the adult
population of the EU, but significant health and social
problems are concentrated within this small group.
Mortality cohort studies show that mortality among problem
drug users is up to 20 times higher than among the general
population of the same age. Much of this high mortality can
be attributed to death from accidental overdose, but other
causes include deaths from AIDS and other infectious
diseases, accidents and suicides. Overdoses and accidental
deaths account for an important part of this mortality in
areas where HIV prevalence among drug users is low,
whereas AIDS plays a significant role in countries with high
injection-related HIV prevalence.
Mortality among injectors is two to four times higher than in
non-injecting problem drug users, and (until recently)
mortality among HIV-infected drug users was two to six times
higher than in non-infected users. With recent improvements
in HIV treatment, this difference appears to be declining.
Trends in mortality among problem drug users
The multi-site study coordinated by the EMCDDA (50) shows
differences in overall mortality rates and distribution of
causes of death between participating sites. The study also
reveals relevant changes over time in overall and cause-
specific mortality (51).
Barcelona presented the highest mortality rates and Vienna
and Dublin the lowest. In several locations, mortality rates
have decreased since the early or mid-1990s. In Barcelona,
rates were particularly high between 1992 and 1996 but
have decreased sharply in recent years, mainly because of
a decrease in deaths due to AIDS. In Lisbon, mortality rates
were increasing until recently (Figure 16).
Direct comparisons across sites should be made with
caution, as there are differences in the typology of
treatment centres where cohorts are recruited, although they
would tend to represent the common types of treatment
available. However, age- and gender-standardised
mortality rates among drug users can provide a useful
measure of the impact of problem drug use on mortality in
different countries.
Analysis of the standardised mortality ratios (SMRs) (52)
from cohorts enrolled within the multi-site study showed that
in Barcelona the risk of death among male and female
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Figure 16: Overall mortality among problem drug users 
in several EU cities or countries
NB: Standardised mortality rates, men and women. Mortality from all causes in
cohorts of opiate users recruited in treatment centres.
There are some differences in typology of recruitment settings (treatment cen-
tres) and treatment modalities across sites, although treatment setting and
modalities tend to represent the common types of treatment available in each
site and therefore the cohorts will tend to be representative of the treatment
using population per site. 
The EMCCDA multi-site study also included a Swedish cohort (see characteristics
of participants in Statistical Table 26 and Bargagli et al., 2002). Presentation of
further results from this cohort has been postponed to allow for Swedish review
of the cohort and additional data analysis. 
For more detailed information see Statistical Table 26: Mortality cohorts par-
ticipating in EMCDDA multi-site project — characteristics of participants
and results (online version).
Sources: EMCDDA projects CT.99.EP.07 and CT.00.EP.13, ‘Mortality of drug users in
the EU’, coordinated by Department of Epidemiology, Rome E Health Authority.
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(53) The term ‘reports’ for drug law offences covers different concepts, varying between countries (police reports of suspected drug law offenders, charges for
drug law offences, etc.). For an exact definition for each country, refer to Box 11 OL: Definitions of ‘reports for drug law offences’ in the EU countries and
Norway (online version). (The term ‘arrests’ was used in previous annual reports.)
(54) Statistical Table 27: Offence type most involved in ‘reports’ for drug offences in the EU countries and Norway (online version). 
(55) In Portugal, drug use has been decriminalised since July 2001. As a result, the proportion of drug offences that were drug use related was lower in 2001
than in 2000, when it was 55 %.
(56) Norway is not able to distinguish between ‘drug dealing/trafficking’ alone and ‘drug use/dealing and trafficking’. The remaining drug law offences are
related to ‘drug use’ alone. 
(57) Statistical Table 28: Drug most involved in ‘reports’ for drug offences in the EU countries and Norway (online version).
(58) Statistical Table 29: Number of ‘reports’ for drug law offences in the EU countries and Norway, 1985–2001 (online version).
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Statistical Table 25: Summary of characteristics of victims
of acute drug-related death in the EU countries
Statistical Table 26: Mortality cohorts participating in
EMCDDA multi-site project — characteristics of participants
and results:
— Characteristics of opiate users enrolled in the cohorts by site
— Standardised mortality ratios (SMRs) by gender and study site
— Distribution of causes of death of cohort participants
Drug-related crime
Drug-related crime can be considered to include criminal
offences in breach of drug legislation, crimes committed
under the influence of illicit drugs, crimes committed by users
to support their drug habit (mainly acquisitive crime and
drug dealing) and systemic crimes committed as part of the
functioning of illicit markets (fight for territories, bribing of
officials, etc.). Except for drug law offences, routinely
available data do not provide information on these
categories and, when available, they come from ad hoc local
studies and are not suitable for extrapolation.
Drug law offences
‘Reports’ (53) of offences against national drug legislation
(use, possession, trafficking, etc.) reflect differences in law
but also the different ways in which the law is enforced and
applied, and the priorities and resources allocated to
specific problems by criminal justice agencies. In addition,
information systems on drug law offences/offenders vary
considerably between countries, especially as regards
recording procedures, definitions and statistical units. These
differences lead to major difficulties when comparing data
from several EU countries. For this reason, whenever
possible, trends, rather than absolute figures, are compared.
The majority of reported drug offences are related to drug use
or possession for use (54) — ranging from 39 % of all drug
law offences in Portugal (55) to 89 % in Austria. In Spain, Italy
and the Netherlands, where drug use is not a criminal
offence, all drug offences relate to dealing or trafficking.
Finally, Luxembourg and Norway (56) report a majority of
offences for both drug use/dealing and drug trafficking.
In 2001, cannabis remained the drug most often involved in
drug law offences — accounting for 34 % of drug-related
reports in Portugal and Sweden and as many as 86 % in
France. In Luxembourg, heroin is the most commonly
involved drug, while in the Netherlands most drug offences
are related to ‘hard drugs’ (drugs other than cannabis and
its derivatives) (57).
Trends
In the EU as a whole, ‘reports’ for drug law offences
steadily increased over the 15 years from 1985 to 2001 (58),
increasing fourfold in the EU as a whole and from less than
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Drug use and crime: some data (1)
Several sources show that a majority of drug users in
treatment have been in contact with the criminal justice
system. Among individuals charged with crimes and
convicted prisoners, studies in Greece (Aristotelian
University of Thessaloniki, 2000) and England and Wales
(Bennett, 2000) show that drug users are more likely than
non-drug users to have committed several types of crimes.
Property crimes are generally identified as the main type of
crime committed by drug users (Aristotelian University of
Thessaloniki, 2000; Bennett, 2000; Meijer et al., 2002).
As regards the link between drug use and crime, a study of
the Irish prison population (Hannon et al., 2000) found that
51 % of men and 69 % of women claimed to be under the
influence of drugs when they committed the crime for which
they were incarcerated. Another study (Millar et al., 1998)
of juvenile suspected offenders in Ireland estimated that
42 % of cases were related to alcohol use, 17 % to drug use
and 4 % to both, alcohol being most likely to be associated
with public order offences, while drugs were most often
associated with robberies.
Though interesting, these results should be seen as an
example rather than as representative of the link between
drug use and crime: first, because they come from studies
carried out in specific populations; second, because they
might vary considerably according to the drug used; and,
third, because a link — especially a causal one — between
drug use and crime is particularly difficult to determine.
(1) The results shown in the box were provided by Greece, Ireland, the
Netherlands and the United Kingdom in their 2002 national reports to
the EMCDDA.
(59) The decrease in Portugal is mainly due to the decriminalisation of drug use since July 2001. 
(60) At the time of writing, 2001 data were not available for Belgium, Norway and the United Kingdom.
(61) See Figure 16 OL: Proportion of ‘reports’ for use/possession offences out of the total of drug law offences, 1996–2001 (online version).
(62) Up to 2000, as at the time of writing 2001 data were not available for the United Kingdom. 
(63) Up to 2000, as at the time of writing 2001 data were not available for the United Kingdom.
(64) See Figure 17 OL: Proportion of reports for cannabis-related offences out of the total of drug law offences, 1996–2001 (online version).
(65) See Figure 18 OL: Proportion of reports for heroin-related offences out of the total of drug law offences, 1996–2001 (online version).
(66) See Figure 19 OL: Proportion of reports for cocaine-related offences out of the total of drug law offences, 1996–2001 (online version).
(67) See Statistical Table 30: Proportion of drug users among prisoners in the EU countries and Norway (online version).
(68) See Figure 20 OL: Estimates of levels of drug use within prison in the EU countries and Norway (online version).
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However, studies show that, compared with the wider
community, drug users are over-represented among the
prison population (67). The proportion of inmates in the EU
reporting ever having used any illicit drug varies between
29 % and 86 % depending on the prisons and countries
(more than 50 % in most studies) (Figure 18). As in the
wider community, cannabis is the most frequently used
drug, but several studies also show high levels of a history
of heroin use (50 % of inmates or more in some cases).
According to several studies, prisoners reporting more
regular and/or harmful use, such as injecting drug use,
regular use or dependence, represent 6–69 % of the prison
population. In particular, several studies in the EU show that
around one-third of adult male prisoners are drug injectors
(Bird and Rotily, 2002).
Most drug users stop or reduce their drug use after
imprisonment. However, some continue to use drugs, and
others only start on incarceration. Drug use within prison is
reported by 12–60 % of inmates and regular drug use by
10–42 %. Between 3 % and 34 % of the prison population
have ever injected drugs while incarcerated (68).
twofold in Denmark, Luxembourg and the Netherlands to
more than sixfold in Ireland and Finland.
Over the last three years for which data are available, the
number of drug-related ‘reports’ increased in most EU
countries. The highest increases were reported by Ireland,
Finland and Norway. However, in 2001, Denmark, France,
Italy, Luxembourg and Portugal (59) reported a fall in the
number of drug-related ‘reports’ (60) (Figure 17).
In all countries for which information was available, the
proportion of all drug law offences accounted for by
offences related to drug use/possession for use generally
increased between 1996 and 1999–2000 (61). Since then,
trends have diverged, with a continuous upward trend in
France, Germany and Norway, a decrease in Luxembourg,
Austria, Portugal and Sweden and stabilisation in the
United Kingdom (62).
In 10 EU Member States, available data enable trends in
the drugs involved in reports of drug law offences to be
determined for the period 1996–2001. Over this period,
the proportion of all drug offences that were cannabis
related generally increased in France, Germany, Italy,
Luxembourg, Portugal and Spain, remained stable in
Sweden and decreased in Ireland, Austria and the United
Kingdom (63). In 2001, marked increases were reported in
Spain, Luxembourg and Portugal (64).
Over the same five-year period, the proportion of reports of
heroin-related offences decreased in all Member States for
which data are available, except in the United Kingdom,
where heroin-related offences have increased year on year
since 1996 (65). The opposite trend is apparent for cocaine-
related offences, with the proportion increasing in all
countries except Germany and Portugal (66).
Drug users in the criminal justice system: prisoners
National routine information on type and patterns of drug
use as well as its consequences among prisoners is rare.
Most of the data available in the EU come from ad hoc
studies carried out at local level using samples of prisoners
that vary considerably in size but are generally small. In
addition, prisons studied are often not representative of the
prison system as a whole and a lack of repeat surveys
prevents analysis of trends in most countries. These factors
make extrapolation of results very difficult.
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Figure 17: ‘Reports’ for drug law offences in the EU countries
and Norway, 1991–2001 — three-year moving averages
indexed (1991 = 100)
NB: For definitions of reports for drug law offences, please refer to Statistical
Table 29: Number of ‘reports’ for drug law offences in the EU countries and
Norway, 1985–2001 (online version). Real values have been input for all
countries in 2001, for Belgium in 1995 and 1997, for Spain in 1996 and
for the United Kingdom and Norway in 2000, as available data do not allow
calculation of moving averages in these cases. The series is discontinued for
Belgium in 1996 (data not available).
Sources: Reitox national focal points.
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NB: Whenever possible, data refer to adult prisoners, although some figures
might also include young offenders. Values shown in the figure were derived
from the following data. Caution in drawing comparisons is necessary as defi-
nitions, periods of reference and methodologies vary widely between sur-
veys and countries. Most data come from local ad hoc studies (not compa-
rable). For additional information on each survey, see Statistical Table 30:
Proportion of drug users among prisoners in the EU countries and Norway.
Belgium
■ 50 % last month drug use before prison, 1999 (n = 246).
■ 9 % regular drug injecting before prison, 1999 (n = 246); 24 % drug 
injecting before prison, 1997 (n = 115).
Denmark
■ 37 % last six months repeated drug use before prison, 2001 (n = 3 445).
Germany
■ 60 % drug users, 1996 (n = 16).
■ 33 % drug injecting before prison, 1997 (n = 437).
Greece
■ 48 % lifetime drug use before prison (n = 136), 2000; 66 % lifetime heroin
use before prison, 1995 (n = 544).
■ 34 % lifetime drug injecting, 1996 (n = 861); 31 % injecting drug users,
1995 (n = 1 183); 69 % drug injecting before prison, 1995 (n = 544).
Spain
■ 43 % last month cannabis use before prison, 2000 (n = 5 028); 31 % last
month cocaine use before prison, 1998 (n = 2 223); 70 % (women) lifetime
drug use (alcohol included), 1998 (n = 356); 35 % (women) regular drug
use (alcohol included), 1998 (n = 356); 56 % drug users, 1998 (n = 10 11).
■ 18 % last month heroin injecting before prison, 1998 (n = 2 223); 47 % drug
injecting before prison, 1997 (n = 101).
France
■ 43 % last year drug use before prison, 1998 (n = 1 212); 32 % last year reg-
ular drug use before prison, 1997 (n = 8 728); 35 % last year cannabis use
before prison, 1997 (n = 960).
■ 12 % lifetime drug injecting before prison, 1998 (n = 1 212); 9 % last year
drug injecting before prison, 1998 (n = 1 212); 6 % last year drug injecting
before prison, 1997 (n = 8 728); 14 % drug injecting before prison, 1997
(n = 960); 23 % lifetime drug injecting before prison, 1996 (n = 574).
Ireland
■ 35 % lifetime heroin use, 1999 (n = 607); 52 % lifetime heroin use, 1998
(n = 1 205); 70 % lifetime heroin use, 1997 (n = n.a.); 86 % (men) lifetime
drug use, 1996 (n = 108).
■ 29 % lifetime drug injecting, 1999 (n = 607); 43 % lifetime drug injecting,
1998 (n = 1 205); 56 % (men) lifetime drug injecting, 1996 (n = 108).
Italy
■ 28 % lifetime drug dependence before prison, 2001 (n = 55 275).
Luxembourg
■ 41 % regular drug injectors, 1998 (n = 362); 32 % regular drug injecting
before prison, 1998 (n = 362).
Netherlands
■ 29 % with drug addiction problems, 1997 (n = 528); 44 % drug addicts, 1997
(n = 319).
Austria
■ 72 % lifetime drug use (in one prison specialising in drug-related offences),
1994 (n = 307).
■ 26 % (men) and 32 % (women) drug injecting before prison, 1999 (n = 143
and 69 respectively); 15 % intravenous drug users, 1996 (estimated by
experts).
Portugal
■ 62 % lifetime drug use, 2001 (n = 2 057).
■ 27 % lifetime injecting drug use before prison, 2001 (n = 2 057); 52 % drug
injecting before prison, 1997 (n = 535).
Finland
■ 58 % lifetime drug use, 2001 (n = 825); 31 % lifetime drug use, 1995 
(n = n.a.).
Sweden
■ 51 % last year injecting or daily drug use before prison, 2000 (n = 3 352).
■ 51 % last year injecting or daily drug use before prison, 2000 (n = 3 352).
England and Wales
■ 84 % (women) lifetime drug use before prison, 2001 (n = 301); 69–85 % life-
time drug use before prison, 1997 (n = 3 140).
■ 38 % (women) lifetime drug injecting before prison, 2001 (n = 301); 24 %
(men) and 29 % (women) lifetime drug injecting, 1997–98 (n = 2 769 and
407 respectively); 23–40 % lifetime drug injecting, 1997 (n = 3 139).
Scotland
■ 32 % (men) and 46 % (women) lifetime drug injecting, 1991–96 (n = 2 286
and 132 respectively).
Sources: Reitox national focal points; see also Statistical Table 30: Proportion of drug
users among prisoners in the EU countries and Norway (online version).
Figure 18: Estimates of lifetime prevalence of drug users in prison in the EU
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(69) See Figure 21 OL: Quantities of drugs seized in the EU countries and Norway (indexes, 1996 = 100), 1996–2000; and Figure 22 OL: Quantities of
cannabis, cocaine, heroin and amphetamines seized in the EU countries and Norway, 1985–2000 (online version).
(70) See Figure 23 OL: Number of drug seizures in the EU countries and Norway (indexes, 1996 = 100), 1996–2000; and Figure 24 OL: Number of
cannabis, heroin, cocaine, amphetamine, ecstasy and LSD seizures in the EU countries and Norway, 1985–2000 (online version).
(71) Caution is required when analysing trends at EU level, as series start at different years in different countries. For more information, see Statistical
Tables 31–43 (online version). 
(72) See Figure 25 OL: Quantities and numbers of drug seizures in EU countries (indexes 1996 = 100), 1996–2000 (online version).
(73) For Italy and the Netherlands: 2001 data on numbers of seizures are missing. For Belgium and the United Kingdom, 2001 data on numbers of seizures
and quantities seized are missing. 
(74) Further information from Europol can be found in Box 12 OL: Drugs trafficking in the EU.
(75) This should be checked against United Kingdom data when available.
(76) As reported in the national reports from these countries.
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all types of illicit drugs occurring in just a few countries.
These include Spain, the Netherlands and the United
Kingdom in the trafficking of cannabis resin, in addition to
Morocco and Pakistan; Spain in cocaine trafficking, along
with the United States, Colombia, Mexico and Panama; and
the Netherlands and the United Kingdom in the trafficking
of synthetic drugs, together with the United States, Thailand
and China (74).
Cannabis
Cannabis is the most seized drug in every Member State
except Portugal, where heroin seizures predominate. Since
1996, Spain has been seizing the largest quantities of
cannabis, more than half the total amount seized in the EU.
Up to 2000, the United Kingdom reported a higher number
of cannabis seizures than Spain, but on average involving
smaller quantities (75).
In 2001, Morocco remained the major producing country
of cannabis resin seized in the EU. Cannabis can be
smuggled directly from Morocco but, in many cases, it
comes via the Iberian Peninsula. Cannabis resin is also
smuggled from the Nordic and Baltic countries to Finland
and from Albania to Italy and Greece. Most cannabis herb
seized in Belgium, Germany, France, Luxembourg and the
Netherlands originates in the Netherlands (76). In addition,
See http://annualreport.emcdda.eu.int for statistical tables related
to this section:
Statistical Table 27: Offence type most involved in ‘reports’ for
drug offences in the EU countries and Norway
Statistical Table 28: Drug most involved in ‘reports’ for drug
offences in the EU countries and Norway
Statistical Table 29: Number of ‘reports’ for drug law offences
in the EU countries and Norway, 1985–2001
Statistical Table 30: Proportion of drug users among prisoners
in the EU countries and Norway
Drug markets and availability
The number of drug seizures in a country is usually
considered to be an indirect indicator of the supply and
availability of drugs, although it also reflects law-enforcement
resources, priorities and strategies, as well as vulnerability of
traffickers to enforcement. Quantities seized (69) may fluctuate
more widely from one year to the next, for example if in one
year a few of the seizures are very large. For this reason, the
number of seizures (70) is considered by several countries to
be a better indicator of trends (71). In all countries, the
number of seizures includes a major proportion of small
seizures at the retail level (72). Where known, origin and
destination of drugs seized may indicate trafficking routes
and producing areas. The price and purity of drugs at retail
level are reported by most of the Member States. However,
data come from a range of different sources which are not
always comparable or reliable, making accurate
comparisons between countries difficult.
As a result of a lack, at the time of writing, of data on
2001 seizures (73) from Belgium, Italy, the Netherlands and
the United Kingdom, analyses of the 2001 situation and of
trends up to 2001 are incomplete. Data on drug seizures in
the EU and Norway in 2001 are detailed in Table 1. In the
text below, trends between 2000 and 2001 have been
inferred from the evolution of the EU totals calculated from
figures from the only countries for which data were
available for both years.
According to Europol, global statistics show a concentration
of drug seizures, with some 75 % of worldwide seizures of
36
Drug availability in 15- to 24-year-olds
The Eurobarometer (EORG, 2002) survey carried out in
2002 on the attitudes to drugs and opinions of young
people in the EU Member States provides data on exposure
to cannabis as well as perceived availability of illicit drugs.
In the EU as a whole, 65 % of respondents claim to know
people who use cannabis, and 46 % have already been
offered cannabis. Depending on the country, 34–69 %
(55 %) (1) consider it easy to obtain drugs near their
school/college, 39–71 % (62 %) near where they live,
46–90 % (72 %) in pubs/clubs and 49–90 % (76 %) at
parties.
(1) Figures in brackets relate to the EU average.
(77) See Figure 26 OL: Number of cannabis seizures, 1996–2001 (indexes) (online version).
(78) See Figure 27 OL: Quantities of cannabis seized, 1996–2001 (indexes) (online version).
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France mentions its own national territory, Italy and Belgium
as other sources of supply for cannabis herb. Cannabis
herb also reaches Greece and Italy from Albania and
Portugal from Angola. Local production of cannabis is
reported in most Member States.
In 2001, the retail price of cannabis resin was reported to
vary, on average, between EUR 2.3 (United Kingdom) and
26.6 (Norway) per gram, and that of cannabis leaves
between EUR 1.9 (Spain) and 8 (Belgium, Sweden) on
average per gram. The content of the active ingredient,
tetrahydrocannabinol (THC), in cannabis resin is usually
between 5 % and 14 %, although samples with a THC content
of 0.15–39 % were reported in the EU in 2001. The average
THC content of cannabis leaves is similar, around 5–11 %,
although in Norway it is typically lower (1–3 %) and it was
reported to reach 34 % in some samples in Germany.
Trends
The number of cannabis seizures (77) increased steadily in
the EU from 1985 but seems to have stabilised since 1999.
In 2001, cannabis seizures increased in Denmark, Spain,
Ireland, Luxembourg, Austria, Finland, Sweden and
Norway. Quantities seized (78) also increased from 1985,
but have stabilised since 1995.
37
n.a., data not available.
(1) Amphetamines data also include metamphetamines.
(2) A small number of amphetamine tablets were also seized in 2001.
(3) One tablet of LSD was also seized in 2001.
(4) 11 026 tablets of amphetamines were also seized in 2001.
(5) 23 seizures and 0.975 kg of methylamphetamines were also seized in 2001.
(6) 10 tablets of LSD were also seized in 2001.
(7) 20 592 tablets of amphetamines were also seized in 2001.
(8) 884 609 ‘nederwiet plants’ were also seized in 2001 (cannabis).
(9) 113 grams of ecstasy was also seized in 2001.
(10) 25 tablets of amphetamines were also seized in 2001.
(11) The number of heroin seizures also includes seizures of liquid heroin.
(12) 100 grams of ecstasy was also seized in 2001.
(13) The number of cannabis seizures includes hashish only.
Sources: Reitox national focal points.
Country Amphetamines Cocaine Cannabis Heroin LSD Ecstasy
Number Quantity Number Quantity Number Quantity Number Quantity Number Quantity Number Quantity
(kg) (kg) (kg) (kg) (doses) (tablets)
Belgium n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Denmark 954 161 815 26 5 788 1 763 1 304 25 29 159 331 150 080
Germany (1) 3 459 263 4 044 1 288 29 824 8 942 7 538 836 289 11 441 4 290 4 576 504
Greece (2) (3) n.a. 0.078 n.a. 297 n.a. 11 926 n.a. 330 n.a. 577 n.a. 58 845
Spain (4) 4 574 18 26 127 33 681 74 391 518 620 11 800 631 n.a. 26 535 11 947 860 164
France 111 57 1 583 2 094 45 789 62 121 2 652 351 115 6 718 1 589 1 503 773
Ireland (5) (6) 162 18 300 5 6 233 10 157 802 30 6 323 1 485 469 862
Italy n.a. 0.6 n.a. 1 808 n.a. 53 078 n.a. 2 005 n.a. 1 139 n.a. n.a.
Luxembourg 7 0 58 8 490 16 211 1 1 1 17 8 359
Netherlands (7) (8) (9) n.a. 579 n.a. 8 389 n.a. 33 419 n.a. 739 n.a. 28 731 n.a. 3 684 505
Austria 161 3 768 108 5 249 456 895 288 32 572 352 256 299
Portugal (10) (11) (12) 4 0 1 100 5 575 2 411 6 707 2 430 316 6 3 588 160 126 451
Finland (13) 3 778 137 55 7 5 846 622 557 8 14 1 026 465 81 228
Sweden 5 513 231 328 39 6 935 739 1 271 32 28 629 595 86 336
UK n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Norway 4 214 93 477 21 10 254 861 2 501 68 52 417 829 61 575
Total n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Table 1: Drug seizures in the EU countries and Norway, 2001
(79) Figure 28 OL: Number of heroin seizures, 1996–2001 (indexes) (online version).
(80) Figure 29 OL: Quantities of heroin seized, 1996–2001 (indexes) (online version).
(81) Although this should be checked against missing 2001 data when available.
(82) Further information from Europol is given in Box 13 OL: Cocaine trafficking (online version).
(83) See Figure 30 OL: Number of cocaine seizures, 1996–2001 (indexes) (online version). 
(84) This should be checked against 2001 missing data when available.
(85) See Figure 31 OL: Quantities of cocaine seized, 1996–2001 (indexes) (online version).
(86) This situation should be checked against 2001 United Kingdom data when available.
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Cocaine
Spain remains the EU country with the highest level of
cocaine seizures, in 2001 accounting for more than half (81)
of the EU total for both number of seizures and quantities
seized. The cocaine seized in Europe comes from Latin
America (mainly from Andean countries such as Peru and
Colombia, but also from Ecuador), directly or via Central
America, Spain and/or the Netherlands. Although Spain
has been reported by some EU countries to be a transit
country for cocaine into the EU, the Spanish authorities
report that that there was no evidence of big shipments of
cocaine in Spain corresponding to international trafficking.
According to Europol, some 200 tonnes of cocaine enters
the EU each year via maritime shipments and air couriers,
facilitated by the presence of large ports and airports (82).
The retail price of cocaine in 2001 varied from EUR 47 to
187 per gram on average. The lowest prices were found in
Spain, and the highest in Finland and Norway. Cocaine
purity is generally high, between 45 % and 80 % in most
countries, except in Ireland, where it was on average lower
(23 %) in 2001.
Trends
The total number of cocaine seizures (83) in the EU has risen
steadily since the mid-1980s — apart from a decrease in
2000 — and seems to have continued to rise in 2001 (84).
The quantities of cocaine seized (85) also fluctuated within
the context of an overall upward trend between 1985 and
2001. In 2001, a marked increase was reported — mainly
due to a large increase in the total amount of cocaine
seized by Spain.
Cocaine street prices have stabilised or decreased in all
countries in recent years, but increased in 2001 in Norway.
Cocaine purity remains generally stable or is decreasing in
every Member State, though increases were reported in
2001 by Denmark, Germany, Portugal and the United
Kingdom.
Synthetic drugs: amphetamines, ecstasy and LSD
In Finland, Sweden and Norway, amphetamines are the
second most commonly seized drug (after cannabis).
Ecstasy is the second most seized drug in Ireland. In the last
five years, the largest quantities of amphetamines and
ecstasy seizures have been in the United Kingdom (86).
The retail price of cannabis has generally been stable in the
EU, except in the United Kingdom, which reports a
downward trend in the last four years. In 2001, the price
increased in Belgium, France, Luxembourg, the Netherlands
(leaves) and Norway (resin). In 2001, Portugal and the
United Kingdom reported an increase in the purity of
cannabis resin and leaves at street level. Cannabis resin
purity also rose in Belgium and Italy.
Heroin
In 2000, almost nine tonnes of heroin was seized in the EU,
of which over one-third was seized in the United Kingdom.
Heroin seized in the EU comes mainly from Afghanistan
(and Pakistan), followed by South-East Asian countries, via
Iran, Turkey and the Balkan route. However, increased
trafficking via eastern Europe (Russia, Estonia, Byelorussia,
Bosnia) and central Asian countries from the former USSR is
reported.
At street level, heroin prices in 2001, on average, varied
from EUR 31 to 194 per gram across the EU. The highest
prices are reported in the Nordic countries and Ireland.
Heroin (white or brown) average purity ranges from 14 %
to 48 %, but in 2001 Norway reported a higher average
purity of white heroin.
Trends
At EU level, heroin seizures (79) increased up until 1991–92
and then stabilised. In 2001, they decreased in Denmark,
Germany, France, Luxembourg and Portugal. Compared
with the situation in 1985, quantities seized (80) at EU level
have been increasing. They stabilised during the period
1991–98, but have been increasing again since then. In
2001, a majority of countries reported increases in the
amount of heroin seized. According to Europol, the
spectacular decrease in Afghan opium production in 2001
was not reflected to the same extent in the availability of
heroin in the EU drugs market, probably because of the
vast opium and heroin stocks that built up after the record
harvests of 1999 and 2000.
Heroin street prices are generally stable or decreasing,
though in 2001 an increase was reported in Belgium
(brown heroin) and Denmark. Heroin purity is generally
reported to be stable or decreasing in all countries,
although recently the purity of brown heroin has increased
in Belgium, Denmark, Ireland and the United Kingdom.
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(87) Further information from Europol is given in Box 14 OL: Synthetic drugs trafficking (online version).
(88) See Figure 32 OL: Number of amphetamine seizures, 1996–2001 (indexes) (online version).
(89) See Figure 33 OL: Quantities of amphetamine seized, 1996–2001 (indexes) (online version).
(90) This trend should be checked against 2001 missing data (especially from the United Kingdom) when available.
(91) This trend should be checked against 2001 missing data (especially from the United Kingdom) when available.
(92) See Figure 34 OL: Number of ecstasy seizures, 1996–2001 (indexes) (online version).
(93) See Figure 35 OL: Quantities of ecstasy seized, 1996–2001 (indexes) (online version).
(94) See Figure 36 OL: Number of LSD seizures, 1996–2001 (indexes) (online version). 
(95) See Figure 37 OL: Quantities of LSD seized, 1996–2001 (indexes) (online version)
(96) This trend should be checked against 2001 missing data when available. 
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According to Europol (87), the number of production sites for
synthetic drugs discovered each year in the EU is consistent at
around 50–70. However, although the number of production
facilities is relatively stable, advances in methodology,
increased sophistication of manufacturing equipment and
increasing involvement of specialists is resulting in ever-
increasing production efficiency and capacity. For the time
being, the Netherlands, and to a lesser extent Belgium, are
major sites for the production of ecstasy, amphetamines and
related drugs, but production in other Member States (Spain,
France, the United Kingdom) and in central and east
European countries (the Czech Republic, Estonia, Lithuania,
Poland), as well as in Thailand, is also reported. According to
Europol, while the European Union remains the primary
source of ecstasy, production is spreading worldwide, with
facilities discovered in South-East Asia, China, North
America, South Africa and South America.
The price of amphetamines is reported to be, on average,
between EUR 12 and 40 per gram, while ecstasy tablets cost
between EUR 6 and 20 each on average. Data for 2001
show that synthetic drugs are cheapest in Belgium and the
United Kingdom. Amphetamine purity is very variable, from
2 % in Ireland to 52 % in Norway. Most tablets sold as
ecstasy do in fact contain ecstasy or ecstasy-like substances
(MDMA, MDEA, MDA), varying from 58 % of the tablets
analysed in Finland to 99 % in Germany, Spain, the United
Kingdom and Norway and 100 % in Portugal.
Amphetamines (or metamphetamines) are found in 2–20 %
of tablets, but various other psychoactive substances (2-CB,
2-CT7, 4-MTA, MDE, PMA and PMMA) may also be found.
Trends
Amphetamine seizures — both numbers (88) and
quantities (89) — increased throughout the EU between
1985 and 1998 or 1999. The number of amphetamine
seizures fell in 1999 and 2000, mostly because of a
decrease in the United Kingdom, but apparently increased
again in 2001 at EU level (90). Quantities seized decreased
between 1998 and 2000, but rose again in 2001 in
a majority of countries (91).
Ecstasy seizures (92) have been increasing in most of the
EU since 1985 — except in 1997 and 1998 — with marked
increases in 2001, especially in Spain, which reported
11 947 ecstasy seizures in 2001 (compared with 3 750 in
2000). The amounts of ecstasy seized (93) followed the same
upward trend from 1985 until 1993, when they stabilised.
However, this was followed by a peak in 1996, and
quantities seized have, since 1999, again been increasing.
At EU level, the number of ecstasy tablets seized seems to
have stabilised in 2001, but this trend should be further
confirmed by the United Kingdom data, as the United
Kingdom is the main ecstasy-seizing country in the EU. LSD
seizures are less common. At EU level, both numbers (94)
and quantities (95) increased until 1993, and decreased from
then on (96), except for a slight increase in 2000.
Following significant decreases in the 1990s, amphetamine
and ecstasy prices have stabilised in the EU. However, in
2001, Norway reported a significant decrease in the price
of amphetamines sold at street level. The average price of
ecstasy tablets decreased in 2001 in most countries. In
2001, the proportion of tablets containing ecstasy or
ecstasy-like substances increased in Belgium, Denmark,
Portugal and Spain, while those containing amphetamines
(and metamphetamines) decreased. Finland reported the
opposite, as well as a high proportion of tablets containing
buprenorphine (23 %).
See http://annualreport.emcdda.eu.int for statistical tables related
to this section:
Statistical Table 31: Number of seizures and quantities seized
(all drugs), 2001
Statistical Table 32: Number of amphetamine seizures, 1985–2001
Statistical Table 33: Number of cannabis seizures, 1985–2001
Statistical Table 34: Number of cocaine seizures, 1985–2001
Statistical Table 35: Number of ecstasy seizures, 1985–2001
Statistical Table 36: Number of heroin seizures, 1985–2001
Statistical Table 37: Number of LSD seizures, 1985–2001
Statistical Table 38: Quantities of amphetamine seized,
1985–2001 (kg)
Statistical Table 39: Quantities of cannabis seized, 1985–2001 (kg)
Statistical Table 40: Quantities of cocaine seized, 1985–2001 (kg)
Statistical Table 41: Quantities of ecstasy seized, 1985–2001 (tablets)
Statistical Table 42: Quantities of heroin seized, 1985–2001 (kg)
Statistical Table 43: Quantities of LSD seized, 1985–2001 (doses)
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(97) This report focuses on new developments. A full picture of national strategies and coordination in the field of drugs is provided at:
http://www.emcdda.eu.int/policy_law/national/strategies/strategies.shtml.
(98) Available at http://www.emcdda.eu.int/policy_law/national/strategies/strategies.shtml.
(99) The ‘gateway effect or theory’ implies the existence of a sequential stage of progression in the use of drugs. For further information, see ODCCP (2000). 
National drug policy developments
Reorganisation in drug coordination systems
The trend observed in recent years to organise national
drug policy through national action plans and coordinated
systems continued in 2002 (97). Germany, Italy, some
Austrian provinces, Sweden and Norway joined other
EU partners in adopting a coherent drugs plan, programme
or strategy. However, it is interesting to note how this area
is subject to frequent changes. Often, changes in
government result in a change in drugs strategy or the
organisation of drugs agencies.
In Portugal, the new government that took office in 2002
merged the Portuguese Institute for Drugs and Drug
Addiction (IPDT) and the Service for the Prevention and
Treatment of Drug Abuse (SPTT) into the IDT (Instituto da
Droga e da Toxicodependência), and transferred
responsibility for the new agency from the Presidency of the
Council to the Ministry of Health. In the United Kingdom,
following its re-election in 2001, the government presented
an updated drug strategy in December 2002 for England
and also instituted some restructuring within its local crime
reduction partnership. Drug action teams were restructured
in 2000 to conform to the boundaries of local authorities.
In Norway, the Central Health and Social Administration
was reorganised to place more emphasis on knowledge
and experience as a basis for strategic planning and
development of drug policy, while in Ireland the new
government (2002) assigned responsibility for the national
drugs strategy 2001–08 to the newly created Department of
Community, Rural and Gaeltacht Affairs. A Minister of State
was appointed with responsibility for the national drugs
strategy and community affairs, and for housing and urban
renewal — areas which in Ireland are considered to be
interlinked. In addition, the government highlighted
initiatives to tackle drug abuse and crime and to regenerate
disadvantaged communities aimed at ‘building a caring
society’. In Austria, the Federal Criminal Agency was
created within the Ministry of the Interior to ensure greater
coordination in combating crime. Moreover, and for the
first time in Austria, staff resources have been allocated to
the Federal Drug Coordination, which is in charge of
coordination of drug policy at federal level.
The EMCDDA constantly monitors these trends, patterns and
changes, and in December 2002 published an online
comparative study of drug strategies and coordination in
the field of drugs (98).
Public perception of drugs and drug policy
Members of the public are becoming increasingly aware of
drug abuse and its consequences and are taking an interest
in national drug policy. However, the results of several
surveys and opinion polls show that attitudes to drugs are
not uniform throughout the EU.
A survey conducted in Voralberg, Austria, found that 63 %
of students and 40–45 % of adults are opposed to
punishment for cannabis use by persons over 18. In
Vienna, 78 % of people surveyed expressed the opinion
that cannabis should be prohibited but favoured
decriminalisation for drug addicts, constituting a large
proportion of the 86 % who agreed that drug addicts
should receive therapy rather than punishment. Another
survey, conducted in Spain in 2002 by the Centro de
Investigaciones Sociológicas, found that drugs and alcohol
are perceived as an important social problem, behind
unemployment and terrorism, but ahead of delinquency and
civic insecurity. In France, the percentage of people in
favour of cannabis being sold openly rose from 17 % in
1999 to 24 % in 2002, and almost three quarters of French
people (Beck et al., 2002) think that it is not possible to
achieve a world without drugs. However, half of
respondents believed that experimentation with cannabis is
dangerous, two thirds of people questioned believed in the
‘gateway effect’ (99) and 65 % opposed decriminalisation of
cannabis even under certain conditions (while 88 %
opposed decriminalisation of heroin use). In Ireland, a
survey of attitudes to cannabis use conducted by
Lansdowne Market Research (involving face-to-face
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This chapter presents an overview of developments in national and EU drug policies
and strategies. Responses to the drugs problem in the fields of education, healthcare, 
social care, criminal justice and supply reduction are also covered.
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dependency. As a result, drug-treatment centres were able
to admit residents directly from anywhere in the country
and, with the authority of a certificate of dependence,
require a drug user’s local SerT (drug addiction service) to
pay for the treatment provided. However, following an
amendment to the Italian Constitution, transferring
competence for healthcare and social care from the central
to regional administrations, the Constitutional Court
determined that the decree was unconstitutional as it
concerned a matter that was the responsibility of the
regions. In Norway, the State assumed ownership and
operational responsibility for hospitals in 2002, and
responsibility for low-threshold health services and
medically assisted rehabilitation of drug abusers resides
with the Ministry of Health. County responsibility for
specialist health services for drug abusers should be
transferred to the State in 2004, and the Ministry of Social
Affairs has proposed that county responsibility for specialist
social services and care of drug abusers should be
transferred to the municipalities as of 2004. This aims to
provide drug abusers with a more comprehensive and
coherent system of care and treatment measures.
In Austria, there is a problem providing the health-related
measures required by Article 11 of the Narcotic Substances
Act. Officially, effort should focus on the elimination of
(organised) drug trafficking, but despite this a large
proportion of offences concern cannabis use, for which
district health authorities usually, under Article 11,
prescribe health-related measures. As a result, drug-
treatment centres do not have sufficient resources to meet
demand and are unable to fulfil their responsibilities.
Monitoring of traffickers
Against a background of increased security, a number of
countries report legal changes to improve monitoring of
traffickers and users. In Denmark, a law that came into
force in June 2002 requires providers of
telecommunications services to record and store for one
year any telecommunications and Internet communication
data that may prove relevant to police investigations.
Provided they have a court warrant, police may now, using
computer programs or other equipment, read non-public
data held on computers. Similarly, in Portugal, a law
introduced in January 2002 established special measures
(in the areas of evidence collection, information
confidentiality and confiscation of assets) to help fight
organised financial crime and other serious crimes,
including drug trafficking. In Finland, an amendment to the
Police Act extended the rights of the police to acquire
telecommunications information (e.g. in cases of suspected
interviews of a national representative sample of
1 159 adults aged 15 years and older), indicated that
opinion is highly variable. While almost two thirds of those
eligible to vote (18 years and over) felt that cannabis
should be allowed for medical reasons (provided medical
benefit had been proven), only a minority (one in seven)
were in favour of outright legalisation. The low level of
support for legalisation probably reflects the fact that
cannabis is believed to be a gateway drug. In the United
Kingdom, the reclassification of cannabis from a class B to
a class C drug stimulated a widespread debate, with some
people for and others against the reclassification.
Legal developments
Legal developments over the reporting period have
occurred in the areas of improved treatment and
rehabilitation conditions for addicts, State monitoring of
traffickers and users and stronger action against breaches
of public order and nuisance caused by drugs at street
level.
Treatment and rehabilitation
Last year, several countries in the EU introduced legislative
changes to facilitate the treatment and rehabilitation of
addicts. In Luxembourg, a national decree established the
legal framework for drug substitution treatment at the
national level, with a licensing system for doctors,
admission criteria for patients and a committee for
surveillance of the programme. In Greece, a pilot scheme
authorising buprenorphine substitution was implemented in
the public general hospital in Rhodes. In Finland, opiate
addicts are entitled to receive detoxification and substitution
treatment, complemented by maintenance treatment, and as
a result there has been an increase in the number of units
assessing the need for and providing pharmaceutical
treatment of drug addicts. And in Germany, since the ninth
book of the German Social Security Code came into effect
in July last year, addicts have benefited from improved
rights and legislation that defines more clearly how and
when health insurance schemes should pay for
detoxification and pension insurance schemes should pay
for rehabilitation.
In April 2002, the Danish Parliament decided to abolish
legal provisions which, although they had never been
implemented, had previously allowed county authorities to
retain drug addicts in treatment. And in June last year, a
ministerial decree in Italy, in line with the national drugs
plan and aiming to improve abstinence-focused treatment,
gave private treatment services the authority to certify drug
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drug-related crime) and to engage in technical surveillance.
In 2002, the government also put forward the Coercive
Means Act. This will extend the means for telesurveillance
and monitoring communications although the details are
still to be specified.
In January 2002, the Code of Criminal Procedure of the
Netherlands was changed to allow, in addition to body
cavity searching, the use of X-rays and ultrasound scans in
anyone suspected of having swallowed small packages of
drugs, provided these procedures are carried out by a
physician. User detection techniques also increased, and
last summer the United Kingdom’s drug-testing pilot
programme in England and Wales was extended. This
scheme allows samples to be taken from adults in police
detention who are charged with a ‘trigger offence’ (mainly
acquisitive crimes and drug offences) in order to test for
heroin and cocaine. Those who test positive are offered the
opportunity to see an arrest referral worker for an
assessment for treatment, and the drug test results are made
available to the courts to assist with bail and sentencing
decisions. Early pilot findings were published in March
2003. Drug testing on charge is being extended during
2003 to 30 high-crime police basic command units (police
divisions within a police area) in the United Kingdom.
Measures to reduce public order/nuisance offences
Over the last year, legislative provisions in some Member
States have aimed at minimising the social impact of drug
use by providing stricter control of public order and public
nuisance.
In Ireland, the Criminal Justice (Public Order) Bill, 2002,
was introduced to strengthen the 1994 Act relating to
public order. Persons convicted under the 1994 Act for a
public order offence, including intoxication (by drug use) in
public, and who could endanger themselves or others, may
be issued with an exclusion order prohibiting them from
entering or being in certain premises, including licensed
premises, dance halls or premises that serve food.
In the United Kingdom, Section 8 of the Misuse of Drugs
Act, which applies to individual occupiers and managers of
certain types of premises, was amended to cover the
unlawful consumption of any controlled drug (previously it
applied only to smoking of cannabis or opium) in order to
deal with crack houses. However, these powers are wide in
scope, and the government has subsequently decided that
the Section 8 proposals may not be sufficiently effective in
dealing with this problem. Consequently, it is seeking to
introduce new legislation in the form of the Anti-Social
Behaviour Bill, which is targeted at premises rather than
individuals, which will enable the police, in consultation
with local authorities, to shut crack houses within 48 hours.
Consequently, the UK is not intending to implement the
amendment to Section 8(d) for the time being, although this
may yet be the case if the sanctions incorporated in the
Anti-Social Behaviour Bill are found to be less than
completely effective over the next two years.
In the Netherlands, the 1997 Victoria Act gave town
mayors the power to close down premises where drug use
or trafficking was causing a public nuisance. However, as
the closure of buildings may adversely affect the
appearance and social structure of a neighbourhood, the
new Victor Act of May 2002 allowed municipalities to
reassign closed premises, for example by permitting new
tenants to move in. In the city of Venlo, a four-year pilot
project involving police, prosecutors and the government is
aimed at reducing the nuisance caused by the many drug
tourists who buy cannabis at unlicensed coffee shops. And
in July 2002, the mayor of Rotterdam, exercising powers
provided under the Municipality Act, personally imposed a
six-month ban on about 50 drug addicts who were
troubling the residents of a local borough. However, the
regional court decided that, although the mayor was
entitled to combat nuisance, a six-month ban was too long
and not justified; despite this, the city of Rotterdam intends
to continue with its banning policy.
In Denmark, an act prohibiting visiting in certain premises
became effective in June 2001. The objective of the act is to
provide more effective intervention in relation to cannabis
clubs and other types of organised crime being perpetrated
on premises and causing concern to neighbours. It allows
the police, after advance warning, to issue a three-month
injunction against the owner of such premises, prohibiting
visitors from arriving or staying there. Violation of a
injunction is punishable by a fine, with repeated violations
attracting a prison sentence of up to four months.
Developments at EU level
In November 2002, the European Commission issued a
communication regarding the mid-term evaluation of the
EU action plan on drugs (2000–04) (100). The aim of this
mid-term evaluation was to assess the level of achievement
of the activities set out in the action plan. As the EU action
plan comprises actions to be undertaken by the Member
States, the European Commission, the EMCDDA and
Europol, the mid-term evaluation was based on
complementary tools, including the replies of the Member
States to a questionnaire and a follow-up table of the
achievements of the Commission, the EMCDDA and
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(101) See http://europa.eu.int/comm/public_opinion/archives/eb/ebs_172_en.pdf.
(102) Attitudes and opinions of young people aged 15–24 in a sampling which is representative of the EU.
(103) 2002/188/JHA: Council decision of 28 February 2002 concerning control measures and criminal sanctions in respect of the new synthetic drug PMMA
(OJ L 063, 6.3.2000, p. 14). Proposal for a Council decision defining PMMA as a new synthetic drug which is to be made subject to control measures and
criminal provisions ((COM)2001 734 final).
(104) Decision No 1786/2002/EC of the European Parliament and of the Council of 23 September 2002 adopting a programme of Community action in the
field of public health (2003–08) (OJ L 271, 9.10.2002, pp. 1–12).
(105) Proposal for a Council recommendation on the prevention and reduction of risks associated with drug dependence ((COM)2002 201 final). Proposal for a
regulation of the European Parliament and of the Council on drug precursors ((COM)2002 494 final, OJ C 20 E, 28.1.2003, pp. 160–170).
(106) Agreement between the European Community and the Turkish Republic on precursors and chemical substances frequently used in the illicit manufacture of
narcotic drugs or psychotropic substances (OJ L 64, 7.3.2003, pp. 30–35). 
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On 28 February 2002, the European Council adopted a
decision concerning control measures and criminal
sanctions in respect of a new synthetic drug, PMMA. PMMA
is not currently listed in any of the schedules to the 1971
United Nations Convention on Psychotropic Substances, but,
as a result of this decision, PMMA is now subject to control
measures and criminal provisions within the Member
States (103).
Another important development is Decision
No 1786/2002/EC of the European Parliament and of the
Council of 23 September 2002, which instigates a
programme of Community action in the field of public
health (2003–08) (104). The aims of the programme are:
• to improve information and knowledge to further the
development of public health;
• to enhance capability to respond rapidly and in a
coordinated fashion to threats to health;
• to promote health and prevent disease by addressing
health determinants across all policies and activities.
This programme will, among other things, support
implementation of monitoring and rapid reaction systems
and actions in the field of health determinants. Both
areas should allow follow-up of initiatives launched by
stakeholders in Member States in the context of the
programme of Community action on the prevention of
drug dependence within the framework for action
in the field of public health (1996–2000 and extended
to 2002).
In 2002, the European Commission also made some
proposals, discussed by the Council during the reporting
period (March 2003), that concern the drugs field: one is
related to reduction of risks associated with drug
dependence and the other to drug precursors (105). In
December, the European Community concluded an
agreement with the Republic of Turkey on precursors and
chemical substances frequently used for the illicit
manufacture of narcotic drugs and psychotropic
substances (106).
Europol. These were supplemented by the results of the peer
evaluation of law-enforcement systems in the Member States
and information on drug-related initiatives at the EU level.
The communication summarised achievements in each area
covered by the action plan and highlighted the areas where
progress is needed at each level.
While acknowledging achievements, the Commission
stressed that much work remains to be done, including the
development of systems of evaluation of national and EU
activities. It also stressed the need to cooperate closely with
the candidate countries to ensure their future contribution to
the European Union drugs strategy. The document sets out
methodological bases for the final evaluation. In particular,
the Commission proposed to pursue the evaluation process
with the support of a steering group including
representatives from the Commission, the European
Parliament, the Council Presidency, Europol and the
EMCDDA. This group will help to create the final evaluation
setting. As part of the final evaluation, the EMCDDA will
compare data available in 2004 in the field of drugs with
the 1999 baseline it produced in association with Europol.
The EMCDDA will also assist the Commission in
implementing the second Eurobarometer study on youth
attitudes and drugs and update the follow-up table on
activities of the EMCDDA. It should be noted that, according
to a special Eurobarometer survey entitled ‘Attitudes and
opinions of young people in the European Union on drugs’
(2002) (101), the two most effective ways of tackling drug-
related problems in Europe are tougher measures against
drug dealers and traffickers (supported by 59.1 % of the
sample, EU-15) and improved treatment and rehabilitation
services for drug users (favoured by 53.2 %, EU-15) (102).
The Council of the European Union has also adopted an
implementation plan on actions to be taken on synthetic
drugs, which sets out a number of issues with regard to the
supply of synthetic drugs that should be further addressed
by the European Union over the coming years. The plan
proposes actions to address the problems identified and
defines appropriate bodies to take the work forward within
specified timeframes.
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(107) See www.school-and-drugs.org.
(108) See Drugs in focus No 5 at http://www.emcdda.eu.int/multimedia/publications/Policy_briefings/pb4_6/pb_05_EN.pdf.
(109) See Figure 38 OL: National plans for school-based prevention (online version).
(110) See Figure 39 OL: Organisation of prevention (online version).
(111) See Table 3 OL: Overview on policies and frameworks for prevention (online version).
(112) See Drugs in focus No 5 at http://www.emcdda.eu.int/multimedia/publications/Policy_briefings/pb4_6/pb_05_EN.pdf.
(113) See Drugs in focus No 5 at http://www.emcdda.eu.int/multimedia/publications/Policy_briefings/pb4_6/pb_05_EN.pdf.
(114) See Drugs in focus No 5 at http://www.emcdda.eu.int/multimedia/publications/Policy_briefings/pb4_6/pb_05_EN.pdf.
(115) See Table 4 OL: Main quantitative parameters of school-based prevention programmes (online version).
(116) See Table 5 OL: Prevention programmes in schools and kindergarten (online version).
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Prevention
Prevention is often divided into ‘universal’ prevention
(targeting children and young people in general and
implying a no-use objective) and ‘targeted’ or ‘indicated’
prevention (aimed at particular high-risk groups). The latter
is discussed in Chapter 3 (p. 63). School is the preferred
setting for universal prevention interventions as this
environment guarantees long-term and continuous access to
large populations of young people. A recent research
project on good practices in school-based prevention,
funded by the European Commission (107), drafted
recommendations for school-based prevention programmes
as well as for necessary frameworks: school policy and
school environment. There is a broad evidence base from
the international literature identifying approaches that are
potentially promising or confirmed to be effective (108).
In all Member States, prevention is included in school
curricula, in the sense that the topic ‘drugs’ has to be dealt
with in one way or other, but this might simply mean that
teachers or police officers provide information about drugs
and risks. Purely informative and unstructured approaches
have been found to be ineffective (Hansen, 1992; Tobler,
2001). Only a few Member States have national plans for
school-based prevention that detail the scope of actions to
be carried out (and to be avoided) and by whom (109).
Other countries, however, prefer to develop municipal or
departmental plans into which school-based prevention is
integrated (110). Even fewer Member States have clear
standards for the content of school-based prevention
(mandatory only in Ireland and the United Kingdom) (111).
However, EU countries are beginning to recognise the need
to provide high-quality prevention measures rather than just
reiterating the importance of prevention in their national
strategies. Sweden is one of the few countries to admit that
its school-based prevention ‘was very often arranged with
methods that research has shown have little or no result,
while effective methods were seldom in use’ (Skolverket,
2000) and that lack of quality control led to a situation
‘where any school principal was able to decide how drug
education should be accomplished’. Now, the whole
strategy is being refocused towards ‘regular programmes
based on evaluated, effective methods’. Similarly, in France
‘the relative silence […] in the legislative and statutory texts
and the early implication of associations […] has resulted
in a multiplicity of active participants in prevention, […]
without any model or action theory being imposed or
particularly encouraged’ (French national report). In reality,
this description could be applied to many more Member
States. In contrast, Spain, Ireland and the United Kingdom
have developed a clear quality control and evidence-based
orientation in their prevention policies and intend to further
strengthen this focus (112). In addition, stricter quality
requirements are now being introduced in Portugal.
Systematic mapping and documentation of programmes as
the cornerstones of quality improvement (113) are gaining in
importance: recently, Denmark, Germany and Portugal
have set up pilot projects to develop monitoring systems
similar to those already existing in Belgium, Greece, Spain,
France, the Netherlands and the United Kingdom.
Curricular interventions (i.e. formal prevention programmes
with detailed contents and outline for sessions) are,
according to existing knowledge (Tobler, 2001), the most
useful way to deliver effective prevention in a controlled
manner that also allows evaluation of both process (good
delivery) and outcome (positive results). The proportion of
schools covered by such curricular programmes is relatively
low in some Member States, either because the necessary
information systems are missing (Germany, Italy) or
because a non-programme-based treatment of prevention in
daily school life is preferred (Austria and Finland (114) (115)).
Because it is a relatively well-defined concept, school-based
prevention is the most accessible area for the mapping and
quantification of prevention coverage; in this respect, the
information systems within the EU are beginning to yield
results, whereas information on other important fields still
needs to be structured and improved (116).
Community-based prevention, on the other hand, is a very
heterogeneous concept partly because it is, by definition,
decentralised. The only common feature across Europe is
the setting itself: ‘community’. Interventions include general
activities (such as staff training and training of trainers),
structural measures (development of local policies and
networks as well as involvement of decision-makers) and
45
(117) More information on the ‘night ravens’ is provided on page 63.
(118) http://www.mir.es/pnd/publica/pdf/intervencion_familiar.pdf.
(119) See EMCDDA annual report 2002; EMCDDA Drugs in focus No 4; Council recommendation on the prevention and reduction of health-related harm
associated with drug dependence (Cordrogue 32).
(120) See Table 6 OL: Role of harm reduction (online version).
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Mass media campaigns, despite the weak evidence base for
their impact on consumption behaviour when used alone
(Paglia and Room, 1999), as well as their considerable
cost, often remain important pillars of prevention strategies.
Harm-reduction responses
Measures to minimise drug-related health damage, reduce
deaths and mitigate public nuisance (119) have become an
integral part of many national drugs strategies and a clear
policy priority in a majority of countries (120).
Implementation of harm-reduction activities is described by
the national focal points as ‘very important’, ‘of key
significance’, ‘fundamental’, ‘a priority’ or ‘a pivotal aspect 
of our national drug strategy’.
Syringe-exchange programmes, outreach initiatives 
and low-threshold services have continued to expand 
and in various countries have diversified to include basic
medical care, vaccinations, safer use education, 
overdose emergency care, first aid courses for drug users
or supervised consumption rooms. Table 2 provides an
overview of selected harm-reduction initiatives in the
EU Member States and Norway. Increased geographical
coverage of syringe-exchange programmes is among 
the most important measures to reduce injection-related
infections. Other interventions are generally less
widespread and are presented here as ‘indicators’ of the
orientation of drugs services responses towards the basic
health needs of marginalised drug users. In all countries,
drug-treatment initiatives, especially substitution
programmes, also make an important contribution to
reducing drug-related health damage.
specific actions such as the provision of local centres for the
prevention of addiction and marginalisation (France) or
parent patrols/’night ravens’ (Denmark, Sweden and
Norway) (117). Interventions are not necessarily organised
by community groups, but — as, for example, in
Luxembourg — may be managed top-down by a national
agency responsible for initiating projects, including drug
awareness programmes. Often, there is a lack of a solid
foundation and of any clear goal; only in Greece are the
aims and structure of community projects subject to any
monitoring process. Except in Luxembourg and Ireland, no
significant evaluations have been reported.
Family-based prevention, despite being frequently
mentioned as a key element in national strategies, seems to
be developed on a disparate, intuitive and impromptu
basis, without any notable experience or evidence base. A
frequent feature is the training of parents in parenting skills
and/or dissemination of information (Belgium, Denmark,
Germany, France, Italy, Portugal and Norway). Only
Ireland, the Netherlands and the United Kingdom have
focused projects in place, which target families at risk and
concentrate on socially deprived neighbourhoods. Spain,
however, has issued a systematic and exhaustive overview
on family-based prevention practices (118), while Greece has
also developed well-organised and well-documented family
projects nationwide.
Until now, it has been impossible to compare the amounts
spent on prevention in the different Member States, even if
focusing only on resources for school-based prevention
plans.
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(1) See Table 7 OL: Provision and types of syringe-exchange programmes 
(SEPs), pharmacy involvement, numbers of syringes distributed/sold (online ver-
sion).
(2) At least one low-threshold medical care service.
(3) At least one service regularly provides safer use training courses.
(4) Regular first aid courses for drug users in at least in one city.
See Table 11 OL: Strategies and selected measures to reduce drug-related 
deaths in the EU Member States and Norway.
Table 2: Geographical coverage of syringe-exchange schemes and the availability of other selected 
health services for drug users in the EU Member States and Norway
Country Geographical coverage of Low-threshold Safer use First aid courses Supervised drug Heroin prescription
syringe-exchange programmes (1) medical care (2) education (3) for drug users (4) consumption rooms
Belgium > 40 sites, major cities Yes Yes Trials under discussion
Denmark 10 of 14 counties Yes Yes
Germany Almost all cities Yes Yes Yes 20 facilities in 11 cities Three-year medical 
study started in 2002
Greece Athens Yes Yes Yes
Spain 18 of 19 regions, prisons Yes Yes Yes 2 facilities Trial in Andalucia 
and Cataluña 
France 87 of 100 départements Yes Yes Yes
Ireland 20 sites and outreach, Yes
mainly Dublin area
Italy SerT and non-government Yes Yes
organisations in ‘many cities’; 
machines in smaller urban settings
Luxembourg Specialised services in three Yes Yes Yes 1 (planned) Legal framework created
main cities; machines in five cities
Netherlands > 95 % of bigger cities Yes Yes Yes 21 rooms in 11 cities Randomised clinical trial 
completed; 300 clients 
continue treatment
Austria 13 towns across most provinces Yes Yes Yes
Portugal National coverage through Yes Yes Yes Legally possible,
pharmacy-based programme; not foreseen
SEP/outreach network under 
construction
Finland Over 70 % of cities > 50 000 Yes Yes Yes
inhabitants, plus five smaller cities
Sweden Malmö and Lund Yes (at SEP)
UK Major programmes in most English Yes Yes Recommendation by Limited, ongoing heroin 
and Scottish cities; SEPs introduced Home Affairs Select prescription. Expansion 
in N. Ireland in 2001 Committee not recommended by Select 
supported by Home Committee (and agreed 
Secretary in principle by 
government) 
Norway Oslo since 1988 and most major Yes Yes
municipalities
(121) See Table 7 OL: Provision and types of syringe-exchange programmes (SEPs), pharmacy involvement, numbers of syringes distributed/sold (2001 data are
presented in Table 8 OL of the 2002 annual report at: http://ar2002.emcdda.eu.int/en/popups/oltab08-en.html).
(122) See Table 8 OL: Provision of HIV voluntary counselling and testing (VCT) and treatment (online version).
(123) Highly active anti-retroviral treatment.
(124) See Table 9 OL: Provision of hepatitis B virus (HBV) vaccination for injecting drug users (IDUs) in some European countries (online version).
(125) See Table 10 OL: Treatment for hepatitis C-infected injecting drug users (IDUs) (online version).
(126) Years of life lost: based on the age to which any individual would be expected to live if he or she had not died as a result of drug use (ACMD, 2000, p. 56).
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immunisation rates. Combined vaccination against hepatitis
virus A and B is recommended for drug users (BAG, 1997).
Although vaccination is available and covered by health
systems in most countries, reported immunisation rates are
low.
Drug users may not remain long enough in contact with one
treatment service to complete the course of vaccinations and
achieve full immunisation. Solutions that are tried include
vaccine administration at different services, rapid dose
schedules and specialised easy access programmes.
Hepatitis C
Treatment for hepatitis C is offered in all countries, but in
practice access is difficult for drug users (Wiessing, 2001).
Current guidelines suggest that drug users should not be
treated until they are off drugs or have been stable on oral
substitution for at least one year because of the risk of
reinfection among active users. Limited access to treatment
or low treatment compliance is reported by many
countries (125). New possibilities to improve uptake and
compliance by drug users include pegylated interferon,
which involves a less demanding regime, and development
of evidence-based treatment guidelines.
There are few national action plans to reduce hepatitis C
virus infection. Safer use training and information and
awareness campaigns for drug users have been
implemented in several countries. Prison programmes to
raise awareness about infectious diseases are reported in
some countries, as are efforts to improve knowledge of
hepatitis C prevention among professionals working with
drug users.
Reducing drug-related deaths
Around 8 000 acute drug-related deaths are recorded each
year throughout the EU and Norway, mostly involving
young people. The burden of drug-related deaths for
society becomes even more apparent if represented in terms
of ‘years of life lost’ (126). Thus, the burden due to drug-
related deaths in England and Wales in 1995 was 70 % of
that due to deaths in road traffic accidents (ACMD, 2000).
Prevention of infectious diseases
Syringe-exchange programmes are available in all
countries, but coverage is very limited in Sweden and
Greece. A proposal to continue the two existing
programmes and to expand needle-exchange programmes
nationwide has recently been made in Sweden. In many
other countries, accessibility of sterile injecting equipment
has further improved, and better coverage of rural areas
has been achieved through installation of vending machines
and involvement of pharmacists (121).
HIV
Voluntary counselling and testing (VCT) for HIV is
commonly available in all EU countries, and is mostly
free (122). Efforts to access ‘hard-to-reach’ drug users and
encourage them to make use of VCT through new low-
threshold services and outreach work have increased,
though in several countries availability of free testing with
full anonymity is limited.
Combination antiretroviral therapy (HAART (123)) is provided
by healthcare systems in all EU countries, but serious
problems of both access and compliance by HIV-infected
drug users are observed. Active drug users are not well
covered by HIV treatment, especially those who are
homeless or leading unstable lives. Further obstacles include
the attitudes of treatment providers and a lack of
information among drug users about dramatic reductions in
morbidity and mortality achievable through treatment.
Some countries (e.g. Belgium, Germany, Austria, Portugal
and Finland) have implemented innovative approaches,
such as providing HIV treatment at drugs services and low-
threshold centres or changing medicine-dispensing
modalities to match clients’ lifestyles, but improving
treatment uptake and success remains a challenge.
Hepatitis B
Free vaccination campaigns against hepatitis B are
currently implemented in some countries (124). More
proactive offers of vaccination by drug services and efforts
by drug services to make vaccination available to drug
users through contact points for high-risk populations can
be noted. Pilot programmes in Germany, the Netherlands
and Austria are proving successful in increasing
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(127) Toxicological aspects, social and personal correlates and risks, and the circumstances under which deaths and non-fatal overdoses occur and prevention
strategies have been researched, e.g. Varescon-Pousson et al. (1997), Hariga et al. (1998), Seaman et al. (1998), Víllalbi and Brugal (1999), ACMD (2000),
Ferrari et al. (2001), Lepère et al. (2001), Brugal et al. (2002), Buster (2002), Kraus and Püschel (2002), Origer and Delucci (2002) and Pant and Dettmer (2002).
(128) Table 11 OL: Strategies and selected measures to reduce drug-related deaths in EU Member States and Norway (online version).
(129) Table 11 OL: Strategies and selected measures to reduce drug-related deaths in EU Member States and Norway (online version).
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Findings indicate a considerable potential to reduce the
number of deaths through medical and educational
approaches (127). Increased availability of substitution
treatment, which has a substantial protective effect on
mortality (WHO, 1998), has been found to be correlated
with reductions in overdose deaths in France and Spain,
though decreasing rates of drug injecting in Spain may also
have made an important contribution (EMCDDA, 2002a).
Educational programmes for drug users to identify risks,
recognise overdose signs and respond correctly have
yielded positive effects by increasing drug users’
competence to help when witnessing an overdose.
Local strategies to reduce overdose deaths in Oslo,
Copenhagen, Amsterdam and Frankfurt have been the topic
of a study that found that, although existing levels and
patterns of drug use set limits on what can be achieved,
local policies on responses can help reduce the number of
deaths (Reinås et al., 2002).
A reduction in drug-related deaths, which is a key objective
in target 2 of the EU drugs strategy (2000–04), is
increasingly being taken seriously as an achievable goal. It
is identified as a priority in the new national drug strategies
of Germany, Greece, Ireland, Luxembourg, Portugal,
Finland and the United Kingdom. Local strategies to reduce
overdose deaths are also reported (128).
Information resources on overdose prevention are available
in most countries. Training in basic resuscitation methods
for drug users is offered by drugs and health services,
though geographical coverage of these first aid courses is
often limited to major urban centres (129).
Distribution of an opiate antagonist, naloxone, is one
measure taken in some countries with the aim of reducing
heroin overdoses (Sporer, 2003). In Italy, a significant
number of Unità de Strada (street drugs services) provide
drug users with naloxone, which can be administered as an
interim emergency measure while awaiting medical help.
A pilot study in Berlin of combined first aid training and
naloxone distribution found increased competence to react
adequately in drug emergencies and medically justified use
of the antagonist in the large majority of cases (93 %)
(Dettmer, 2002). The same study also pointed to the
relevance of naloxone for emergencies occurring in
domestic settings.
Overdose deaths in public places have been of particular
concern in European cities with large open drugs scenes. In
some German and Spanish cities, supervised consumption
facilities have been introduced, targeting the often
marginalised populations of open drug scenes. Supervised
consumption rooms are also to be found in the
Netherlands. Among other services, they provide immediate
emergency care in cases of overdose. A study of
consumption rooms in Germany (Poschadel et al., 2003)
found that they contributed significantly to a reduction in
drug-related deaths at city level and improved access to
further health and treatment services for problem drug users
who are not reached by other services.
Treatment
Medically assisted treatment and drug-free treatment are
the two main modalities of treatment related to illegal drug
use. Medically assisted treatment is almost exclusively
provided in an outpatient setting, whereas drug-free
treatment can be given in residential or outpatient settings.
In the EU, in practice, only agonists (e.g. methadone) or
combined antagonists/agonists (e.g. buprenorphine) are
used for long-term treatment, whereas antagonists (e.g.
naloxone) may be used in withdrawal treatment.
Medically assisted treatment
Methadone is by far the most used substitution substance.
Buprenorphine, the most used substitution substance in
France for years, is also prescribed by private doctors in
Portugal and Luxembourg. Sweden is preparing restrictions
on the prescription of buprenorphine, and in Finland illicit
misuse of buprenorphine has caused demand for treatment,
with a few deaths reported related to misuse of
buprenorphine and depressants. Currently, buprenorphine
is used to a much lesser extent than methadone in Belgium,
Denmark, Germany, Greece, Spain, Austria and the United
Kingdom.
Information on the number of persons receiving substitution
treatment has been available for some years (Farell et al.,
1996, 2000) and it is now possible to follow development
in this area. Table 3 compares information on substitution
treatment as reported in 1997/98 with the latest
information from Member States. Table 3 shows that
there has been a substantial increase in the overall
availability of medically assisted treatment. The aggregate
increase at EU level is about 34 % in approximately
five years.
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Karlsruhe and Munich launched a heroin-assisted treatment
programme in the framework of a scientific randomised
controlled trial. A total of 1 120 clients were admitted to
the heroin trial, which will be closely monitored and
evaluated by the Centre for Interdisciplinary Addiction
Research, Hamburg (Zentrum für Interdisziplinäre
Suchtforschung), for two study periods each of 12 months
(http://www.heroinstudie.de/).
In Spain, the autonomous regions of Cataluña and
Andalucia are preparing trials of co-prescription of heroin.
In Barcelona (Cataluña), the total cohort of the study will be
180 male clients aged 18–45. The heroin prescribed will be
for oral administration.
In Luxembourg, a decree of 30 January 2002 allows for a
trial of heroin prescription to be conducted in the framework
of a pilot project managed by the Directorate of Health.
In the United Kingdom, heroin is prescribed through
general practitioners to an estimated 500 clients.
Drug-free treatment
Drug-free treatment involves the application of psychosocial
and educational techniques to achieve long-term abstinence
from drugs.
Available data on drug-free treatment do not allow a
quantitative comparison, partly because they come from
both centres targeted exclusively at illegal drug users and
those aimed at addiction treatment in general, i.e. treatment
of alcoholism and other kinds of abuse, and partly because
‘treatment’ is not readily defined (e.g. as a minimum
number of sessions) and cannot be measured in
quantifiable units, such as registered prescriptions, as is the
case with medically assisted treatment.
There is a trend towards a north–south divide in treatment
provision, with treatment predominantly supplied through
specialised services for illegal drug use in the southern part
of Europe and through generic addiction services in the
north (with the exception of Denmark). One explanation
could be that northern countries (except Denmark) have a
longer history of drug-free treatment of alcoholics than
southern countries. Perhaps once illegal drug use began to
develop, the already existing treatment facilities were
adapted to deal with this particular group within the
facilities. Conversely, the other countries did not have the
same network of treatment facilities and additional
specialised services were created for illegal drug users (130).
Standards and quality of treatment
Setting up accreditation systems, establishing quality
standards, developing guidelines, training staff and
(130) See Figure 40 OL: Problem drug users in drug-free treatment (online version).
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Co-prescription of heroin
The Netherlands has already conducted a trial with medical
co-prescription of heroin and presented its findings in
February 2002 (http://www.ccbh.nl; Central Committee on
the Treatment of Heroin Addicts, 2002). Clients admitted to
the trial received both methadone and heroin. The
evaluation showed that the clients in the experimental group
experienced considerable health benefits compared with the
control group, which received methadone treatment only.
Between March 2002 and February 2003, the German
cities of Bonn, Cologne, Frankfurt, Hamburg, Hannover,
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(1) For some countries numbers refer to clients, for other countries they refer
to estimated slots.
(2) In the case of Germany, figures also include patients receiving 
dihydrocodeine, which was estimated to be around 8 800 patients in 1998
and 3 700 patients in 2000.
(3) 186 and 156 clients were registered in the State-run methadone proj-
ect in1998 and 2001 respectively, whereas 745 and 849 received sub-
stitution treatment through general practitioners.
(4) England and Wales only.
Sources: EMCDDA annual report 1998 (with data from 1997 or earlier national
reports) and national reports 2001 and 2002.
Table 3: Development of substitution treatment
in the 15 EU Member States and Norway
Estimated number Change (%)
of persons in substitution 
treatment reported (1)
1997/1998 2001/2002 
Belgium 6 617 7 000 5.8
Denmark 4 298 4 937 14.9
Germany (2) 45 300 49 300 8.8
Greece 400 1 060 165.0
Spain 51 000 78 806 54.5
France 53 281 85 757 61.0
Ireland 2 859 5 865 105.1
Italy 77 537 86 778 11.9
Luxembourg (3) 931 1 007 8.2
Netherlands 13 500 13 500 0
Austria 2 966 5 364 80.8
Portugal 2 324 12 863 453.5
Finland 200 400 100.0
Sweden 600 621 3.5
UK (4) 28 776 35 500 23.4
Norway 204 1 853 808.3
Total 290 793 390 611 34.3
(131) See guidelines at Euromethwork web site at http://www.q4q.nl/methwork/home2.htm.
(132) http://www.ntors.org.uk.
(133) www.studio-vedette.it/pubblicazioni.htm.
(134) http://www.crf-au.dk/danrisenglish/default2.asp.
(135) See Table 12 OL: Recent prison drug strategies, ministerial directives and service standards in the EU and Norway (online version).
(136) http://eddra.emcdda.eu.int.
(137) EMCDDA criminal justice based drug demand and harm-reduction interventions in the EU — an analysis of police station, court and prison-based
programmes (http://eddrapdf.emcdda.eu.int/eddra_cjs.pdf). 
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monitoring and evaluation are all examples of measures
aiming at assuring a certain standard and quality level of
treatment related to illegal drugs.
Accreditation or certification systems are reported from
Germany, France, Luxembourg, Austria and Portugal and
imply that an authorised independent external body
monitors services to ensure that they meet pre-established
specific requirements. In some countries, for example
France and Luxembourg, treatment providers must be
certified or accredited in order to receive funding for
treatment. In other countries, national certification is
possible but optional, although the opportunity to become
certified according to international standards, such as ISO,
is available throughout Europe.
Guidelines on treatment implementation in order to assure
quality are reported from many Member States, such as
Greece, Italy, the Netherlands, Austria and Finland.
However, their extent of use and implementation as well as
their nature vary. Guidelines can be non-binding advice
that is widely available or semi-binding principles that have
to be adhered to for funding to be considered. At EU level,
non-binding guidelines for the provision of methadone
treatment have been developed and are available in
German, English, French and Spanish (131).
Staff training is available in all Member States, although no
Member State reports nationwide systematic training of
treatment staff. The availability, diversity and level of
training vary widely across the EU, as does the involvement
of treatment-related authorities in setting up such activities.
Treatment evaluation and research
Evaluation of and research into drug treatment, which takes
various forms, is reported from all countries. However, the
vast majority of studies are small scale and conducted at
institutional or local level. In the United Kingdom, a
nationwide treatment outcome survey was conducted in
England and Wales with results over five years (132). Italy’s
VEdeTTE study, which involves almost 12 000 clients in
118 outpatient treatment centres (SerT), is still ongoing, and
so far only initial results are available. The preliminary
results show that the daily average dose of methadone was
40 mg and only 10 % of clients received 60 mg or more,
the required dose according to the scientific literature.
Annual treatment drop-out rates for drug-free treatment and
for methadone maintenance treatment were 52 % and 35 %
respectively. It also appears that higher doses of methadone
reduce the risk of drop-out. The study also confirmed that
psychosocial intervention is effective (133). The Danish
DANRIS study (134), which started in May 2000, aims to
monitor treatment and its efficiency at roughly 40 inpatient
treatment centres. At European level, the Treat 2000
project, partly financed by the fifth research framework
programme, aims to analyse and compare healthcare
systems and their efficiency in dealing with opioid addicts
in six European regions.
Responses targeting drug users 
in criminal justice settings
Policy framework
Drug addiction plays a central role in violation of drug laws
as well as petty acquisitive crime. A high proportion of
drug users are arrested, and many are incarcerated. In
addition, some prisoners start taking drugs while in prison.
These observations are taken into consideration in the
criminal justice systems of all the EU Member States and
Norway. The majority of EU countries have included in their
drug strategies a focus on the improvement of psychosocial
and health services addressing drug addicts in prisons.
A need for flexible penal justice systems has emerged because
of the growing number of imprisoned drug users and the
consequent overcrowding of prisons. The notion that drug
users might not be best accommodated in prison settings has
resulted in the expansion of alternative measures to sentence
proceedings and to incarceration. Cooperation between the
criminal justice structures, namely prison and probation, and
between these and health structures, is generally considered to
be in need of improvement, and appropriate measures are
developing (135).
Prison-based psychosocial and health interventions
In prisons, services targeting drug-using inmates are
expanding. Most of the countries where addiction treatment
is generally available in prisons also provide harm-
reduction measures (Table 4). However, an analysis of
prison-based programmes contained in EDDRA (Exchange
on European Drug Demand Reduction Action) (136) found
that the dominating objective of the interventions is not
health related but the reduction of drug-related crime (137).
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(1) Data from Germany are missing owing to the federal structure of the justice system.
(2) An extended version of this table is available as Table 13 OL: Prison-based interventions for drug users (online version).
Source: Reitox national reports (2002).
Generally, in any particular country, specific services exist
either in almost all prisons or in almost none. This is
especially true for harm-reduction measures, as shown in
Table 4. Blood-screening and vaccination programmes are
available and disinfectants provided in almost all prison
establishments in approximately two thirds of the countries,
but are completely lacking in approximately one third of
Member States. This reflects the crucial role of national
policies in determining the availability of prison services.
However, pilot projects at the level of individual prisons are
usually tried before any policy is rolled out nationwide.
Detoxification is the measure most universally provided. It is
available in almost all prisons in nine countries and less
widely in only three countries, Greece (2001 data), Italy
and Norway. Needle exchange is the most uncommon of
the investigated interventions: needle-exchange
Percentage Abstinence-oriented Substitution Harm-reduction-oriented
of prisons Detoxification Drug-free Therapeutic treatment Blood Vaccination Provision Needle Provision of
offering units communities screening programmes of disinfectants exchange condoms
the services in prison
All Belgium, Belgium, Belgium, Denmark, Belgium, Belgium,
Denmark, Denmark, Greece, Greece, Denmark, Denmark,
Spain, Spain, Spain, Spain, Spain, Spain,
France, France, France, France, France, France,
Luxembourg, Austria, Ireland, Ireland, Austria, Austria,
Netherlands, Portugal Luxembourg, Luxembourg, Portugal, Portugal
Austria, Netherlands, Austria, Norway Sweden,
Portugal, Austria, Portugal Norway
Sweden Portugal, 
Sweden
More than half Ireland, Finland, Luxembourg Finland Finland, Finland Luxembourg,
Finland, UK UK Finland,
UK UK
Less than half Greece, Denmark, Belgium, Ireland, UK Germany,
Italy, Netherlands, Denmark, Italy, Spain
Norway Belgium, Spain, Finland, 
Greece, Greece, UK 
Spain, Austria, 
Ireland, Portugal, 
Austria, Finland, 
Portugal, Norway
Sweden, 
Norway
None Italy, France, Greece, Denmark, Belgium, Greece, Belgium, Greece,
France, Ireland, Netherlands, UK, Netherlands, Ireland, Denmark, Ireland,
Luxembourg Italy, Sweden Norway Sweden Italy, Greece, Italy,
Luxembourg, Luxembourg, France, Netherlands
Netherlands, Netherlands, Ireland,
Sweden, Sweden Italy,
UK Luxembourg,
Netherlands,
Austria,
Portugal,
Finland, 
Sweden,  
UK, 
Norway 
Table 4: Availability of socio-health services targeting drug users in EU prisons (1) (2)
(138) See Table 13 OL: Prison-based interventions for drug users (online version).
(139) Figure 41 OL: Alternatives to prison — conceptual framework (online version).
(140) See Table 14 OL: Alternatives to prison targeting drug-using offenders — a comparative EU description (online version).
(141) The evaluation of a Swedish alternative to prison project showed lack of financial sources to pay the treatment at the end of the sentence period (Swedish
national report, 2003).
(142) http://www.emcdda.eu.int/multimedia/project_reports/responses/alternatives_prison_expert.pdf.
(143) More details are given in Box 15 OL: Interdiction measures (online version). 
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programmes are available only in Spain (11 of 68 prisons)
and in Germany (four of 222 prisons). The accessibility of
substitution treatment follows the pattern of availability in
community settings (except in the Netherlands) and is
available in almost all prisons in six Member States. Other
countries offer it in very few of their prison establishments
or not at all (138).
Alternatives to incarceration
Community-based alternatives to incarceration (139)
targeting drug-using offenders have expanded in EU
Member States since the late 1990s (140). They have been
developed within an extensive framework of innovations in
penal policy, the other main components of which are
mediation and reparation (i.e. a trend towards community
service). Basically, the alternatives consist in the provision of
drug treatment. There is evidence that treatment is effective
in reducing drug use and crime (Stevens et al., 2003).
Treatment could be especially effective in reducing crime if
it is targeted towards long-term drug users, who are
responsible for the majority of minor offences. In addition,
prison sentences have been found to be ineffective as a
deterrent against petty crime (Brochu, 1999).
There is no clear evidence that quasi-compulsory treatment
approaches are successful. European research tends to be
more sceptical in this regard than American research,
which since the 1970s has reported positive findings. More
research is needed on the process and outcomes, and this
research should include both quantitative and qualitative
studies. However, the evaluation of a Danish scheme that
allows offenders to serve their sentence in a special in-
prison treatment department found that the crime rate
decreased, especially when the alternative to incarceration
was offered to criminals of long standing (Danish national
report, 2002). The Triple Ex project in The Hague, a
coercive type of treatment, found that longer duration in
treatment was associated with a reduced relapse rate
(Vermeulen et al., 1999).
Many of the factors identified as leading to lack of success
of alternatives to punishment are linked with the lack of
coordination across the different sectors involved, namely
justice, health and social welfare. Typically, evaluations
reveal gaps in funding for treatment (141), a lack of any
clear demarcation between the roles of judges and
treatment staff regarding who should determine the best
type of treatment, and inadequate community treatment
services (142) (EMCDDA, 2003a). An evaluation of the
Community Service Order, one of the tools available to the
Irish legal establishment to redirect drug users from prisons
to an alternative forms of punishment, shows that formal
and/or informal collaboration across the justice, social and
health services is crucial for success (Expert Group on The
Probation and Welfare Services, 1999).
The justice systems in Member States have designed special
measures targeting young drug users, including early
interventions and alternatives to prosecution. Early
interventions aim to prevent criminality by acting at the
early stages of criminal careers. One of the measures most
commonly applied across Member States is to avoid or to
delay the first prison sentence by diverting young people
from the criminal justice system to an alternative socio-
health programme. In Portugal, the commissions for the
dissuasion of drug abuse are an example of a structure
created to implement alternatives to prosecution. They were
established when the possession of drugs for personal use
was decriminalised in 2001. An evaluation after one year
shows positive results in preventing development of a drug
problem and diminishing the time period between initiation
of problematic drug use and the contact with treatment
institutions (Portuguese annual report, 2002).
Supply reduction
Interdiction measures
According to ‘Europol’s organised crime report’, production
and trafficking of drugs remain prime activities among
criminal groups in the EU. No other field of organised
crime delivers such an enormous profit (143).
‘Interpol at work 2001’ reports that increased international
cooperation has resulted in a number of relevant law-
enforcement operations. For instance, Project Exit, based on
shared intelligence, resulted in large-scale ecstasy seizures
in Europe. In addition, important shipments smuggled from
European airports to North America were detected. The
drug data sharing programme, in which Interpol, UNDCP
(now the United Nations Office on Drugs and Crime,
UNODC) and WCO (World Customs Organisation)
participate, exchanging intelligence, continued to play a
key role in the fight against smuggling of synthetic drugs.
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(144) http://www.interpol.int/Public/FinancialCrime/MoneyLaundering/EthnicMoney/default.asp.
(145) Further details in Box 16 OL: Anti-money laundering measures (online version). 
(146) http://www.fatf-gafi.org/pdf/AR2002_en.pdf.
(147) Box 17 OL: Level of compliance (FATF) (online version).
(148) Box 18 OL: Measures against diversion of chemicals under control (INCB) (online version). 
(149) Potassium permanganate is a licit compound that is an important reagent in analytical and synthetic organic chemistry; it is used in bleaching applications,
disinfectants and antibacterial and antifungal agents. It is also used in water purification processes. 
(150) Box 19 OL: Operation Purple (online version). 
(151) Acetic anhydride is an acetylating and dehydrating agent used in the chemical and pharmaceutical industries for the manufacture of cellulose acetate, in
textile sizing agents and cold bleaching activators, for polishing metals and in the production of brake fluids, dyes and explosives. 
(152) http://www.incb.org/e/ind_ar.htm.
(153) Box 20 OL: INCB (online version).
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The international operation, Operation Topaz, which
monitors traffic of acetic anhydride (151), continues to
function well in terms of both international tracking of licit
shipments and law-enforcement investigations to trace the
origin of seized, or intercepted, chemical shipments.
Between January and November 2002, 2 800 export
shipments were reported, involving nearly 300 000 tonnes
of acetic anhydride. Belgium and the Netherlands, where
the majority of consignments originated, were particularly
helpful in ensuring that the international tracking
programme functioned smoothly. The majority of the
transactions take place between EU Member States, and a
total of 92 % of the monitored shipments were reported by
EU Member States. The concentration of licit trade within
the EU and the success of the control procedures of
Operation Topaz have led to a review to find a viable
alternative to the shipment-by-shipment tracking within
the EU.
Europol believes that up to 90 % of heroin seized on the
EU markets originates from south-west Asia (Afghanistan).
Despite efforts to eradicate opium cultivation, production in
2002 is believed to have amounted to 3 400 metric tonnes.
Taking into account the fact that some of the acetic
anhydride diverted from licit supply channels is smuggled
into Afghanistan, an international task force from Germany,
the United Kingdom and the United States was established
to provide technical assistance in combating trafficking in
this region.
During 2001, over 200 tonnes of acetic anhydride was
seized. This is the largest amount ever reported for a single
year. The largest single seizure was reported by the United
Kingdom, when an attempted diversion of 70 tonnes to
Yugoslavia was uncovered. Other European countries
reporting seizures of acetic anhydride were Belgium,
Germany, Italy and Slovenia.
To help prevent diversion of chemical precursors used in
manufacturing amphetamine-type stimulants, such as
ephedrine, norephedrine and 3,4-MDP-2-P, INCB, in
cooperation with the European Commission and the
United States, agreed to initiate a voluntary international
project, Project Prism, to assist governments in achieving
this goal (152) (153).
Anti-money laundering measures
Europol estimates that the cocaine trade generates billions
of euro within the EU. Laundering methods involve both
physical and electronic cash movements. It remains difficult
to link cash movements and related drugs business
transactions. Interpol has developed important tools to
counter specific money laundering systems. In 2001,
specialised studies were made available to allow
investigators to become better acquainted with
these (144) (145).
According to the Financial Action Task Force (FATF)
2001–02 annual report (146), seven EU Member States fully
comply with 28 out of its 40 recommendations requiring
specific national action; the other countries do not comply
fully (147).
Measures against diversion of chemicals under control
The International Narcotics Control Board (INCB) 2002
report on ‘chemicals under control’ notes that most
exporting countries now provide export data, but that,
unfortunately, France, which previously provided
comprehensive data on its exports of controlled substances,
did not supply such data for 2001. Most exporter countries
submitted data on precursors used for manufacturing
amphetamine-type stimulants. Data on the export of
norephedrine, which for the first time in 2000 was included
in Table I of the INCB report (imposing pre-export
notifications), were provided by Denmark, Spain, Germany
and the United Kingdom. In addition, most of the P-2-P and
safrole EU producer countries submitted data (148).
Governments continued to achieve successes in preventing
diversion of potassium permanganate (149), used for the
illegal manufacturing of cocaine, in particular through
Operation Purple. In 2001, the number of shipments and
the volume of trade monitored decreased (150).
Seven illicit laboratories manufacturing potassium
permanganate were dismantled in Colombia under
Operation Purple, from April to September 2002. As
potassium permanganate becomes more difficult to divert
from licit trade, cocaine producers attempt to manufacture
this chemical themselves.
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(154) Defined as ‘a document which has not been published in a peer-reviewed journal’. For more information see QED Network Journal
(http://qed.emcdda.eu.int/journal/bulletin27.shtml).
(155) Based on responses to having been ‘drunk from drinking alcoholic beverages’.
(156) Figure 42 OL: Comparison of ‘binge’ drinking with cannabis use in last 30 days.
(157) Based on responses to ‘sniffed a substance (glue, aerosols, etc.) to get high’.
(158) Statistical Table 3: School surveys — lifetime prevalence among students, 15–16 years of age (online version).
(159) Statistical Table 3: School surveys — lifetime prevalence among students, 15–16 years of age (online version).
(160) See Table 15 OL: Relationship of consumption of different substances among Spanish school students (14–18 years) (online version).
Drug and alcohol use among young people
Young people are often at the leading edge of social
change, and upward trends in alcohol and illicit drug use
by young people constitute an important social development
in the EU. The inclusion of alcohol in this section of the
report is new and arose out of concerns about complex
patterns of substance use and associated dependency,
health damage and criminal behaviour. These patterns of
psychoactive substance use present a particular challenge
for policy-makers to develop an appropriately wide and
timely range of responses for effective action.
The EU has set itself a target to reduce significantly, over a
period of five years, the prevalence of illicit drug use, as
well as recruitment to it, particularly among young people
under 18 years of age, and to develop innovative
approaches to prevention (COR 32).
Material consulted in the writing of this chapter includes the
Reitox national reports and population survey data.
Comparable data on young people are largely based on
the European school survey project (ESPAD) reports from
1995 and 1999 (ESPAD, 1999), which covered 15- to 
16-year-old school students and in which nine Member
States participated. The data from the Netherlands in
ESPAD surveys are not strictly comparable with those from
other participating Member States. Published research, grey
literature (154) and government publications on drugs and
alcohol use by young people (particularly from France and
the United Kingdom) have also been used for reference.
Prevalence, attitudes and trends
Prevalence
Excluding tobacco and caffeine, alcohol is the psychoactive
substance used most by young people across the EU. The
proportion of 15- to 16-year-old students who have been
drunk at some time in their lives ranges from 36 % in
Portugal to 89 % in Denmark (155) (Figure 19) (156). The
majority of young people in the EU have never used illicit
drugs but, among those who have, cannabis is the most
commonly used drug, followed by inhalants/solvents (157).
According to the 1999 ESPAD survey in Greece and
Sweden, lifetime experience of inhalants/solvent use is as
high as or higher than lifetime experience of cannabis use
among 15- to 16-year-old students (158).
National school surveys do not measure problem substance
use among young people, but they are a very useful source for
assessing experimental drug use and attitudes among young
people. On the basis of Reitox reports and 1999 ESPAD data,
lifetime prevalence of cannabis use was lowest in Portugal
(8 %), Sweden (8 %), Greece (9 %) and Finland (10 %). Lifetime
prevalence was highest in France (35 %), the United Kingdom
(35 %) and Ireland (32 %), followed by Spain (30 %). School
survey sample sizes may be found in Statistical Table 3 (159).
Strict comparability of data in this table is limited as not all
Member States used the same school survey methods.
Among 15- to 16-year-old students, in general, lifetime
prevalence of use of cannabis, inhalants, tranquillisers and
sedatives (without a doctor’s prescription) is higher than use
of stimulant and hallucinogenic drugs. School students
experimenting with cocaine and heroin are relatively rare
throughout the EU, with lifetime use of these drugs ranging
from 0 % to 4 % (Statistical Table 3).
Most young people who have tried cannabis will have some
experience of alcohol and tobacco. Young people who use
ecstasy, amphetamines, cocaine and hallucinogens tend to
form a separate cluster and belong to specific social
groups. Relationships in consumption of different drugs are
shown in Table 15 OL (online version) based on Spanish
school survey data (Observatorio Español sobre Drogas,
2002) (160). A major challenge is to respond to the
Chapter 3
Selected issues
This chapter highlights three specific issues relating to the drug problem in Europe: 
drug and alcohol use among young people; social exclusion and reintegration; 
and public expenditure in the area of drug-demand reduction.
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(161) See Figure 43 OL: Percentage of 15- to 16-year-old students who disapprove of getting drunk compared with trying cannabis and ecstasy (online version). 
(162) Figure 44 OL: Changes in drinking five or more drinks in a row during past 30 days. 
Annual report 2003: the state of the drugs problem in the European Union and Norway
experimenting with drugs such as ecstasy, cocaine and
heroin were generally very high among 15- to 16-year-old
school students. Disapproval of trying ecstasy ranged from
71 % in Greece to 90 % in Denmark.
Trends
Concern is growing about increased levels of drunkenness
and ‘binge’ use of alcohol for recreational purposes (162).
Between 1995 and 1999, marked increases in lifetime
experience of being drunk occurred in Greece and Norway
(Figure 20). Strictly comparable data for alcohol use are
not available for Member States that do not participate in
the ESPAD surveys, but trend data from both Germany
(1973–2001) and Spain (1994–2000) show recent
decreases in alcohol consumption by young people
(Bunderszentrale für Gesundheitliche Aufklärung, 2002;
Observatorio Español sobre Drogas, 2002). However, it is
possible for overall consumption to decrease while patterns
of ‘binge’ drinking increase.
During the 1990s, lifetime prevalence of cannabis use
increased to such a level that it could be described as
widespread in a number of Member States. However, by
1999, the use of cannabis among young people in Ireland,
the Netherlands and the United Kingdom had decreased.
This may indicate that prevalence has reached saturation in
these countries, with a trend towards stabilisation at levels
of around 30 %.
complexities and idiosyncrasies of different patterns of drug
use (Calafat et al., 1999; Parker and Eggington, 2002;
Smit et al., 2002).
A higher level of drug use among males than among
females is more marked in adult populations than in school
students. However, among school students, gender
differences are greatest in Greece, France, Italy and
Portugal. One exception is that the use of tranquillisers and
sedatives without a doctor’s prescription and of alcohol
together with ‘pills’ is generally higher among girls.
Variations in prevalence also occur between regions within
Member States. In Germany, the gap between east and
west is closing faster in students than in adults. Other
aspects of drug prevalence, such as the spread of cannabis
into rural areas, are the same as those observed in older
populations.
Attitudes
Attitudes towards different drugs can help predict future
prevalence of drug use. In 1999, disapproval of getting
drunk once a week varied widely, from relatively low in
Denmark (32 %) to high in Italy (80 %). Disapproval of
cannabis experimentation was less variable and was lowest
in France (42 %) and highest in Portugal (79 %) and
Sweden (78 %) (161). Attitudes help to predict trends, but
other factors are also involved. In all Member States,
disapproval and perceptions about ‘great risks’ attached to
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Figure 19: Lifetime prevalence of being drunk and illicit substance use (15- to 16-year-old students)
(1) Limited comparability.
Source: ESPAD school survey project (1999).
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There are also indications of stabilisation of lifetime use of
ecstasy at very much lower levels than for cannabis. In the
case of the United Kingdom, decreased lifetime prevalence of
both cannabis and ecstasy was accompanied by a decrease
in perceived availability (163) (164) and an increase in
disapproval (165). In 1999, the proportion of students who
perceived that the risk associated with trying ecstasy once or
twice was great was highest in the two Member States
(Ireland and the United Kingdom) in which lifetime prevalence
of ecstasy was also highest (166) and where much media
coverage was given to a relatively small number of ecstasy-
related deaths. Media coverage, together with an increasingly
negative image, appears to have influenced the downward
prevalence of ecstasy use in these two Member States.
Young people judge each other on the basis of image, style
and possession of status symbols. Such symbols, which may
include drugs, change constantly. Currently held negative
images of heroin users and the ready accessibility of other
drugs are important factors in current drug choices
(FitzGerald et al., 2003). A recent analysis of drug lyrics in
English-language popular music since the 1960s has shown
that musicians today are more likely than in the past to
decry the harm that cannabis does (167) (Markert, 2001).
The results of a recent survey of 878 young people up to
the age of 19 conducted in 10 EU cities signal a possible
tendency in urban mainstream culture towards decreasing
amphetamine and ecstasy use and increasing cocaine use.
This sample was not sufficiently representative or large
enough to draw definitive conclusions. This study also found
that respondents spend more money on alcohol than on
drugs or any other single category of recreational
consumption, such as admission to discos, clubs or cinemas,
mobile phones and tobacco (Calafat et al., 2003) (168).
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Figure 20: Lifetime prevalence for (A) being drunk, (B) taking
cannabis and (C) taking ecstasy (15- to 16-year-old students)
Figure 20 (A): Being drunk
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Figure 20 (B): Taking cannabis
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(163) Based on responses that the drug would be ‘very easy’ or ‘fairly easy’ to obtain if wanted.
(164) Figure 45 OL: Changes in the perceived availability of (A) cannabis and (B) ecstasy (online version).
(165) Figure 46 OL: Change in the percentage of 15- to 16-year-olds who disapprove of (A) getting drunk once a week or (B) trying cannabis once or twice or
(C) trying ecstasy once or twice (online version).
(166) Figure 47 OL: Percentage of 15- to 16-year-old students who perceive a ‘great risk’ associated with using ecstasy once or twice and lifetime prevalence of
ecstasy use (online version).
(167) Figure 48 OL: Percentage of positive images in contemporary popular music, 1960s to 1990s (online version).
(168) Figure 49 OL: Euro spent each weekend by 13- to 19-year-olds in 10 EU cities in 2001–02 (online version).
(1) The data for France and Greece for 1995 are based on surveys in 1993.
Source: ESPAD school survey project (1995 and 1999).
Figure 20 (C): Taking ecstasy
(169) See Figure 1 OL: Patterns of cannabis use among the general population — lifetime experience versus current use (last 30 days), National (drug use)
prevalence survey 2001 (the Netherlands).
(170) This is based on the hypothesis that use of cannabis per se increases risk of initiating hard drugs. 
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are due to a range of common risk factors, including
vulnerability and access to drugs and propensity to use
drugs. Findings from cohort studies show that illicit drug use
is rarely the first sign of trouble for adolescents. Alcohol
use, antisocial behaviour, truancy and crime often occur at
Almost all of the EU Member States (Belgium, Denmark,
Germany, Spain, France, Luxembourg, Italy, the
Netherlands, Austria, Portugal and the United Kingdom)
report rising concerns about a possible increased cocaine
and base/crack market for young problem drug users.
Further information about trends in availability can be
found on p. 36.
Initiation, patterns and risk factors
In general, the likelihood of young people aged
12–18 years getting drunk or being offered cannabis, or
any other illegal drug, as well as their willingness to try
drugs, increases sharply with age. This is illustrated here
by data from the French Escapad survey (Beck, 2001).
Figure 21 A shows that, among boys aged 13 and 14,
the proportion who had lifetime experience of being drunk
was 15.9 % and the proportion who had experimented with
cannabis was 13.8 %. Among 17- to 18-year-olds it had
increased to 64.5 % and 55.7 % respectively.
In a recent EU young population survey, ‘curiosity’ was
given as the main reason for trying drugs (EORG, 2002).
Of those who experiment with drugs, the majority do not
continue to use them on a regular basis. In a small but
significant minority, use escalates to intensive levels. This is
illustrated in Figure 21 B, which shows the distribution of
cannabis use among the general population of 18-year-olds
in France. General population surveys show that lifetime
experience of illicit drug use is significantly higher than
recent or current use (169). Comparable information on
patterns of use among regular drug users is less developed
than in the field of alcohol research. This limits
understanding about the patterns of drug use and,
consequently, the development of effective responses.
Definitions of ‘problem cannabis use’ are being explored in
some Member States, and it has been suggested that people
who have used cannabis on 20 or more occasions during
the past month are most at risk of developing a problematic
pattern of use (Beck, 2001; Dutch national report). By this
definition, one out of every five people in the Netherlands
who have used cannabis during the past month can be
classified as ‘at risk’. According to Figure 21 B, in France
13.3 % of 18-year-old men, compared with only 3.6 % of
18-year-old women, fall into the ‘at-risk’ category.
One major concern about experimental use of cannabis is
related to the ‘gateway effect’ (170). However, the association
between cannabis use and other illegal substances is
complex and not reducible to a simple causal model. An
alternative ‘common factor’ model demonstrates how
correlations between the use of cannabis and hard drugs
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Figure 21: Cannabis use among 17- to 18-year-olds in 2001. 
(A) Age at initiation of use. (B) Level of use.
Figure 21 (A): Age of initiation to being drunk and cannabis use
among 17- to 18-year-old boys in France in 2001
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Figure 21 (B): Level of cannabis use at the age of 17-18
in France in 2001
Sources: Escapad (2001), OFDT. National representative sample.
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(171) Figure 50 OL: Percentage of 15- to 16-year-old students who have been drunk or tried cannabis aged 13 or younger (online version).
(172) Figure 51 OL: Comparison of drug use by vulnerable group (online version).
(173) Figure 52 OL: Acute drug-related deaths reported in the EU among young people up to the age of 19 (online version).
(174) The current EU average life expectancy is 75 years for men and 80 for women.
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a younger age than cannabis use (171). Adolescents rarely
use illicit substances without concomitant exposure to other
illicit users and believe that the potential benefits of use
outweigh the potential costs (Engineer et al., 2003).
Evidence for the ‘gateway effect’ may be explained by
cannabis bringing users into contact with an illicit market,
increasing access to other illegal drugs and providing a
platform of acceptability for using other illicit drugs (Grant
and Dawson, 1997; Petraitis et al., 1998; Adalbjarnardottir
and Rafnsson, 2002; Brook et al., 2002; Morral et al.,
2002; Parker and Eggington, 2002; Pudney, 2002;
Shillington and Clapp, 2002).
In the Netherlands, a youth survey conducted in 1999
found that the majority of young cannabis users purchased
cannabis from friends (46 %) and from coffee shops (37 %)
(De Zwart et al., 2000).
Identifying a range of risk factors that influence both the
initiation and escalation of drug use in an extremely
heterogeneous adolescent population is an approach that
has begun to gain currency. These factors span a continuum
from individual to community to macroenvironmental factors
and are probably different for recreational and problem
drug use.
Risk factors
Targeted surveys have shown that particular groups of
young people have much higher levels of drug use than
those found in the general national population. These are
often young people who have been excluded from school or
truanted, committed a crime, been homeless or run away
from home, and those whose siblings are drug users (Lloyd,
1998; Swadi, 1999; Goulden and Sondhi, 2001;
Hammersley et al., 2003). The United Kingdom youth
lifestyles survey 1998/1999 found that prevalence of 
drug use was significantly higher among these vulnerable
groups (172). The size of these vulnerable groups at national
level suggests that current school-based surveys are
underestimating drug prevalence by failing to identify the
populations of high-risk adolescents not found in the school
environment. Comparable EU data on ‘vulnerable groups’
of young people at present are scarce. Young people who
go out at night to particular dance music settings constitute
another vulnerable group. The links between specific youth
cultures and drugs are well documented, most recently in
relation to the diffusion of ecstasy (MDMA) use (Griffiths et
al., 1997; Springer et al., 1999). In techno dance settings,
lifetime prevalence of ecstasy use ranges from 12.5 %
(Athens) to 85 % (London), compared with a lifetime
prevalence of 1 % (Greece) and 8 % (United Kingdom)
among the general young adult populations (EMCDDA,
2002a).
Community
In recent years, increased attention has been given to
social, economic and cultural determinants including
physical environment (Spooner et al. 2001; Lupton et al.,
2002). Drug problems are often concentrated in particular
geographical areas and housing locations. For example,
the Irish national report cites that children in focus groups
recounted routine encounters with drug users and made
casual reference to the presence of drug paraphernalia on
stairs and balconies. Parents living there expressed extreme
anxiety about their children’s high level of exposure to
drugs (O’Higgins, 1999).
Deaths and hospital emergencies
Drug- and alcohol-related deaths among the under-20s are
relatively rare. However, during the 1990s, the number of
drug-related deaths among young people in the EU overall
rose steadily. A total of 3 103 deaths among young people
were recorded in the EU between 1990 and 2000 (173). The
comparable loss of years for the death of a young person is
higher than for an older person when years of life
expectancy lost (174) are calculated. Detailed information on
drug-related deaths can be found on pp. 28–32. The
United Kingdom is the only Member State that reports on
deaths specifically related to inhalation of volatile
substances. Over a period of 18 years, there were
1 707 deaths specifically related to this phenomenon.
The majority of these deaths occurred in people between
the ages of 15 and 19 (Field-Smith et al., 2002).
Despite the media attention given to ecstasy-related deaths,
inhalants probably constitute a greater health risk to
adolescents than other forms of drug use.
There are no routinely collected EU data on drug-related
hospital emergencies because of the hidden nature of illicit
drug use, combined use of alcohol and other drugs and
lack of toxicological analyses (Tait et al., 2002). The limited
data that are available suggest that alcohol is a greater
burden on the health services in some Member States than
illicit drug use. WHO estimates that in developed countries
alcohol accounts for 10–11 % of all illness and death each
year (Rehn et al., 2001). For example, a Danish survey of
young people in 2001 found that fewer 17-year-olds had
reported hospital attendance for drug-related problems
than for alcohol-related problems (Danish national report).
In Ireland, a regional study of hospital case notes over a
three-month period found that almost all of the 55 hospital
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(175) Figure 53 OL: Selective prevention — targets of intervention (online version).
(176) See EDDRA http://eddra.emcdda.eu.int:8008/eddra/plsql/showQuest?Prog_ID=36.
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night-time curfews. Also, in Ireland, two national public
order initiatives are operated by the police. Operation
Oíche focuses on under-age drinking, illicit drug use and
under-age alcohol sales and Operation Encounter
concentrates on antisocial conduct on the streets as well
as in licensed premises, nightclubs and fast food outlets.
For further details about legal responses, see p. 42.
A broad continuum of needs and responses
A major EU objective for addressing drugs and alcohol
misuse is to make appropriate interventions in order to
have the most effective impact. The main focus is on five
broad, sometimes overlapping, target groups for
intervention strategies: (1) school-age young people; (2)
young experimental and recreational drug users; (3) young
people in socially deprived areas; (4) young offenders; and
(5) young people with a need for drug treatment (175).
School-age young people
Prevention in schools is a widely used response for this
target. Details can be found on p. 45.
At a school policy level, several Member States have issued
recommendations on how to react to drug incidents and
drug-using students. In France, there is a strong focus on
‘Reference points for the prevention of at-risk behaviour in
schools’ and the resolution of problems through targeted
counselling. There is a major focus on professional training
for school staff in order to handle deviant youth behaviour.
In Austria and Germany, the STEP-by-STEP
programmes (176) help schoolteachers to identify and
intervene with drug-using pupils. In Norway, a handbook
for this purpose has been launched.
The United Kingdom Drug Prevention Advisory Service
evaluated a drug-prevention programme aimed at young
people excluded from school and concluded that drugs
programmes are clearly needed, but that brief periods of
drugs education are inadequate. Many young people
targeted by the programme were already taking drugs,
implying that programmes should be implemented at a
younger age, and should clearly identify and deal with
problems. The new Portuguese national framework for
prevention anticipates allocating EUR 400 000 for
alternative school curricula and early professional training
for school drop-outs. Almost all Spanish autonomous
communities have such programmes in place. In Greece,
early interventions are aimed at adolescent drug users and
their families (family therapy), as well as at adolescents
who have problems with the law.
admissions among young people aged 10–18 were related
to alcohol alone or deliberate self-poisonings (Mid-Western
Health Board, 2002; reported in the Irish national report).
Legal responses and recommendations
In almost all Members States, availability of alcohol is
controlled by means of State monopoly or a licensing
system. Attempts to control the availability of alcohol to
young people have been made in most EU Member States
by applying age restrictions (usually either 16 or 18
years) to off-premises and on-premises sales of alcohol.
Portugal introduced its age restrictions relatively recently,
in January 2002. Alcohol advertising restrictions vary
from complete bans to voluntary advertising codes or no
restrictions (Rehn et al., 2001; Bye, 2002). In the United
Kingdom, the sale of cigarette lighter refills to under-18s
was restricted by the 1999 Cigarette Lighter Refill (Safety)
Regulations (Field-Smith et al., 2002). A decrease in
deaths is thought to have been achieved as a result of
this legislation together with information campaigns
targeted at parents. There are some variations in
legislation, and little is known about practice. An
example of a new initiative to address issues of practice
is to be found in Germany, which has recently introduced
the ‘Apple juice’ law, which requires bars to offer at least
one non-alcoholic drink cheaper than the cheapest
alcohol (German and Dutch national reports). In the
United Kingdom, a new scheme is being launched by
retailers, with the support of government, to provide a
special ‘pass’ for young customers to help enforce age
restrictions on the purchase of alcohol and volatile
substances (BBC News).
In recent years, the Netherlands has increased controls over
coffee shops and coffee shops selling cannabis near schools
have been closed. Under-18s are not permitted to
purchase cannabis. Advertising of cannabis products is
prohibited, and in recent years the tighter control of coffee
shops has significantly reduced the number of customers
under 18 years old (Dutch national report). In Copenhagen,
Denmark, police have closed down approximately
50 cannabis clubs since an act to prohibit visitors in certain
premises came into effect (Danish national report).
In Ireland and the United Kingdom, initiatives have been
taken recently to reduce problems linked with drugs and
alcohol in young people. For example, the Children’s Bill
(1999) in Ireland places responsibility on parents to control
children. Penalties for parents include treatment for their
own substance abuse and training in parenting skills.
Children considered to be out of control may be subject to
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(177) Figure 54 OL: Target group prevention in recreational settings (online version).
(178) See http://eddra.emcdda.eu.int:8008/eddra/plsql/showQuest?Prog_ID=356.
(179) See http://www.emcdda.eu.int/responses/infosites.shtml.
(180) See http://eddra.emcdda.eu.int:8008/FurtherReading/eddra_party_settings.pdf.
(181) Table 16 OL: Main quantitative parameters of prevention in recreational settings; Table 17 OL: Outreach work/prevention in recreational settings; and
Table 18 OL: Overview of polices and frameworks for outreach work/prevention in recreational settings (online version).
(182) See http://eddra.emcdda.eu.int:8008/eddra/plsql/showQuest?Prog_ID=2828.
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Young experimental and recreational 
drug users in the community
The potential harm caused by alcohol and illicit drug use in
the lives of a small but significant proportion of the young
population is increasingly recognised. A major target for
more effective action are vulnerable groups of young
people who consume alcohol and experiment with drugs for
recreational purposes while being unaware of, or unable to
control, the risks associated with their patterns of substance
use (overdosing, accidents, criminal behaviours, violence,
loss of capacity to study or work, sexually transmitted
infections and longer-term health damage to liver/brain,
etc.) (Boys et al., 1999; Parker and Egginton, 2002).
Concern about changing patterns of use of alcohol and
drugs for recreational purposes is growing in the EU, and
particularly about the health risks for women. Recreational
facilities such as bars, discos, sport clubs and youth clubs
would seem to be suitable settings for drug prevention as
they guarantee contact with a large number of young
people, many of whom use drugs or are at risk of doing
so (177). There is an urgent need for methodological
documentation and thorough evaluation of interventions in
this setting.
In France, by 2001, at least 30 % of départements were
taking preventative actions or providing first aid at dance
events. In one regional health board area in Ireland,
nightclub staff and clubbers are targeted by ‘The sound
decisions’ project (178). However, in Luxembourg, no legal
framework exists for drug agencies’ interventions in
nightclubs.
Train-the-trainer courses in first aid for drugs incidents in
recreational settings are organised in the Netherlands.
The Dutch ‘Going out and drugs’ initiative includes
interventions for different settings outside school where
youngsters use drugs, such as coffee shops, discos, parties
and clubs, and places where major musical events are
organised.
Several projects approach drug users within the music
scene to minimise the risks of consuming legal and illegal
drugs. Sometimes, project staff drive to different events in a
mobile home, providing a quiet atmosphere for informal
counselling. Special hotlines or web sites (179) can be
additional features.
An overview and analysis of examples of prevention in
party settings has been carried out on the projects in
EDDRA (180). An overview of current projects and policies is
provided in a series of online tables (181).
Specific on-the-spot counselling services and on-site pill
testing at rave events are — according to a recent
Commission-funded study — effective in reaching those
young people who, although they take drugs regularly, do
not think of themselves as drug users and would not contact
established drug help services. The study also found that pill
testing does not counteract abstinence-oriented prevention
interventions (182). In Austria and Spain, these services have
now expanded, while in the Netherlands they are restricted
to services with high standards of methodological accuracy.
Another set of interventions involves peers, self-help groups
and alternatives to drugs use such as information and
psychosocial support as well as involvement in cultural or
sports activities (e.g. in summer camps in Greece). In Spain,
alternative leisure programmes have for some years been
available throughout the country.
In Norway, Sweden and Denmark, ‘The night ravens’ are
volunteer adults who patrol the city centre streets during
weekend evenings and nights. Their mission is to be visible
and available to young people. The idea is that their
presence will reduce the likelihood of violence and harm.
Young people in socially deprived neighbourhoods
In Sweden, the Drugs Commission conducted a review of
the research literature on preventative responses
(Narkotikakommissionen, 2000), and concluded that three
types of initiative are needed: specific initiatives targeting
the poorest people; general initiatives to improve public
health; and initiatives aimed at helping vulnerable families.
Ireland, Portugal and the United Kingdom are the only
Member States that identify particular areas with a view to
providing special programmes in these areas. Ireland’s
Young People’s Facilities and Services Fund (YPFSF) aims to
attract ‘at-risk’ young people in disadvantaged areas into
facilities and activities that divert them from the dangers of
substance abuse. In the United Kingdom, Positive Futures is
operating in 57 deprived areas to divert vulnerable young
people from drugs and crime through involvement in sport.
The initial results are encouraging, showing reductions in
criminal activity and truancy and improved community
awareness. Health action zones (HAZs) are multi-agency
partnerships located in some of the most deprived areas in
England, and their aim is to tackle health inequalities
through healthcare and social care modernisation
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(183) See Auftrieb in http://eddra.emcdda.eu.int:8008/eddra/plsql/showQuest?Prog_ID=2086).
(184) See http://www.asemanlapset.fi/walkers-nuorisokahvilat/walkers-kahvilat_suomessa/.
(185) See EDDRA http://eddra.emcdda.eu.int:8008/eddra/plsql/showQuest?Prog_ID=2091).
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Luxembourg MSF Youth Solidarity project operates on a
similar basis in direct collaboration with youth magistrates
and competent law-enforcement actors.
The FRED project in Germany aims at early interventions
with first notified drug users (185). Finnish law-enforcement
projects operate under the same principles. 
Young people with a need for treatment services
Demand for drug treatment is a significant indicator of drug
dependency and severe need. In 2001 in the EU, young
people up to the age of 19 accounted for just under 10 %
of the total reported specialist drug-treatment demand.
Over half of these young people were receiving treatment
for cannabis as their main drug of use. Nearly a quarter
were being treated for opiate problems, and the remainder
were evenly divided between treatment for use of cocaine
and other stimulant drugs. However, there are national
variations; for example, Ireland treats a larger proportion
of young people than any other country in the EU.
Treatment for under-18s is complicated by issues of
parental consent and concerns about prescribing
substitution drugs in the absence of adequate research into
the effects of such drugs in this age group. Most young
people in treatment with severe drug problems attend
ordinary treatment settings.
Specialised treatment services have been developed in some
countries. For example, in the Netherlands, there is a small-
scale clinic targeting 13- to 18-year-olds. In Finland, special
emphasis is on a sustained and intensive psychosocial
treatment continuum, with necessary institutional treatment.
Based on 1999 information, there were six treatment units for
young substance abusers, with a total of 40 beds. In addition,
reform schools had three units specialising in drug treatment,
with a total of 23 beds. In Luxembourg, there is one specialist
centre, 43 % of whose clients are under the age of 16 years.
In Greece, early interventions are aimed at adolescent drug
users and their families (family therapy), as well as at
adolescents who have problems with the law.
In Sweden, young people aged between 12 and 21 who
have serious psychosocial problems, often in association
with elements of criminal behaviour and psychoactive
substance use, can be placed in institutional care without
their consent. Methods of treatment include environmental
therapy, functional family therapy, cognitive behavioural
therapy and, for substance abuse, the 12-step method.
Young offenders will, as an alternative to prison, be
taken care of according to the Care of Young Persons
(Special Provisions) Act in closed institutional youth care
programmes to cover a wide spectrum of vulnerable young
people thought to be a risk of misusing drugs (130 projects
and initiatives in the 26 HAZs). Connexions is a United
Kingdom support and advice service for young people
aged 13–19 that incorporates the identification of young
people at risk and makes referrals to specialist drug
services. Twenty-seven partnerships were operational in
2002, with another 20 expected to be introduced by 2003.
In the United Kingdom, all drug action teams (DATs)
conducted a young people’s needs assessment in 2001
and are required, through young people substance misuse
plans (YPSMPs), to plan services for young people from
universal prevention services through to substance misuse
treatment services, which are based on local need.
In Austria, mobile centres targeting young people in the
streets are working in close cooperation with other relevant
help organisations to provide assistance to drug-using
adolescents and young adults at an early stage. It is
anticipated that the geographical coverage of these centres
will increase in future (183).
In Finland, Walkers youth cafés (184) provide early
intervention and currently operate in 24 localities. An
important role is played by trained adult volunteers
supported by youth work professionals. An effort has been
made to develop the youth cafés into safe meeting places.
Similarly, in one regional health board area in Ireland a
health advice café, which aims to provide a combined
prevention and direct access health service for young
people, is in place.
In Norway, most large municipalities have outreach
services. Their objectives include various preventative
interventions aimed at older children and young people as
well as counselling and referral to the support and
treatment services.
Young offenders
Some Member States provide targeted support, training
and outreach programmes for at-risk young people such as
young offenders. A major impact of some of these
initiatives has been to reduce the number of young people
receiving criminal sentences.
Interventions provide alternatives to law-enforcement and
punishment strategies, with the aim of reducing or
preventing young people falling into a life of crime, with
irreversible consequences. In the United Kingdom, youth
offending teams (YOTs) include drug workers who assess
young offenders for drug abuse and, where appropriate,
offer interventions to prevent further abuse. The
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(186) See http://www.stat-inst.se/article.asp?articleID=87.
(187) Eurobarometer survey 56.1 (http://europa.eu.int/comm/employment_social/soc-prot/soc-incl/eurobarometer_en.pdf).
(188) According to the EMCDDA (2002b), immigrants are defined as ‘black and minority ethnic groups’ and include immigrant populations from diverse
communities living in EU countries.
(189) Table 19 OL: Distribution of primary addiction problems (alcohol, heroin, cocaine, cannabis and gambling) in the Netherlands among immigrants and
native Dutch (online version).
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treatment (186). For further information about treatment
responses see p. 49.
Social exclusion and reintegration
Definitions and concepts
According to the last survey on ‘social precarity and
integration’ (187), the proportion of the European population
at risk of poverty and social exclusion in Europe varies from
9 % to 22 % (European Council, 2001). People are
considered to be socially excluded if they ‘are prevented
from participating fully in economic, social and civil life
and/or when their access to income and other resources
(personal, family and cultural) is so inadequate as to
exclude them from enjoying a standard of living that is
regarded as acceptable by the society in which they live’
(Gallie and Paugam, 2002).
Social exclusion can thus be defined as a combination of
lack of economic resources, social isolation, and limited
access to social and civil rights; it is a relative concept
within any particular society (CEIES, 1999) and represents
a progressive accumulation of social and economic factors
over time. Factors that could contribute to social exclusion
are problems related to labour, educational and living
standards, health, nationality, drug abuse, gender
difference and violence (European Council, 2001; National
reports, 2002).
Drug use could be viewed as either a consequence or a
cause of social exclusion (Carpentier, 2002): drug use can
cause a deterioration of living conditions, but, on the other
hand, processes of social marginalisation can be a reason
for starting drug use. Nevertheless, the relation between drug
abuse and social exclusion is not necessarily a causal one,
because social exclusion ‘does not apply to all drug
consumers’ (Tomas, 2001).
Taking into account this complexity, it is possible both to
analyse drug use among socially excluded populations and
study social exclusion among drug addicts (Figure 22).
Drug-use patterns and consequences observed 
among socially excluded populations
In the literature and research, the following populations are
usually considered to be at risk for social exclusion:
prisoners, immigrants (188), the homeless, sex workers and
vulnerable young people. Bias and methodological
limitations in the presented information on drug use and
patterns of use among socially excluded groups have to be
considered, because of the lack of information sources and
comparable data across Europe.
The association between being prisoner and using drugs
has been shown to be quite strong (see also p. 34). A large
proportion of prisoners are drug users before being
imprisoned, and the reason for their incarceration is often
associated with drug use. However, some people follow the
opposite course, becoming drug users only after being
incarcerated for committing crimes. Studies suggest that
between 3 % and 26 % of drug users in European prisons
start taking drugs in prison and between 0.4 % and 21 %
of incarcerated IDUs first inject while in prison. Drug use
within prison is very common: up to 54 % of inmates report
using drugs while incarcerated, and up to 34 % report
injecting in prison (Stoever, 2001; EMCDDA, 2002a).
The relation between ‘black and minority ethnic groups’
and drug use is less clear, as little information is available.
There is no scientific evidence to suggest that drug use is
higher among immigrants than in the general population.
However, some studies in specific ethnic minority groups
have found a higher proportion of problematic drug users
among those groups than among the general population,
such as among the Ingrian in Finland (1–2 % of whom are
estimated to be drug users, especially heroin users), Kurds
in Germany, Gypsies in Spain and several ethnic 
groups in the Netherlands (Vrieling et al.,
2000) (189). The reasons for this could be a
combination of socially disadvantageous factors,
such as poor command of the local language,
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Figure 22: Relationship between social exclusion and drug use
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(190) The British Home Office reports that in the United Kingdom over one-third of homeless people have injected heroin, and one-fifth have injected crack. In
the last month, over 10 % are likely to have used someone else’s syringe or passed on their own syringe (Carlen, 1996; Goulden and Sondhi, 2001).
(191) According to a survey conducted in England and Wales in 1998–99 among 4 848 young people (Goulden and Sondhi, 2001).
(192) The Social Exclusion Unit of the British Office of the Deputy Prime Minister defines a ‘young person running away’ as ‘a child or young person under the
age of 18 who spends one night or more away from the family home or care without permission, or has been forced to leave by their parents or carers’ (Social
Exclusion Unit, 2002).
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‘young runaways’ (192) appear to be more likely to misuse
drugs. Rates of lifetime drug use are two to eight times
higher than in young people who have never run away.
The drugs most used are crack, heroin and solvents.
Problems at school are another risk factor for taking drugs:
a high prevalence of drug use is reported in children not
attending school (Amossé et al., 2001), among those
attending reform schools (40 % of reform school students in
Finland were reported to have had an addiction problem at
some time, in 16 % of whom this was related to drugs)
(Lehto-Salo et al., 2002) and in those with poor educational
grades (13.5 % in Norway) (Vestel et al., 1997).
Among sex workers, drug use is often a motive for
prostitution, but could also be a consequence (as is the case
for other factors associated with drug use). Drug-use
patterns vary depending on whether prostitution comes
before or after drug addiction. An Italian qualitative study
among street prostitutes found that, when sex workers start
to use drugs in order to deal with problems related to
prostitution, they mainly use alcohol, tranquillisers or other
psychoactive medicines; in contrast, when drug addiction is
the main reason for prostitution, heroin is the primary drug
used (Calderone et al., 2001).
Research findings or data on other socially excluded groups
are less readily available; Denmark reports that among
patients of psychiatric services 50–60 % are drug addicts,
probably because of the widespread availability of drugs
and the fact that such patients are familiar with taking
psychoactive medicines (National report, 2002).
Relationship between social exclusion and drug use
More data are available on social conditions among the
treated population. Socioeconomic factors related to drug
use include low educational levels, early school leaving and
drop-out; unemployment, low salaries and difficult jobs; low
income and debt; insecurity of accommodation and
homelessness; mortality and drug-related diseases; poor
access to care; and social stigma (Table 5).
Relevant differences in the social conditions of drug use are
found by substance used and drug-use patterns; the worst
conditions are found among heroin and opiates users and
chronic drug addicts.
unemployment and housing problems, poor living
conditions and lack of economic resources (National
reports, 2002).
As regards patterns of drug use, differences are found
among ethnic groups. Use of qat is reported only by Somali
populations and black Africans while heroin is smoked by
immigrants from Surinam and from Bangladesh. And drug
use among Gypsies in Spain appears to start at a younger
age (by two to three years) than in the native population
(Eland and Rigter, 2001; Reinking et al., 2001; Fundación
Secretariado General Gitano, 2002).
Homeless people are also reported to be at risk for drug
use. Although comparable data across Europe on the
relation between homelessness and drug use are not
available, specific studies have been conducted in many
countries, and drug use is reported as a frequent problem
among the homeless (National reports, 2002). Denmark,
France, the Netherlands and the United Kingdom report
that up to 80 % of homeless people living in shelters are
drug dependent; and prevalence rates are even higher
among people living on the streets or among homeless
people with other social problems. For example, according
to a small study carried out in Ireland, 67 % of homeless
ex-prisoners are drug dependent (Hickey, 2002). Among
the homeless, heroin is the most commonly used drug,
followed by cocaine and polydrug use. Other high-risk
behaviours, such as injecting drug use and needle sharing,
are also reported to be high among homeless people (190).
Among vulnerable young people, the use of drugs is
reported to be frequent; high prevalence is found among
children who have experienced family and social problems
or problems at school. High prevalence of drug use has
been found among the children of drug addicts: rates of
lifetime drug use among children whose parents have used
drugs in the past year are significantly higher than those
found in the ‘non-vulnerable’ group (lifetime prevalence of
37–49 % compared with 29–39 % among children of non-
user parents) (191). Several studies report that children who
have suffered sexual or physical abuse within the family
have a higher risk of using drugs when adults (Liebschutz et
al., 2002). In Portugal, young victims of family abuse and
violence are reported to be seven times more likely to use
heroin than young people in the general population
(Lourenço and Carvalho, 2002). In the United Kingdom,
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The living conditions of drug users are often reported to be
very poor: 10.4 % of clients live in unstable accommodation
and 7.5 % live in an institution. Furthermore, many
countries report high homelessness rates (up to 29 %)
among drug addicts (196).
With regard to nationality, characteristics resemble the
general population structure (197); clients are mainly
nationals of the country where they request treatment, and
the number of clients from other countries (European or
non-European) is consistent with the proportion of
foreigners in the general population. However, it should be
remembered that in some countries registration of clients’
nationality/ethnicity is not allowed and consequently such
information is not consistently available.
Apart from direct health consequences (see pp. 24 and 28),
drug users can find it difficult to access care because of a
reluctance to deal with services or poor education, a low
degree of acceptance by mainstream medical services and
unique health problems for which appropriate services are
not available.
Finally, drug users suffer from a negative social image and
may face hostility from the general population and public
authorities. Research conducted in a prison in Vienna found
that drug users may experience violence and abuse from
police officers or other public officials (Waidner, 1999).
Social reintegration
Measures to deal with social exclusion among groups with
or without drug addiction problems and with the social
consequences of drug use/abuse are set out in the
European countries and Norway.
On the basis of the European Union drugs strategy
(2000–04) (Council of European Union, 2000) and a
specific study on social reintegration in the EU and Norway
(EMCDDA, 2003b), social reintegration could be defined as
‘any integrative efforts for drug users in the community’.
Social reintegration interventions target both current and
former problem drug users, ranging from well-functioning
‘clean’ former addicts and long-term methadone clients to
very deprived street addicts. A treatment component,
whether medical or psychosocial, is not necessarily
required. This also implies that social reintegration does not
necessarily take place after treatment but can take place
(193) Figure 55 OL: Level of education among all clients by country (online version).
(194) Average unemployment rate among the 15 Member States (Eurostat, 2002).
(195) Figure 56 OL: Labour status among all clients by country (online version).
(196) Figure 57 OL: Living conditions among all clients by country (online version).
(197) Figure 58 OL: Clients’ nationality by country (online version).
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Some 47 % of all clients in treatment in 2001 never went to
school or only completed primary school; high rates of early
school leaving and drop-out are also frequent among drugs
users. Differences are found according to main drug used
and by country (193): opiates users (in particular heroin users)
have the lowest educational level (National reports, 2002).
Because of their precarious social conditions, drug users
also have problems related to labour status; unemployment
rates are very high compared with the general population
(47.4 % among drug clients compared with 8.2 % (194) in
the general population); finding a job is difficult and it is
rare for drug addicts to keep a job for long or to progress
in a career (DrugScope, 2000) (195). A precarious labour
status can lead to financial problems; drug addicts
frequently have low income or no financial resources
(32–77 % of clients in treatment survive on social benefits).
Debts are also common.
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(1) Percentages are calculated on the total number of cases reported under
each single item; the total does not sum to 100 % as only the values of
interest for this chapter are reported (never went to school, unemployed,
etc.); for the complete figures, see Figure 55 OL: Level of education
among all clients by country; Figure 56 OL: Labour status among all clients
by country; and Figure 57 OL: Living conditions among all clients by coun-
try (online version).
Source: Reitox national reports — TDI data 2001.
Table 5: Social conditions (education, labour
status, housing) of clients in treatment 
in EU Member States in 2001
Social conditions Drug users 
in treatment 
(valid %) (1)
Education (n = 98 688) Never went to school/never 8.0
completed primary school
Primary level of education 43.6
Labour status (n = 100 000) Unemployed 47.4
Economically inactive 9.6
Housing (n = 41 299) Unstable accommodation 10.4
Institutions 7.5
(198) For more in-depth information and country overviews, see the study ‘Social reintegration in the European Union and Norway’
(http://www.emcdda.eu.int/multimedia/project_reports/responses/social_reintegration_eu.pdf).
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auspices of the employment programme ‘Self-employment
promotion’ (this kind of intervention overlaps with
education/training).
Finally, providing housing or assistance to find housing
aims at bringing some stability into clients’ lives. Offering
housing can be an intervention in itself but will often be
accompanied by psychosocial assistance and some degree
of supervision. An example of parallel psychosocial care is
Haus am Seespitz in the Tyrol, which runs an open after-
care group for clients that meets in housing facilities. In
Belgium, ‘Habitations protégées’ provides both housing and
psychiatric care. Research performed in Ireland (Irish
national report (Hickey, 2002)) showed that 79 % of female
and 76 % of male ex-prisoners indicated that finding
suitable housing was their main problem and reason for
their social exclusion, suggesting that housing is an
important social reintegration intervention.
irrespective of prior treatment, being either the final step in
a treatment process or a separate and independent post-
treatment intervention carried out by non-treatment services
with their own goals and means. Social reintegration
services do not target problem drug users exclusively but
may target all kinds of addicts (including those addicted to
alcohol and legal drugs) or even all socially excluded
groups (e.g. homeless people and rough sleepers).
A quantitative overview of social reintegration measures in
EU Member States is impossible to achieve, as the term
‘social reintegration’ is not used consistently. Although
different services may exist alongside each other, at country
level, there are typically general ‘provision modes’ for
social integration:
• targeting all excluded groups with or without addiction
problems;
• targeting persons with addiction problems in general;
• targeting explicitly and exclusively problem drug users
of illegal drugs  (Figure 23) (198).
It is difficult to quantify the availability of social
reintegration services and assess the adequacy of service
provision although the evidence would suggest that the
number of facilities is probably inadequate. For example,
Germany estimates that it needs around 25 000 social
reintegration places, whereas the actual number available
is roughly 4 000. An employment project in Austria
registered twice as many applications as places and had to
turn down an average of 15 persons a day.
Social reintegration can be broken down into three main
types of interventions: education (which includes training),
housing and employment.
Many drug users have a poor level of education, and many
national reports describe a poor relationship between
problem drug users and the labour market (Greece
(Kavounidi, 1996), Denmark (Stauffacher, 1998), the
Netherlands (Uunk and Vrooman, 2001)). Hence,
interventions aimed at upgrading academic, technical or
practical skills would improve clients’ chances in the labour
market.
Employment measures can take many different forms, for
example providing financial support to companies which
employ a drug user in a competitive job, as is reported
from Greece. Other measures include setting up
employment services, such as the Vienna Job Exchange in
Austria, or helping clients to establish their own businesses,
as also occurs in Greece as well in Spain under the
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Figure 23: Main provision modes for social reintegration for
problem drug users in the EU and Norway
Social reintegration for all excluded groups
Social reintegration for addicts in general
Social reintegration exclusively for problem
users of illegal drugs
No predominant provision mode
Source: Reitox national reports.
(199) The differences in the data available limited the possibility of drawing cross-country comparisons. For a more complete picture of expenditure in the field
of drugs in the individual EU Member States, see http://www.emcdda.eu.int/policy_law/national/strategies/public_expenditure.shtml.
(200) Year of reference for the European Union drugs strategy (2000–04) ‘snapshot’ reporting exercise.
(201) The EMCDDA is particularly grateful to the Greek, Austrian and Portuguese focal points for undertaking specific research and investigations in this field,
increasing the value of this annual report. Acknowledgement should also be given to Professor Pierre Kopp for peer review of the research.
(202) Belgium (2003), Luxembourg (2002), the United Kingdom (2002); for more references see
http://www.emcdda.eu.int/policy_law/national/strategies/public_expenditure.shtml. 
(203) Our desire to include as many countries as possible in order to provide a complete European picture conflicts with the scarcity of data in some of the
countries considered. Consequently, while a broad scope has been maintained, the capacity for analysis and comparison has been very much diminished by
the uncertainty of the final figures. 
(204) Belgium (2003), Luxembourg (2002), the United Kingdom (2002); for more references see
http://www.emcdda.eu.int/policy_law/national/strategies/public_expenditure.shtml.
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Public expenditure 
in the area of drug-demand reduction (199)
The European Union drugs strategy (2000–04) specifies
that the Council and the EU Commission should, based on
work by the EMCDDA and the Pompidou Group, attempt to
itemise a list of all public expenditure in the field of drugs.
In its efforts to respond to the European Union drugs
strategy, the EMCDDA, with the valuable contribution of the
Reitox national focal points, is investigating in this report
direct public expenditure in the field of drug-demand
reduction incurred in 1999 (200). It concentrates on
expenditure at national and regional level, on drug-use
prevention, treatment of addiction (in- and outpatient,
substitution and drug-free), rehabilitation and reintegration,
outreach work, harm reduction and education, and research
and coordination when related to demand reduction. To
better delineate our research, we have excluded direct
expenditure sustained by private health organisations
(therapy centres, clinics, etc.) and indirect expenditure
sustained by general services such as general hospitals and
emergency rooms. Finally, the broader and much more
complex question of the social costs of illegal drugs has not
been considered.
In addressing the question of public expenditure in the field
of drugs (albeit in a restricted domain), this report aims
primarily to increase awareness in the EU countries of the
relevance of a drug policy indicator, rather than to produce
empirical evidence.
Limitation and reliability of data
Nevertheless, although we have restricted our scope, the
results that emerge confirm the difficulties caused by limited
data availability and data collection in a field that is
relatively undeveloped in the EU. In fact, other than the ‘ad
hoc’ research undertaken during the preparation of this
report (201), only a few studies have been conducted with the
aim of quantifying public resources allocated to drug issues
in the EU (202). As matter of record, the majority of countries
in the EU cannot say precisely how much they spend on
combating drugs and drug addiction.
Most of the participants in this research, therefore, could
not provide comprehensive data. In fact, some figures are
missing, and often calculations have been based on
estimation and extrapolation methodologies (203).
As reported by a large number of focal points, and
confirmed by literature in the field, at least five factors can
limit such research: (1) the lack of data for some areas and
some countries; (2) the difficulty in isolating data on illicit
drugs from data covering both illicit drugs and alcohol; (3)
the variety of actors and organisations at central, regional
and local level accountable for spending; (4) the difficulty
of precisely dividing public expenditure among theoretical
categories, such as demand and supply reduction; and (5)
the complexity of breaking down expenditure, within these
two categories, by area of intervention (treatment, primary
prevention, rehabilitation, cooperation, coordination, etc.).
It is, however, interesting to note that, although studies of
this kind are obviously complicated by methodological
problems, decision-makers are showing growing interest in
public spending reviews (204) both as a basis upon which to
make decisions and as a means of measuring performance.
Expenditure in drug-demand reduction
In the process of calculating ‘a list’ of all direct public
expenditure in drug-demand reduction in the EU Member
States, and on the basis of the data received from national
focal points, a comparison of similar expenditure has been
attempted.
Although all possible statistical precautions have been
taken, it is not possible to avoid the problem that the
reported figures may sometimes correspond to different
categories in different countries and the fact that in some
countries figures are just not available. Indeed, for Belgium,
Denmark, Italy and especially Germany and Sweden, some
relevant information on demand-reduction expenditure is
missing and, thus, the total figure is certainly grossly
underestimated. In the case of other countries (Greece,
Spain, France, Luxembourg, Austria and Portugal), data
can be considered to be more comprehensive despite some
residual uncertainty regarding the categories of spending
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(205) Injecting drug use or long duration/regular use of opiates, cocaine and/or amphetamines. To calculate expenditure per problem drug user, the estimates of
numbers of problem drug users as reported by the national focal points using average rates were used. For more information, see Statistical Table 4: Estimated
number of problem drug users in EU Member States, 1995–2001 (online version).
included. In the Netherlands and Norway, in particular, the
reported estimates concern both illicit drugs and alcohol,
making the final figures for those two countries, in
comparison with others, rather high. Finally, most data refer
to 1999 as baseline figures for the EU action plan
evaluation process, but there are some exceptions. For
Ireland, the figures reported are planned State expenditure
in the area of demand reduction for the year 2000, for
France, the data date back to 1995; and for the United
Kingdom, the data refer to the financial year 2000–01. The
reading of the amounts shown in Table 6 must therefore
take into account the above-mentioned constraints.
The total amounts spent by EU countries in the field of drug-
demand reduction in 1999 basically seem to reflect the size
and wealth of each country (Kopp and Fenoglio, 2003).
Unsurprisingly, the largest and richest countries (Germany,
France, Italy and the United Kingdom) appear to allocate,
in absolute terms, more financial resources than the small
countries, although spending is also relatively high in the
Netherlands and Norway (possibly because alcohol
addiction interventions are included in the figures).
Research shows (Godfrey et al., 2002; Origer, 2002; Kopp
and Fenoglio, 2003) that estimates of this kind could be a
valuable source of information at national level.
Comparisons over time within a country can reveal an
increase or decrease in drugs-related budgets. Comparison
across sectors (demand, supply, international cooperation,
etc.) might reveal, in addition to formal strategies, the
concrete financial effort expended in tackling the drugs
phenomenon.
At EU level, ‘cross-country’ comparisons (the most complex)
can determine common patterns, or differences, in the
amounts allocated to drug policy and allow expenditure to
be compared against a European average or across world
regions.
In addition, the use of macroeconomic indicators (such as
gross domestic product (GDP), total population, total
government expenditure or number of problem drug users)
at national and European level can help to measure the
extent of the expenditure and to give a more informative
interpretation of data that, taken alone, would be of little
value.
Indeed, the comparison of expenditure on drug-demand
reduction and, for example, the GDP of each country could
reveal how much of its wealth a country is likely to spend to
prevent drug use and combat the consequences of drugs.
According to the data collected in this research, it appears
that in 1999 Norway allocated approximately 0.1 % of its
economic wealth (GDP), followed by the Netherlands
(0.078 %) (although both countries included in their
estimation drugs and alcohol). Portugal (0.074 %), Finland
(0.073 %) and Ireland (0.070 %) spent the greatest
proportion of GDP on drug demand-reduction activities; in
comparison, the largest and apparently richest countries
seem to lag behind. However, the known incompleteness of
the data for the latter may bias the comparison.
The interpretation of this information is not straightforward,
and not only because of the lack of data. The proportion of
wealth that is dedicated to drug addiction control in the EU
Member States can be interpreted as reflecting the extent of
the drug problem or the size of the response to it (or both),
or the level of the social and health interventions in the
population. Exploring such questions can contribute to a
better understanding of the phenomenon and deeper
comprehension in the field of cost estimates.
Another way of analysing public expenditure is to look at it
in the context of the area it is intended to deal with, in this
case problem drug users (205). Using as an indicator the
estimated number of problem drug users, expenditure per
individual most in need of assistance can be calculated.
Unfortunately, this calculation is beset by two problems:
first, the figures do not necessarily relate directly to problem
drug users — drug addicts — as prevention, education and
coordination can also be targeted at individuals who are
not classified as problem drug users; and, second,
calculation of the number of problem drug users is, for
obvious reasons, rather uncertain.
Again, according to our data, the value of services consumed
by each drug addict in need is considerably higher in some
countries (Finland, Luxembourg, Austria) than in others
(Greece, Portugal, France, United Kingdom). This could be
interpreted as the result of a stronger commitment to drug
services in the former group; however, it is more likely that
the figures depend on the quality and type of intervention.
Indeed, differences in the levels of expenditure do not
automatically translate into the level of commitment, but
rather represent a different level of reaction, which is
determined by the specificity of the situation.
Together with the expenditure per problem drug user, it is
useful to calculate the burden of drug demand-reduction
policy on society as a whole. Considering the expenditure
on drug-demand reduction in the 16 countries studied
(15 Member States and Norway), and from the limited data
available (Table 6), the total (minimum) amount spent in the
EU in 1999 on prevention of drug use and the care of drug
addicts amounted to around EUR 2.3 billion. This means
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Table 6: Breakdown of direct public expenditure figures in millions of euro as reported 
in the Reitox national reports 2002
Sources: Reitox national reports, 2002.
Country EUR million Categories of expenditure in 1999
Belgium 139 Treatment (100); rehabilitation (22.5); methadone (8.9); communities and regions: prevention, care, training, coordination (8.3) (not included:
EUR 7 million allocated to the prevention of criminality by the Ministry of Internal Affairs)
Denmark 67 Expenditures on ‘drug addiction’ by counties and municipalities DKK 495.5 (66.5); prevention at central level DKK 6.2 (0.8), in counties and
municipalities not known
Germany 343.2 Emergency accommodation (3.0); psychosocial accompanying (13.3); 951 outpatient counselling facilities (57.9); inpatient rehabilitation
(25 % of EUR 434 million (99.7)); integration in work (4.3); cared housing (8.0); treatment in addiction departments in hospitals (97.0);
substitution treatment (not known but estimated minimum of 30.0), Länder budget ‘addiction’ 23.9 % (drugs share) of EUR 127 million (30.0)
(not included: prosecution and enforcement expenditure)
Greece 16.2 39 prevention centres (OKANA), salaries and staff (KETHEA), housing and operational costs (2.4); treatment: drug-free, substitution and low
threshold (11.9); social rehabilitation (0.3); research (0.3) OKANA, data not included; education (0.8), some central administration costs (0.5)
Spain 181.5 Central level: Ministries of the Interior (GDNPD), Defence (prevention), Health and Consumption, Education and Culture; Foreign Affairs, Work
and Social Matters (19.8); fund of confiscated goods allocated to demand reduction 66 % (2.8); autonomous communities (158.7, of which
22.3 from the GDNPD)
France (1995) 205.8 Subutex (91.4); Social Health and Urban Affairs (101.9); Education (Research) (6.6); Youth and Sport (1.3); Work, Employment and Training
(0.12); MILDT (66 % of EUR 6.9 million (4.5) (not included: international cooperation and subsidies to international organisations)
Ireland (2000) 57.1 Department of Health and Children (treatment, prevention, research) (32.0); Department of Enterprise, Trade and Employment 
Estimated State exp. (reintegration) (6.0); Department of Education and Science (prevention) (7.5); Department of Tourism, Sport and Recreation (prevention,
research, evaluation, coordination) (11.6)
Italy 278.5 Outpatient treatment (99.1); residential and semi-residential treatment (88.8); National Drug Fund projects promoted at the local/regional
level (67.6); National Drug Fund projects sponsored by ministries (23.0). No data were available from eight regions and only partial data
were available from most other regions
Luxembourg 13.7 Ministry of Health (5.7); Family, Social Solidarity and Youth (2.3); Education, Professional Training and Sport (0.5); other ministries (0.3);
Social security reimbursement (4.9)
Netherlands 287.9 General Act on Special Disease Management (to regional care offices and addiction clinics) (76.0); Ministry of Health, Welfare and Sport
(outpatient addiction care) (74.2); funds for homeless addicted, neglected drug addiction (about two thirds of EUR 150 million (112.5)); drug-
related nuisance (24.1); drug-prevention activities (1.1) (most of the figures concern both drugs and alcohol)
Austria 52.3 Federal, provincial and municipal sources including health insurance funds, public employment services and the Healthy Austria Fund: primary
prevention (2.4); outreach work and harm reduction (3.3); counselling, care and treatment (40.7); reintegration (4.2); quality assurance (0.6);
other expenditures/not assignable (0.8)
Portugal 71.7 Presidency of the Council of Ministers (16.2); Ministries of Health (41.6); of Education (3.1); of Employment and Social Affairs (9.5); of
Defence 1.2
Finland 76.2 Healthcare (inpatient) (15.1); healthcare (outpatient) (7.9); drug-related pensions (4.3); drug-related sickness benefits (0.5); compensation
(insurance companies) (0.9); substance abuse services (in/outpatient) (26.5); living allowances (4.8); child welfare (10.9); research and
prevention (5.2)
Sweden 62.5 Very rough estimate on costs for demand-reduction expenditures on alcohol and drugs (Tullverket, 2000). Municipalities SEK 300 (EUR 30),
Counties SEK 250 (EUR 25) and State SEK 50 (EUR 5). Non-governmental organisations, foundations and companies SEK 25 (EUR 2.5)
UK 2000–01 466.3 Estimation for the financial year 2000–01 (12 months to 31 March 2001). ‘Drug treatment’ GBP 234 million (EUR 367.4); ‘Protecting young
people’ (Prevention), GBP 63 million (EUR 98.9) 
Norway 224.9 Estimation of costs at central, county and municipal level for drugs and alcohol-related services prevention, treatment and healthcare 
(in-/outpatient, drug free, substitution), social services for drug addicts outreach work, harm/risk reduction, rehabilitation and reintegration
Annual report 2003: the state of the drugs problem in the European Union and Norway
and harm-reduction activities, seems to be lower, most likely
because of the different scale of expenditure in comparison
with treatment or because partially included in it.
Final considerations
As far as analysis of drug-related expenditure is concerned,
a distinction must be made between research on
expenditure at national level and cross-country comparisons
of this research.
Recent studies in some countries (206) have shown the
possibilities of achieving satisfactory results even without
applying an ‘internationally agreed methodology’. Of
course, on such a basis, the comparability among countries
is certainly limited, but still at national level this research
can increase knowledge of the responses to the drug
phenomenon and can be a useful instrument for decision-
makers, allowing them to assess the level of expenditure in
their own countries over time (if repeated) and across
sectors (if detailed enough). Moreover, when cost estimates
are compared with other indicators, as seen earlier, it is
possible to estimate how much is spent per drug addict or
how much the drug-demand reduction policy costs
compared with other policies, or how much citizens must
contribute to drug-demand reduction.
These ratios and comparisons raise very relevant questions
and hypotheses, the answers to which may be obtained
through more in-depth studies.
Comparison ‘across countries’ (the scope of this study) is
another dimension of drug-related cost estimates research.
As shown in this report, such studies are highly dependent on
different data sources and are therefore hampered by the
lack of uniformity among the different countries’
methodology, statistics and figures. To overcome these (and
other) difficulties, common data collection standards should
be implemented. However, such an approach would require
investments without yet being certain of the quality and
usefulness of the final results. Prior to such investment, further
research is needed, together with a deeper reflection on the
relevance and utility of such studies at European level.
In the meantime, and while reflection on further
development is undertaken among European partners, it is
the role of the EMCDDA to continue promoting the
improvement of the statistical systems in the field and to
disseminate information on the methodologies in use and
the research undertaken.
that each EU citizen contributed between EUR 5 and 10.
Of course, it is likely that this amount may be considerably
higher.
Finally, as emphasised by several participants in the
research, a common methodology would be crucial to
cross-country research, assuming that this type of
information, and its subsequent analysis, turns out to be
relevant for decision-making.
Repartition of expenditure
With current data collection systems, it is very difficult to
obtain a reliable breakdown of figures on spending by
category. Nationally, areas such as treatment, harm
reduction and prevention often merge into each other, and
not all countries apply the same system of categorising
expenditure. Consequently, international comparisons are
hampered by the use of different data collection and
classification methods, making it very difficult to compare
expenditure in specific areas.
However, the methodological constraints aside, one rather
solid conclusion can be drawn on the basis of the best data
provided in this report: the area of healthcare and
treatment seems to attract the lion’s share of the money,
accounting for 50–80 % of all direct government drug
demand-reduction expenditure.
In Austria, ‘counselling, care and treatment’ for drug
addicts in 1999 accounted for 78 % of federal demand-
reduction expenditure. In Greece, the data show that almost
73 % of known expenditure was allocated to treatment
(and secondary expenditure), while in Spain, in 1999,
expenditure on treatment in the communities and
autonomous cities accounted for 74 % of the total. In
Portugal, 49 % of total drug expenditure in 1999 went on
treatment, but with 25 % of the total expenditure allocated
to drug-use prevention this is one of the highest rates (of the
known data) in this area in the EU.
Direct expenditure on ‘prevention’ is, in fact, very difficult
to identify, and as a result the data are more uncertain.
Known rates range from 4 % in Austria, which provided
data only on primary prevention, to 20 % in Greece (again
only primary prevention) and are 15 % in the Spanish
communities and autonomous cities and 10 % in
Luxembourg.
The share of total drug-demand reduction expenditure
allocated to rehabilitation and reintegration, and to outreach
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(206) Uhl (2001), ONDCP (2001); Godfrey et al. (2002) and Origer (2002), Kopp and Fenoglio (2003). See also the national focal points from Austria,
Portugal, Spain and Greece, in the framework of the 2002 Reitox national reports. 
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so,
it provides its audiences with an evidence-based picture of the drug
phenomenon at European level. 
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU Member States and Norway and is an essential
reference book for those seeking the latest findings on drugs in Europe.
The printed publication is complemented by an expanded online version
available at: http://annualreport.emcdda.eu.int.
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